Imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis

Abstract

The present invention relates to imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives of formula (I) or a salt thereof. These compounds are TLR9 inhibitors and are useful for treating, preventing, or slowing the progression of fibrotic diseases, such as hepatic fibrosis, renal fibrosis, biliary fibrosis, pancreatic fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic nephropathy, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

Description

Imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis The present invention relates generally to substituted bicyclic compounds useful as inhibitors of signaling through the Toll-like receptor 9 (TLR9). Substituted bicyclic compounds, compositions comprising such compounds, and such compounds for use in medical treatment methods are provided herein. The invention further relates to pharmaceutical compositions containing at least one compound according to the invention, which are useful for the treatment of conditions related to TLR9 modulation, such as inflammatory and autoimmune diseases, and to methods for inhibiting TLR9 activity in a mammal. Toll-like receptors (TLRs) are transmembrane proteins that have the ability to initiate an inflammatory response upon recognition of pattern-associated molecular patterns (PAMPs) or microbe-associated molecular patterns (MAMPs). A total of 10 human TLRs have been identified and can be located on the cell surface or, as in the case of TLR7, 8, and 9, in endolysosomes. TLR9 recognizes unmethylated single-stranded DNA containing cytosine-phosphate-guanine (CpG) motifs, which are typically found in bacterial and mitochondrial DNA (mtDNA).TLR9 may contribute to fibrogenesis by promoting inflammation through the MyD88-dependent signaling pathway, which ultimately mediates the activation of IL-6, IFN-γ, IL-β, and TNF-γ, among other cytokines. (Barton GM, Kagan JC (2009) Nat. Rev. Immunol. 9 (8) , 535-42; Li X, Jiang S, Tapping RI (2010) Cytokine 49 (1) , 1-9). TLR9 levels are higher in lung biopsies from patients with rapidly progressing idiopathic pulmonary fibrosis (IPF) than in healthy patients or those with stable IPF progression (Sci. Transl. Med. 2010, 2 (57):57ra82). Circulating mtDNA, the TLR9 ligand, has recently been identified as a prognostic biomarker based on the mechanism of IPF (Am J. Resp. and Crit. Care Med. 2017, 196 (12):1502). Furthermore, TLR9 has been observed to be upregulated in human and murine non-alcoholic steatohepatitis (NASH) (Clin. Sci.2017, 131 (16) , 2145), while hepatocyte mitochondrial DNA drives NASH through TLR9 activation (J. Clin. Inv.2016, 126 (3) , 859). Consequently, TLR9 inhibitors / antagonists are predicted to be effective as novel therapeutic agents for treating fibrotic diseases. TLR9 inhibition has been recognized as a potential pathway for therapies for fibrotic diseases, including idiopathic pulmonary fibrosis (Trujillo et al. Sci. Transl. Med. 2010, 2(57):57ra82; Yoshizaki et al. Ann Rheum Dis. October 2016; 75(10):1858-65), non-alcoholic steatohepatitis (García-Martínez et al. J Clin Invest 2Q / 6, 126:859-864; Gabele et al. Biochem Biophys Res Commun. 2008;376:271-276), liver injury (Shaker et al. Biochem Pharmacol. 2016;112:90-101; Hoeque et al. J. Immun. 2013;190:4297-304), and scleroderma (systemic sclerosis or SSc) (Yoshizaki et al. Ann Rheum Dis. 2016 Oct;75 (10): 1858-65) ; as well as heart failure (Oka et al. Nature 485, pages 251255 (2012)) and hypertension (McCarthy et al. Cardiovascular Research, 2015, pages 119-130). Compounds containing imidazopyridine and triazolopyridine are described in, for example, International Patent Publications WO 2017 / 058503 A1 and WO 2018 / 165112 A1, each of which provides bicyclic compounds that can act as inhibitors of the histone methyltransferase SUV39H2. Lesuisse et al. (BioorgMed Chern Lett. 2019, 29:929-932) describe imidazopyridine compounds as agonists of the nuclear receptor Nurrl / NOT. Methods for the sulphenylation of imidazopyridines are described in Le Bescont et al. (Eur J Org Chern. 2020, 14:2101-2109). None of the above-mentioned documents describe imidazopyridine or triazolopyridine derivatives as claimed herein. There remains a need for useful compounds such as TLR9 inhibitors. Furthermore, there remains a need for useful compounds such as TLR9 inhibitors that are selective for TLR7 or TLR8. Given the conditions that may benefit from treatment involving the modulation of Toll-like receptors, it is evident that novel compounds capable of inhibiting TLR9 and methods of using such compounds could provide substantial therapeutic benefits to a wide range of patients. The applicants have identified potent compounds that exhibit TLR9 inhibitor activity. In addition, the applicants have identified compounds that exhibit TLR9 inhibitor activity and are selective for TLR7 or TLR8. These compounds are intended to be useful as pharmaceuticals, possessing desirable stability, bioavailability, therapeutic index, and toxicity values, which are important for their suitability as drugs. Summary This disclosure relates to a novel class of substituted bicyclic compounds that have been found to be effective inhibitors of TLR9 signaling. These compounds are provided for potential use as pharmaceuticals, possessing desirable values ​​for stability, bioavailability, therapeutic index, and toxicity, which are important for their suitability as drugs. This disclosure relates to compounds of formula (I) that are useful as inhibitors of signaling through Toll-like receptor 9 and are useful for the treatment of fibrotic diseases or stereoisomers, N-oxides, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof. The present invention provides compounds of formula (II) according to the appended claims, and stereoisomers, tautomers, solvates and salts thereof. The present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof. The present invention also provides a compound of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts or solvates thereof, for use in the treatment of pathological fibrosis. These and other features of the invention will be set forth in expanded form as disclosure continues. References in this description to medical treatment methods or medical uses are to be understood as references to the compounds of the present invention for use in medical treatment methods. Medical treatment methods or medical uses are not covered by the claimed invention. Detailed description This disclosure relates to compounds of formula (I): or stereoisomers, tautomers, solvates or salts thereof, where: The two dashed lines represent two single or two double bonds; and R5a and R5b are present only if said two dashed lines are two single bonds; X is N or CR3; One of Q1 and Q2 is A and the other of Q1 and Q2 is R5; G is: (i) phenyl substituted with 1 to 3 substituents independently selected from F, CI Br, C1-2 alkoxy, C1-2 fluoroalkoxy, C3-4 cycloalkyl -C(O)NRyRy, -S(O)2CH3, -S(O)2(phenyl), -S(O)2NRXRX and -S(O)(NH)NRxRx; (v) a 9-membered heterocyclic ring selected from: (vi) a 10-membered heterocyclic ring selected from: A is cyclohexyl, phenyl, pyridinyl, pyrimidinyl, 6-azabicyclo[3.2.1]octanyl or azabicyclo[3.2.1]octanyl, each substituted with -L-R4 and zero to 1 R4b; L is a bond, -CRxRx- or -C(0)(CRxRx)0-2-; each R2 is independently halo, -CN, -OH, -NO2, C1-4 alkyl, C1-2 fluoroalkyl, C1-2 cyanoalkyl, C1-3 hydroxyalkyl, C1-3 aminoalkyl, -O(CH2)-2OH, -(CH2)O-4O(C1-4 alkyl), C1-3 fluoroalkoxy, -(CH2)1-4O(C1-3 alkyl), -O(CH2)1-2OC(O)(C1-3 alkyl), -O(CH2)1-2NRXRX, -C(O)O(C1-3 alkyl), -(CH2)O-2C(O)NRyRy, -C(O)NRX(C5 hydroxyalkyl), -C(O)NRx(C2-6 alkoxyalkyl), -C(O)NRx (C3-6 cycloalkyl) , -NRyRy, -NRy (C1-3 fluoroalkyl) , -NRy (C1-4 hydroxyalkyl) , -NRxCH2 (phenyl) , -NRXS(O)2(C3-6 cycloalkyl), -NRXC(O)(C1-3 alkyl), -NRxCH2(C3-6 cycloalkyl), -S(O)2(C1-3 alkyl), -S(O)2N(C1-3 alkyl)2, -S(O)(NH)N(C1-3 alkyl)2, - (CH2)0-2(C3-6 cycloalkyl), -(CH2)o-2(phenyl), morpholinyl, dioxothiomorpholinyl, dimethyl pyrazolyl, methylpiperidinyl, methylpiperazinyl, amino-oxadiazolyl, imidazolyl, triazolyl or -C(O)(thiazolyl); R2a is C1-6 alkyl, C1-3 fluoroalkyl, C1-6 hydroxyalkyl, C1-3 aminoalkyl, -(CH2) 0-4O (C1-3 alkyl), C3-6 cycloalkyl, -(CH2) 1-3C (O) NRXRX, -CH2 (C3-6 cycloalkyl), -CH2 (phenyl), tetrahydrofuranyl, tetrahydropyranyl or phenyl; each R2b is independently hydrogen, halo, -CN, -NRxRx, C1-6 alkyl, C1-3 fluoroalkyl, C1-3 hydroxyalkyl, C1-3 fluoroalkoxy, -(CH2)0-2O (C1-3 alkyl), -(CH2)0-3C(0)NRxRx, -(CH2)1-3 (C3-6 cycloalkyl), -C(O)O (C1-3 alkyl), -C(O)NRX (C1-3 alkyl), -CRx=CRxRx or -CRx=CH(C3-6 cycloalkyl); R2C is R2a or R2b; R2d is R2a or R2b; provided that one of R2c and R2d is R2a, and the other of R2c and R2d is R2b; R3 is hydrogen, F, CI C1-3 alkyl, C1-2 fluoroalkyl or C3-4 cycloalkyl; R4 is: (i) -N (CH3) 2; (ii) pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, pyridinyl, azaspiro[3.3]heptanyl, azabicyclo[3.2.1]octanyl or diazabicyclo[3.2.1]octanyl, each substituted with zero to 2 R4a; either each R4a is independently C1-6 alkyl, C1-3 fluoroalkyl, -(CH2)O-20 (C1-2 alkyl), C3-6 cycloalkyl, -CH2 (C3-6 cycloalkyl), -C(O) (C1-4 alkyl), -C(O) (C3-6 cycloalkyl), -C(O) (phenyl), -C(O)CH2 (C3-6 cycloalkyl), -C(O)CH2 (phenyl), -C(O)O (C1-4 alkyl), oxethanyl, tetrahydrofuran or tetrahydropyranyl; R4b is F, CI, or -CH3; each R4C is independently C1-6 alkyl, C1-3 fluoroalkyl, -CH2 (C3-6 cycloalkyl), -C(O) (C1-4 alkyl), -C(O) (phenyl), -C(O)CH2 (phenyl), -C(O)OCH2CH3 or C3-6 cycloalkyl; each R5 is independently hydrogen, F, CI, C1-3 alkyl, C1-2 fluoroalkyl or C3-4 cycloalkyl; R5a and R5b are, independently, hydrogen, F, CI alkyl, C1-3 alkyl, C1-2 fluoroalkyl or C3-4 cycloalkyl; each Rx is independently hydrogen or -CH3; each Ry is independently hydrogen or C1-6 alkyl; m is zero, 1, or 2; n is zero, 1, or 2; p is zero, 1, 2, 3, or 4; and which is 1 or 2. The compounds of the invention have the structure of formula (II): or stereoisomers, tautomers, solvates or salts thereof, where: X is N or CR3; One of Q1 and Q2 is A and the other of Q1 and Q2 is R5; G is phenyl substituted with 1 to 3 substituents independently selected from F, CI Br, C1-2 alkoxy, C1-2 fluoroalkoxy, C3-4 cycloalkyl -C (O) NRyRy, -S (O) 2CH3, -S (O) 2 (phenyl), -S (O) 2NRXRX, and -S (O) (NH) NRXRX; A is cyclohexyl, piperidinyl, phenyl, pyridinyl, pyrimidinyl, 6-azabicyclo[3.2.1]octanyl or azabicyclo[3.2.1]octanyl, each substituted with -L-R4 and zero to 1 R4b; L is a bond, -CrXRX- or C (0) (CRxRx) or -2-; R3 is hydrogen, F, CI, C1-3 alkyl, C1-2 fluoroalkyl or C3-4 cycloalkyl; R4 is: (i) -N (CH3) 2; (ii) pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, pyridinyl, azaspiro[3.3]heptanyl, azabicyclo[3.2.1]octanyl or diazabicyclo[3.2.1]octanyl, each substituted with zero to 2 R4a; or each R4a is independently C1-6 alkyl, C1-3 fluoroalkyl, -(CH2) O-2O (C1-2 alkyl), C3-6 cycloalkyl, -CH2 (C3-6 cycloalkyl), -C (O) (C1-4 alkyl), -C (O) (C3-6 cycloalkyl), -C (O) (phenyl), -C (O) CH2 (C3-6 cycloalkyl), -C (O) CH2 (phenyl), -C (O) O (C1-4 alkyl), oxetanyl, tetrahydrofuran or tetrahydropyranyl; R4b is F, CI or -CH3; each R4C is independently C1-6 alkyl, C1-3 fluoroalkyl, -CH2 (C3-6 cycloalkyl), -C(O) (C1-4 alkyl), -C(O) (phenyl), -C(O)CH2 (phenyl), -C(O)OCH2CH3 or C3-6 cycloalkyl; each R5 is independently hydrogen, F, CI, C1-3 alkyl, C1-2 fluoroalkyl or C3-4 cycloalkyl; each Rx is independently hydrogen or -CH3; m is zero, 1 or 2; n is zero, 1 or 2; and which is 1 or 2. In the compounds of the invention, X is N or CR3; and one of Q1 and Q2 is A and the other of Q1 and Q2 is R5. In one embodiment, X is CR3. The compounds of this embodiment have the structure of formula (IIa): In one embodiment, X is N. The compounds of this embodiment have the structure of formula (IIb): In one embodiment, X is CR3; Q1 is A; and Q2 is R5. The compounds of this embodiment have the structure of formula (IIa-1): In one embodiment, X is CR3; Q1 is R5; and Q2 is A. The compounds of this embodiment have the formula structure (IIa-2): In one embodiment, X is N; Q1 is A; and Q2 is R5. The compounds of this embodiment have the structure of formula (IIb-1): In one embodiment, X is N; Q1 is R5; and Q2 is A. The compounds of this embodiment have the structure of formula (IIb-2): In the compounds of the invention, G is phenyl substituted with 1 to 3 substituents independently selected from S(O)2CH5, -S(O)2(phenyl), -S(O)2NRXRX and -S(O)(NH)NRxRx. In a compound of formula (I) or stereoisomers, tautomers, solvates, or salts thereof, G can be phenyl substituted with 1 to 2 substituents independently selected from F, -OCH3, -S(O)2CHS, -S(O)2N(CH3)2, and -S(O)(NH)N(CH3)2. For example, G can be phenyl substituted with 1 to 2 substituents independently selected from F, -OCH3, and -S(O)2CH3. In another example, G can be: In one case (not claimed), a compound of formula (I) or stereoisomers, tautomers, is provided. NH (CH2-cyclopropyl), cyclopropyl, methylpiperidinyl, methylpiperazinyl, amino-oxadiazolyl, imidazolyl, or triazolyl. This also includes compounds in which each R2 is independently F, Cl, -CN, -CH3, -OCH3, -NH2, or cyclopropyl. Furthermore, this includes compounds in which p is 2; one R2 is -CH3; and the other R2 is F, Cl, -CN, -CH3, -OCH3, -NH2, or cyclopropyl. In one instance (not claimed), a compound of formula (I) or stereoisomers, tautomers, solvates or salts thereof are provided, wherein G is a 9-membered heterocyclic ring selected from: This includes compounds in which G is: In one instance (not claimed), a compound of formula (I) or stereoisomers, tautomers, solvates or salts thereof are provided, wherein G is a 10-membered heterocyclic ring selected from: This includes compounds in which G is: In a compound of formula (I) or stereoisomers, tautomers, solvates or salts thereof, G can be: (i) phenyl substituted with 1 to 2 substituents independently selected from -OCH3, -S(O)2CH3, -S(O)2N(CH3)2 and -S(O)(NH)N(CH3)2; For example, each R2 can independently be CI, -CH3, -CH2CHs, -CH2OH, -CH2CH2OH, -CH2CN, -OCH3, -CH2 OCH 3 or -CH2CH2S (O) 2CH3. In one case (not claimed), a compound of formula (I) or stereoisomers, tautomers, solvates or salts thereof are provided, wherein p is zero, 1, 2 or 3. This includes compounds where p is 1 or 2. In the compounds of the invention, A is cyclohexyl, piperidinyl, phenyl, pyridinyl, pyrimidinyl, 6-azabicyclo[3.2.1]octanyl or azabicyclo[3.2.1]octanyl, each substituted with -L-R4 and zero to 1 R4b. In a compound of formula (I) or stereoisomers, tautomers, solvates, or salts thereof, A may be cyclohexyl, piperidinyl, phenyl, pyridinyl, 6-azabicyclo[3.2.1]octanyl, or azabicyclo[3.2.1]octanyl, each substituted with -L-R4 and zero to 1 R4b. For example, A may be cyclohexyl, piperidinyl, phenyl, or 6-azabicyclo[3.2.1]octanyl, each substituted with -L-R4. In a compound of formula (I) or stereoisomers, tautomers, solvates, or salts thereof, A can be piperidinyl, phenyl, pyridinyl, pyrimidinyl, 6-azabicyclo[3.2.1]octanyl, or azabicyclo[3.2.1]octanyl, each substituted with -L-R4 and zero to 1 R4b. For example, A can be piperidinyl, phenyl, pyridinyl, pyrimidinyl, 6-azabicyclo[3.2.1]octanyl, or azabicyclo[3.2.1]octanyl, each substituted with -L-R4. In another example, A can be piperidinyl or 6-azabicyclo[3.2.1]octanyl, each substituted with -L-R4. In a compound of formula (I) or stereoisomers, tautomers, solvates, or salts thereof, A can be piperidinyl, phenyl, or pyridinyl, each substituted with -L-R4 and zero to 1R4b. For example, A can be piperidinyl or phenyl, each substituted with -L-R4 and zero to 1R4b. In another example, A can be phenyl or pyridinyl, each substituted with -L-R4 and zero to 1R4b. In a compound of formula (I) or stereoisomers, tautomers, solvates, or salts thereof, A may be piperidinyl, phenyl, pyridinyl, or pyrimidinyl, each substituted with -L-R4 and zero to 1R4b; and L is a bond. For example, A may be piperidinyl, phenyl, or pyridinyl, each substituted with -L-R4 and zero to 1R4b; and L is a bond. In the compounds of the invention, L is a bond, -CRxRx- or -C(0)(CRxRx) or -2-. In a compound of formula (I) or stereoisomers, tautomers, solvates, or salts thereof, L may be a bond. In a compound of formula (I) or stereoisomers, tautomers, solvates, or salts thereof, L may be -CRxRx-. For example, L may be -CH2-. In a compound of formula (I) or stereoisomers, tautomers, solvates, or salts thereof, L may be C(O)(CRxRx)O-2-. For example, L may be -C(O)(CH2)O-2-. In another example, L may be -C(O)(CH2)O-1-. In a further example, L may be -C(O)-. In a compound of formula (I) or stereoisomers, tautomers, solvates, or salts thereof, L may be -CRxRx- or -C(O)(CRxRx)0-2-. For example, L may be -CRxRx- or -C(O)(CRxRx)0-1-. In another example, L may be -CRxRx- or -C(O)-. Additionally, each Rx may be hydrogen. In a compound of formula (I) or stereoisomers, tautomers, solvates, or salts thereof, L may be a bond, -CH2- or -C(O)(CH2)O-2-. For example, L may be a bond or -C(O)-. In the compounds of the invention, R4 is: (i) -N(CH3)2 (ii) pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, pyridinyl, azaspiro[3.3]heptanyl, azabicyclo[3.2.1]octanyl or diazabicyclo[3.2.1]octanyl, each substituted with zero to 2 R4a; or (iii) In a compound of formula (I) or stereoisomers, tautomers, solvates or salts thereof, R4 can be -N (CH3) 2. In a compound of formula (I) or a salt thereof, R4 can be pyrrolidinyl, piperidinyl, piperazinyl, pyridinyl, azaspiro[3.3]heptanyl, or azabicyclo[3.2.1]octanyl, each substituted with zero to 2 R4a. For example, R4 can be piperidinyl, azaspiro[3.3]heptanyl, or azabicyclo[3.2.1]octanyl, each substituted with R4a. In a compound of formula (I) or stereoisomers, tautomers, solvates, or salts thereof, R4 can be pyrrolidinyl, piperidinyl, piperazinyl, or pyridinyl, each substituted with zero to 2 R4a. For example, R4 can be piperidinyl, piperazinyl, or pyridinyl. In another example, R4 can be piperidinyl or piperazinyl. In a compound of formula (I) or stereoisomers, tautomers, solvates or salts thereof, R4 may be For example, n can be 1 or 2. In another example, n can be 1. In an additional example, n can be 2. In a compound of formula (I) or stereoisomers, tautomers, solvates or salts thereof, R4 may be pyrrolidinyl, piperidinyl, piperazinyl or pyridinyl, each substituted with zero to 2 R4a; or In the compounds of the invention, each R4a is independently C1-6 alkyl, C1-3 fluoroalkyl, -(CH2)0-2O (C1-2 alkyl), C3-6 cycloalkyl, -CH2 (C3-6 cycloalkyl), -C(O) (C1-4 alkyl), -C(O) (C3-6 cycloalkyl), -C(O) (phenyl), -C(O)CH2 (C3-6 cycloalkyl), -C(O)CH2 (phenyl), -C(O)O (C1-4 alkyl), oxethanyl, tetrahydrofuran, or tetrahydropyranyl; R4b is F, C1, or -CH3; and each R4c is independently C1-6 alkyl, C1-3 fluoroalkyl, -CH2 (C3-6 cycloalkyl), -C (O) (C1-4 alkyl), -C (O) (phenyl), -C (O) CH2 (phenyl), -C (O) OCH 2CH3 or C3-6 cycloalkyl. In a compound of formula (I) or stereoisomers, tautomers, solvates or salts thereof, each R4a can independently be C1-5 alkyl, C1-2 fluoroalkyl, -(CH2)0-2O (C1-2 alkyl), C3-6 cycloalkyl, -CH2 (C3-6 cycloalkyl), -C(O) (C1-4 alkyl), -C(O) (C3-6 cycloalkyl), -C(O) (phenyl), -C(O)CH2 (C3-6 cycloalkyl), -C(O)CH2 (phenyl), -C(O)O (C1-3 alkyl), oxethanyl, tetrahydrofuran or tetrahydropyranyl. For example, each R4a can independently be -CH(CH3)2, -CH2CH(CH3)2, -CH2CH2OCH3, -C(O)CH(CH3)2, -C(O)(cyclopropyl), -CH2(cyclopropyl), -CH2(cyclobutyl), cyclopropyl, cyclobutyl, oxethanyl, or tetrahydropyranyl. In another example, each R4a can independently be -CH(CH3)2, -CH2CH(CH3)2, -C(O)CH(CH3)2, -C(O)(cyclopropyl), or -CH2(cyclopropyl), cyclopropyl, or cyclobutyl. In a compound of formula (I) or stereoisomers, tautomers, solvates, or salts thereof, R4b can be F or Cl. For example, R4b can be F. In a compound of formula (I) or stereoisomers, tautomers, solvates, or salts thereof, each R4C can be independently C1-4 alkyl, C1-2 fluoroalkyl, -CH2 (C3-6 cycloalkyl), -C(O)(C1-3 alkyl), -C(O)(phenyl), -C(O)(CH2(phenyl), -C(O)(OCH2CH3), or C3-6 cycloalkyl. For example, each R4c can be independently C1-3 alkyl, C1-2 fluoroalkyl, -CH2 (C3-4 cycloalkyl), -C(O)(C1-2 alkyl), -C(O)(phenyl), -C(O)(CH2(phenyl), -C(O)(OCH2CH3), or C3-4 cycloalkyl. In the compounds of the invention, R3 is hydrogen, F, Cl, C1-3 alkyl, C1-2 fluoroalkyl, or C3-4 cycloalkyl. In a compound of formula (I) or stereoisomers, tautomers, solvates, or salts thereof, R5 may be hydrogen, F, Cl, C1-2 alkyl, or C3-4 cycloalkyl. For example, R3 may be hydrogen, C1-2 alkyl, or cyclopropyl. In another example, R3 may be hydrogen or -CH3. In an additional example, R3 can be hydrogen. In the compounds of the invention, each R5 is, independently, hydrogen, F, CI, C1-3 alkyl, C1-2 fluoroalkyl or C3-4 cycloalkyl. In a compound of formula (I) or stereoisomers, tautomers, solvates, or salts thereof, each R5 can independently be hydrogen, F, Cl, -CH3, or cyclopropyl. For example, each R5 can independently be hydrogen, -CH3, or cyclopropyl. In another example, each R5 can be either hydrogen or -CH3. In a compound of formula (I) or stereoisomers, tautomers, solvates, or salts thereof, G may be phenyl substituted with 1 to 2 substituents independently selected from F, -OCH3, and -S(O)2CH3; A may be cyclohexyl, piperidinyl, phenyl, or 6-azabicyclo[3.2.1]octanyl, each substituted with -L-R4; L may be a bond; R3 may be hydrogen; R4 may be piperidinyl, piperazinyl, azepanyl, azaspiro[3.3]heptanyl, azabicyclo[3.2.1]octanyl, or diazabicyclo[3.2.1]octanyl, each substituted with R4a; R4a can be -CH(CH3)2, -CH2CH(CH3)2, -CH2CH2OCH3, -C(O)CH(CH3)2, -C(O)(cyclopropyl), -CH2(cyclobutyl), cyclopropyl, cyclobutyl, oxethanyl or tetrahydropyranyl; and each R5 can be hydrogen, F or -CH3. In a compound of formula (I) or stereoisomers, tautomers, solvates, or salts thereof, G may be phenyl substituted with 1 to 2 substituents independently selected from F, -OCH3, and S(O)2CH3; A may be piperidinyl or 6-azabicyclo[3.2.1]octanyl, each substituted with -L-R4; L may be a bond; R3 may be hydrogen; R4 may be piperidinyl, azaspiro[3.3]heptanyl, or azabicyclo[3.2.1]octanyl, each substituted with R4a; R4a may be -CH(CH3)2, -CH2CH(CH3)2, -C(O)CH(CH3)2, -C(O)(cyclopropyl), or -CH2(cyclopropyl), cyclopropyl, or cyclobutyl; and each R5 may be hydrogen or -CH3. An embodiment of the invention provides a compound, or stereoisomers, tautomers, solvates, or salts thereof, as set forth in appended claim 7. More generally, the present description describes a compound of formula (I) or stereoisomers, tautomers, solvates, or salts thereof, wherein said compound is: 6-(1-cyclopropyl-[1,4-bipiperidin]-4-yl)-2-(3,4-dimethoxyphenyl)-8-methylimidazo[1,2-a]pyridine (1); 2-(3,4-dimethoxyphenyl)-6-(1-isopropyl-[1,4-bipiperidin]-4-yl)-8-methylimidazo[1,2-a]pyridine (2); 2-(3,4-dimethoxyphenyl)-6-(1-isobutyl-[1,4'-bipiperidin]-4-yl)-8-methylimidazo[1,2-a]pyridine (3); 6-(1-cyclopropyl-[1,4-bipiperidin]-4-yl)-2-(3-fluoro-4methoxyphenyl)-8-methylimidazo[1,2-a]pyridine (4) ; 2-(3-fluoro-4-methoxyphenyl)-6-(1-isopropyl-[1,4-bipiperidin]-4-yl)-8-methylimidazo[1,2-a]pyridine (5) ; 2-(3-fluoro-4-methoxyphenyl)-6-(1-isobutyl-[1,4'-bipiperidin]-4-yl)-8-methylimidazo[1,2-a]pyridine (6) ;6-(1-cyclopropyl-[1, 4-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (7) ; 6-(1'-isopropyl-[1, 4'-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (8) ; 6-(1-isobutyl-[1, 4-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (9) ; 6-(1-cyclopropyl-[1, 4-bipiperidin]-4-yl)-2-(3, 4-dimethoxyphenyl)imidazo[1, 2-a]pyridine (10) ; 2-(3,4-dimethoxyphenyl)-6-(1-isopropyl-[1,4-bipiperidin]-4-yl)imidazo[1,2-a]pyridine (11) ; 2-(3,4-dimethoxyphenyl)-6-(1-isobutyl-[1,4'-bipiperidin]-4-yl)imidazo[1,2-a]pyridine (12) ; 2-(3,4-dimethoxyphenyl)-6-(1-(2-isopropyl-2-azaspiro[3.3]heptan-6-yl)piperidin-4-yl)-8-methylimidazo[1,2-a]pyridine (13) ; 6-(1-(2-cyclobutyl-2-azaspiro[3.3]heptan-6-yl)piperidin-4-yl)-2-(3,4-dimethoxyphenyl)-8-methylimidazo[1,2-a]pyridine (14);2- (3, 4-dimethoxyphenyl) -6- (1- (2-isobutyl-2-azaspiro[3.3]heptan-6-yl) piperidin-4-yl) -8-methylimidazo[1, 2-a]pyridine (15) ; 6- (1- (2- (cyclopropylmethyl) -2-azaspiro[3.3]heptan-6-yl) piperidin-4-yl) -2- (3, 4-dimethoxyphenyl) -8-methylimidazo[1, 2-a]pyridine (16) ; 6- (1- (2-cyclopropyl-2- azaspiro[3.3]heptan-6-yl) piperidin-4-yl) -2- (3, 4-dimethoxyphenyl) -8-methylimidazo[1, 2-a]pyridine (17) ; 2-(3, 4-dimethoxyphenyl)-6-(1-(8-isobutyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-8-methylimidazo[1, 2-a]pyridine (18-19) ; 6-(1-(8-(cyclopropylmethyl)-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-2-(3, 4-dimethoxyphenyl)-8-methylimidazo[1, 2-a]pyridine (20-21) ; 2-(3, 4-dimethoxyphenyl)-6-(1-(8-isopropyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-8-methylimidazo[1, 2-a]pyridine (22-23) ; 6-(8-(1-cyclopropylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-2-(3, 4-dimethoxyphenyl)-8-methylimidazo[1, 2-a]pyridine (24) ;6-(8-(1-cyclopropylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-2-(3,4-dimethoxyphenyl)-8-methylimidazo[1,2-a]pyridine (25-26) ; 2-(3,4-dimethoxyphenyl)-6-(8-(1-isobutylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-8-methylimidazo[1,2-a]pyridine (27-29) ; 2-(3,4-dimethoxyphenyl)-6-(8-(1-isopropylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-8-methylimidazo[1,2-a]pyridine (30) ; 2-(3,4-dimethoxyphenyl)-7-(1-isopropyl-[1,4'-bipiperidin]-4-yl)-[1,2,4]triazolo[1,5-a]pyridine (60) ; 2-(3,4-dimethoxyphenyl)-7-(1-isobutyl-[1,4-bipiperidin]-4-yl)-[1,2,4]triazolo[1,5-a]pyridine (61) ; 6-(1-(8-isopropyl-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (62-63) ; 2- (3, 4-dimethoxyphenyl) -8-methyl-6- (4- (4- (oxetan-3-yl) piperazin-1-yl) phenyl) imidazo[1, 2-a] pyridine (64) ; 6- (4- (4-isopropylpiperazin-1 -y 1) phenyl) -8-methyl-2- (4- (methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (65) ;8-fluoro-6-(1'-isopropyl-[1,4-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (67) ; 8-fluoro-6-(1-(8-isopropyl-8-azabicyclo[3.2.l]octan-3-yl)piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (68-69) ; 7-fluoro-6-(1-isopropyl-[1,4'-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (70) ; 8-fluoro-6-(1-(1-isopropylazepan-4-yl)piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (71-72) ; 5-fluoro-6-(1-isopropyl-[1, 4-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (73) ; 6-(1-(8-cyclobutyl-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (83-84) ; 6- (1- (8-isobutyl-8-azabiciclo[3.2.1]octan-3-yl)piperidin-4-yl)-8-methyl-2- (4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (85-86) ;6-(1-(8-(cyclopropylmethyl)-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (87-88) ; 6-(1-(8-(cyclobutylmethyl)-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (89-90) ; 6-(1-cyclobutyl-[1, 4-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (91) ; 6-(1-(cyclopropylmethyl)-[1,4'-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (92) ; 6-(1-(cyclobutylmethyl)-[1,4'-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (93) ; 2-(3,4-dimethoxyphenyl)-6-(4-(4-isobutylpiperazin-1-yl)phenyl)-8-methylimidazo[1,2-a]pyridine (94) ; 6-(4-(4-(cyclopropylmethyl)piperazin-1-yl)phenyl)-2-(3,4-dimethoxyphenyl)-8-methylimidazo[1,2-a]pyridine (95) ; 2-(3,4-dimethoxyphenyl)-6-(4-(4-isopropylpiperazin-1-yl)phenyl)-8-methylimidazo[1,2-a]pyridine (96);2-(3,4-dimethoxyphenyl)-8-methyl-6-(4-(4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyridine (97) ; 2-(3,4-dimethoxyphenyl)-6-(4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)-8-methylimidazo[1,2-a]pyridine (98) ; 6-(4-(4-isobutylpiperazin-1-yl)phenyl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (99) ; 6-(4-(4-(cyclopropylmethyl)piperazin-1-yl)phenyl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (100) ; 6-(4-(4-(cyclobutylmethyl)piperazin-1-yl)phenyl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (101) ; 6-(4-(4-cyclobutylpiperazin-1-yl)phenyl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (102) ; 8-methyl-2-(4-(methylsulfonyl)phenyl)-6-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyridine (103) ; 8-methyl-2-(4-(methylsulfonyl)phenyl)-6-(4-(4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyridine (104) ;6- (4- (4- (2-methoxyethyl) piperazin-1-yl) phenyl) -8-methyl-2- (4- (methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (105) ; 7- (1-isobutyl-[1, 4-bipiperidin]-4-yl)-5-methyl-2- (4- (methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (106) ; 8-fluoro-6- (1-isobutyl-[1, 4'-bipiperidin]-4-yl)-2- (4- (methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (107) ; 6-(1-cyclopropyl-[1,4-bipiperidin]-4-yl)-8-fluoro-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (108) ; 6-(1-(cyclopropylmethyl)-[1,4'-bipiperidin]-4-yl)-8-fluoro-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (109) ; 6-(1-cyclobutyl-[1,4-bipiperidin]-4-yl)-8-fluoro-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (110) ; 8-fluoro-2-(4-(methylsulfonyl)phenyl)-6-(r-(oxetan-3-yl)-[1,4-bipiperidin]-4-yl)imidazo[1,2-a]pyridine (111) ; 8-fluoro-2-(4-(methylsulfonyl)phenyl)-6-(1-(tetrahydro-2H-pyran-4-yl)-[1,4-bipiperidin]-4-yl)imidazo[1,2-a]pyridine (112) ;8-fluoro-6-(1-(8-isobutyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (113-114) ; 6-(1-(8-(cyclopropylmethyl)-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-8-fluoro-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (115-116) ; 6- (1- (8-cyclobutyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-8-fluoro-2- (4- (methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (117) ; 6- (1- (8-cyclobutyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-8-fluoro-2- (4- (methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (118) ; 8-fluoro-2-(4-(methylsulfonyl)phenyl)-6-(1-(8-(oxetan-3-yl)-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl) imidazo[1, 2-a]pyridine (119-120) ; 8-fluoro-2-(4-(methylsulfonyl)phenyl)-6-(1-(8-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl) imidazo[1, 2-a]pyridine (121-122) ; 7-fluoro-6- (1-isobutyl-[1, 4-bipiperidin]-4-yl) -2- (4-(methylsulfonyl)phenyl) imidazo[1, 2-a]pyridine (123) ;6-(1-cyclopropyl-[1, d'-bipiperidin]-4-yl)-7-fluoro-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (124) ; 8-fluoro-6-(1-(1-isobutylazepan-4-yl)piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (125-126) ; 6-(1-(1-(cyclopropylmethyl)azepan-4-yl)piperidin-4-yl)-8-fluoro-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (127-128) ; 8-fluoro-2-(4-(methylsulfonyl)phenyl)-6-(1-(1-(tetrahydro-2H-pyran-4-yl)azepan-4-yl)piperidin-4-yl)imidazo[1,2-a]pyridine (129130) ; 5-fluoro-6-(1-isobutyl-[1,4'-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (131) ; 8-fluoro-7-(1-isopropyl-[1,4'-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (132) ; o 8-fluoro-2-(4-(methylsulfonyl)phenyl)-7-(1-(tetrahydro-2H-pyran-4-yl)-[1,4-bipiperidin]-4-yl)imidazo[1,2-a]pyridine (133).; For example, a compound of formula (I) or stereoisomers, tautomers, solvates or salts thereof are described, wherein said compound is: 2-(3,4-dimethoxyphenyl)-6-(1-isobutyl-[1,4-bipiperidin]-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (31-33); 2-(3,4-dimethoxyphenyl)-6-(1-isopropyl-[1,4-bipiperidin]-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (34-36); 6- (1-cyclopropyl-[1, 4-bipiperidin]-4-yl) -2- (3, 4-dimethoxyphenyl) -5, 6, 7, 8-tetrahydroimidazo[1, 2-a]pyridine (37-38) ; 1-(4-(2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-6-yl)-[1,4-bipiperidin]-1-yl)-2-methylpropan-1-one (39 41) ; cyclopropyl (4-(2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-6-yl)-[1,4-bipiperidin]-1-yl)methanone (42-44) ; - (3, 4-dimethoxyphenyl) -6- (1- (2-isopropyl-2-azaspiro[3, 3]heptan-6-yl) piperidin-4-yl) -5, 6, 7, 8-tetrahydroimidazo[1, 2-a]pyridine (45 47) ;6- (1- (2-cyclobutyl-2-azaspiro[3, 3]heptan-6-yl) piperidin-4-yl) -2- (3, 4-dimethoxyphenyl) -5, 6, 7, 8-tetrahydroimidazo[1, 2-a]pyridine (48-50) ; 6- (1- (2- (cyclopropylmethyl) -2-azaspiro[3.3]heptan-6-yl) piperidin-4-yl) -2- (3, 4- dimethoxyphenyl) -5, 6, 7, 8-tetrahydroimidazo[1, 2-a]pyridine (51) ; 2- (3, 4-dimethoxyphenyl) -6- (1- (2-isobutyl-2-azaspiro[3.3]heptan-6-yl) piperidin-4-yl) -5, 6, 7, 8- tetrahidroimidazo[1, 2-a]pyridine (52-54) ; 6- (1- (cyclopropylmethyl) -[1, 4-bipiperidin]-4-yl) -2- (3, 4-dimethoxyphenyl) -5, 6, 7, 8-tetrahidroimidazo[1, 2-a]pyridine (55-57) ; (6R)-2-(3, 4-dimethoxyphenyl)-6-(1-(8-isobutyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-5, 6, 7, 8-tetrahidroimidazo[1, 2-a]pyridine (75-76) ; (6S)-2-(3, 4-dimethoxyphenyl)-6-(1-(8-isobutyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-5, 6, 7, 8-tetrahidroimidazo[1, 2-a]pyridine (77-78) ;(6R)-6-(1-(8-isobutyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl)-5, 6, 7, 8-tetrahidroimidazo[1, 2-a]pyridine (79-80) ; (6S)-6-(1-(8-isobutyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl)-5, 6, 7, 8-tetrahidroimidazo[1, 2-a]pyridine (81-82) ; (6R)-2-(3, 4-dimethoxyphenyl)-6-(1-(8-isopropyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-5, 6, 7, 8-tetrahydroimidazo[1, 2-a]pyridine (134-135) ; (6S)-2-(3, 4-dimethoxyphenyl)-6-(1-(8-isopropyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-5, 6, 7, 8-tetrahydroimidazo[1, 2-a]pyridine (136-137) ; (6R)-6-(1-(8-(cyclopropylmethyl)-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl)-5, 6, 7, 8-tetrahidroimidazo[1, 2-a]pyridine (138-139); or (6S)-6-(1-(8-(cyclopropylmethyl)-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl)-5, 6, 7, 8-tetrahidroimidazo[1, 2-a]pyridine (140-141).; A compound of formula (I) or stereoisomers, tautomers, solvates or salts thereof are also described, wherein said compound is: 2-(3,4-dimethoxyphenyl)-7-(1-isopropyl-[1,4-bipiperidin]-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (58); or 2-(3,4-dimethoxyphenyl)-7-(1-isobutyl-[1,4-bipiperidin]-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (59). Also described is a compound of formula (I) or stereoisomers, tautomers, solvates or salts thereof, wherein said compound is: 7-(1-isopropyl-[1,4-bipiperidin]-4-yl)-5-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (66); or 8-fluoro-7-(1-isobutyl-[1,4-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (74). This description also describes a compound of formula (I) or foreign isomeres, tautómers, solvates or mixed sales, where I say the compound is: 2- (3, 4-dimethoxyphenyl) - 6- (4- (4-isopropylpiperazin-1-yl) phenyl) -8-methyl-[1, 2, 4]triazole[1, 5-a]pyridine (142) ; 6- (8- (1-cyclopropylpiperidin-4-yl) -8-azabicyclo[3.2.1]octan-3-yl) -2- (3, 4-dimethoxyphenyl) -[1, 2, 4]triazole[1, 5-a]pyridine (146) ; 6-(4-(4-isopropylpiperazin-1-yl)phenyl)-8-methyl-2-(4-(methylsulfonyl)phenyl)-[1, 2, 4]triazole[1, 5-a]pyridine (147) ; 2- (3, 4-dimethoxyphenyl) -6- (8- (1-isopropylpiperidin-4-yl) -8-azabicyclo[3.2.1]octan-3-yl) -[1, 2, 4]triazole[1, 5-a]pyridine (149) ; 2-(3, 4-dimethoxyphenyl)-6-(4-(8-isopropyl-3, 8-diazabicyclo[3.2.1]octan-3-yl) phenyl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (151) ; 6-(4-(8-isopropyl-3, 8-diazabicyclo[3.2.1]octan-3-yl)phenyl)-8-methyl-2-(4-(methylsulfonyl)phenyl)-[1, 2, 4]triazolo[1, 5-a]pyridine (153) ; 6-(8-(1-cyclopropylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-2-(3, 4-dimethoxyphenyl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (155) ; 2-(3, 4-dimethoxyphenyl)-6-(8-(1-isopropylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (156) ; 6-(1-cyclopropyl-[1, 4-bipiperidin]-4-yl)-2-(3, 4-dimethoxyphenyl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (157) ; 2-(3, 4-dimethoxyphenyl)-6-(1-isopropyl-[1, 4-bipiperidin]-4-yl)-8-methyl-[1, 2, 4]triazolo[1, 5-a]pyridine (158) ; 6-(8-(1cyclopropylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)-[1, 2, 4]triazolo[1, 5-a]pyridine (159) ; 6- (8- (1-isopropylpiperidin-4-yl)-8-azabiciclo[3.2.1]octan-3-yl) -8-methyl-2-(4-(methylsulfonyl)phenyl)-[1, 2, 4]triazolo[1, 5-a]pyridine (160) ; 6-(1-cyclopropyl-[1, 4-bipiperidin]-4-yl) -8-methyl-2-(4-(methylsulfonyl)phenyl)-[1, 2, 4]triazolo[1, 5-a]pyridine (161) ; 6-(1-isopropyl-[1, 4'-bipiperidin]-4-yl) -8-methyl-2-(4-(methylsulfonyl)phenyl)-[1, 2, 4]triazolo[1, 5-a]pyridine (162) ; 6-(1-isobutyl-[1,4'-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine (163) ; 6-(1-cyclopropyl-[1,4-bipiperidin]-4-yl)-2-(3,4-dimethoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridine (164) ; 2-(3,4-dimethoxyphenyl)-6-(4-(8-isopropyl-8-azabicyclo[3.2.1]octan-3-yl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine (166) ; o 6-(4-(4-isopropylpiperazin-1-yl)phenyl)-2-(4-(methylsulfonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine (167) . For example, if I describe a composition of formula (I) or estereoisomers, tautómeros, solvatos or sales of the same, where I say the composition is: 2- (3, 4-dimethoxyphenyl) -6- (4- (4-isopropylpiperazin-1-yl) cyclohexyl) -8-methyl-5, 6, 7, 8-tetrahydro-[1, 2, 4]triazole[1, 5-a]pyridine (143) ; 2- (3, 4-dimethoxyphenyl) -6- (4- (4-isopropylpiperazin-1-yl) phenyl) -8-methyl-5, 6, 7, 8-tetrahydro-[1, 2, 4]triazole[1, 5-a]pyridine (144) ; 6- (8- (1-cyclopropylpiperidin-4-yl) -8-azabicyclo[3.2.1]octan-3-yl) -2- (3, 4-dimethoxyphenyl) -5, 6, 7, 8-tetrahidro-[1, 2, 4]triazole[1, 5-a]pyridine (145) ; 2-(3, 4-dimethoxyphenyl)-6-(8-(lysopropylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-5, 6, 7, 8-tetrahydro-[1, 2, 4]triazolo[1, 5-a]pyridine (148) ; 6-(4-(4-isopropylpiperazin-1-yl)phenyl)-8-methyl-2-(4-(methylsulfonyl)phenyl)-5, 6, 7, 8-tetrahydro-[1, 2, 4]triazolo[1, 5-a]pyridine (150) ; 2-(3, 4-dimethoxyphenyl)-6-(4-(8-isopropyl-3, 8-diazabicyclo[3.2.1]octan-3-yl)phenyl)-8-methyl-5, 6, 7, 8-tetrahydro. [1, 2, 4]triazolo[1, 5-a]pyridine (152) ; or 6-(4-(8-isopropyl-3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)-8-methyl-2-(4-(methylsulfonyl)phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine (154). A compound of formula (I) or stereoisomers, tautomers, solvates or salts thereof are also described, wherein said compound is: 2-(3,4-dimethoxyphenyl)-7-(1-isopropyl-[1,4-bipiperidin]-4-yl)-[1,2,4]triazolo[1,5-a]pyridine (60); 2-(3,4-dimethoxyphenyl)-7-(1'-isobutyl-[1,4-bipiperidin]-4-yl)-[1,2,4]triazolo[1,5-a]pyridine (61); or 2-(3,4-dimethoxyphenyl)-6-(1-isopropyl-[1,4-bipiperidin]-4-yl)-[1,2,4]triazolo[1,5-a]pyridine (165). This disclosure describes compounds of formula (I) that have TLR9 IC50 values ​​of 0.6 µm. Compounds of formula (I) may have TLR9 IC50 values ​​of 0.1 µm. Compounds of formula (I) can have IC50 TLR9 values ​​of 0.05 µm. Compounds of formula (I) can have IC50 TLR9 values ​​of 0.025 µm. Compounds of formula (I) can have IC50 TLR9 values ​​of 0.015 µm. Compounds of formula (I) can have IC50 TLR9 values ​​of 0.01 µm. This disclosure describes a composition comprising at least one of the compounds in this disclosure, or a pharmaceutically acceptable stereoisomer, tautomer, salt, or solvate thereof. This disclosure also describes a pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one of the compounds in this disclosure, or a pharmaceutically acceptable stereoisomer, tautomer, salt, or solvate thereof. The pharmaceutical composition may comprise a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds in this disclosure or a pharmaceutically acceptable stereoisomer, tautomer, salt, or solvate thereof. This disclosure further describes a process for preparing a compound of this disclosure. This disclosure also describes an intermediate for preparing a compound of this disclosure. This disclosure further describes a pharmaceutical composition as defined above comprising one or more additional therapeutic agents. Definitions Those skilled in the art can more easily understand the features and advantages of the disclosure and the invention after reading the detailed description below. It will be appreciated that certain features of the description and the invention, which for the sake of clarity have been described above and below in the context of separate instances or embodiments, can be combined to form a single instance or embodiment. Conversely, several features of the description and the invention, which for the sake of brevity are described in the context of a single instance or embodiment, can also be combined to form subcombinations thereof. The examples and embodiments identified herein as examples or preferred embodiments are intended to be illustrative and not limiting. Unless otherwise specified herein, references made in the singular may also include the plural. For example, "a" and "an" may refer to one, or one or more. As used herein, the term "compounds" refers to at least one compound. For example, a compound of formula (I) includes one compound of formula (I) and two or more compounds of formula (I). Unless otherwise stated, any heteroatom with unsatisfied valencies is assumed to have enough hydrogen atoms to satisfy the valencies. The definitions set forth herein take precedence over the definitions set forth in any patent publication, patent application, and / or patent application cited herein. The definitions of various terms used to describe the present disclosure and invention are listed below. These definitions apply to the terms used throughout the specification (unless otherwise limited in specific cases), whether individually or as part of a larger group. Throughout the descriptive memorandum, an expert in the technique can choose the groups and substituents of the same to provide stable residues and compounds. According to a convention used in the technique, it is used in structural formulas of this document to represent the bond that is the point of attachment of the residue or substituent to the nucleus or main structure. The terms "halo" and "halogen", as used herein, refer to F, Cl, Br, and I. The term "cyano" refers to the -CN group. The term "amino" refers to the -NH2 group. The term "oxo" refers to the group =0. The term "alkyl," as used herein, refers to saturated aliphatic hydrocarbon groups, both branched and straight-chain, containing, for example, 1 to 12 carbon atoms, 1 to 6 carbon atoms, and 1 to 4 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and i-propyl), butyl (e.g., n-butyl, i-butyl, sec-butyl, and butyl), pentyl (e.g., n-pentyl, isopentyl, neopentyl), n-hexyl, 2-methylpentyl, 2-ethylbutyl, 3-methylpentyl, and 4-methylpentyl. When numbers appear in a subscript after the symbol "C", the subscript defines more specifically the number of carbon atoms a particular group may contain. For example, "C1-6 alkyl" represents linear or branched chain alkyl groups with one to six carbon atoms. The term "fluoroalkyl," as used herein, is intended to include saturated, straight-chain and branched aliphatic hydrocarbon groups substituted with one or more fluorine atoms. For example, "C1-4 fluoroalkyl" is intended to include C1, C2, C3, and C4 alkyl groups substituted with one or more fluorine atoms. Representative examples of fluoroalkyl groups include, but are not limited to, -CF3 and -CH2CF3. The term "hydroxyalkyl" includes both branched and linear alkyl groups substituted with one or more hydroxyl groups. For example, "hydroxyalkyl" includes -CH2OH, -CH2CH2OH, and C1-4 hydroxyalkyl. The term "aminoalkyl" includes both branched and linear alkyl groups substituted with one or more amino groups. For example, "aminoalkyl" includes -CH2NH2, -CH2CH2NH2, and C1-4 aminoalkyl. The term "cyanoalkyl" includes both branched and linear alkyl groups substituted by one or more cyano groups. For example, "aminoalkyl" includes -CH2CN, -CH2CH2CN, and C1-4 cyanoalkyl. The term "alkoxy", as used herein, refers to an alkyl group attached to the precursor molecular moiety through an oxygen atom, for example, the methoxy group (-OCH3). For example, "C1-3 alkoxy" represents alkoxy groups with one to three carbon atoms. The terms "fluoroalkoxy" and "-O (fluoroalkyl)" represent a fluoroalkyl group as defined above attached through an oxygen bond (-O-). For example, "C1-4 fluoroalkoxy" is intended to include C1, C2, C3, and C4 fluoroalkoxy groups. The term "alkoxyalkyl," as used herein, refers to an alkoxy group bonded through its oxygen atom to an alkyl group, which is bonded to the parent molecular moiety through a carbon atom, for example, a methoxymethyl group (-CH2OCH3). For example, "C2-4 alkoxyalkyl" denotes alkoxyalkyl groups with two to four carbon atoms, such as -CH2OCH3, -CH2CH2OCH3, -CH2OCH2CH3, and -CH2CH2OCH2CH3. The term "cycloalkyl," as used herein, refers to a group obtained from a non-aromatic, monocyclic or polycyclic hydrocarbon molecule by the removal of a hydrogen atom from a carbon atom of the saturated ring. Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, and cyclohexyl. When numbers appear in a subscript after the symbol "C," the subscript more specifically defines the number of carbon atoms a particular cycloalkyl group may contain. For example, "C3-6 cycloalkyl" represents cycloalkyl groups with three to six carbon atoms. The phrase "pharmaceutically acceptable" is used in this document to refer to compounds, materials, compositions and / or dosage forms that, within the scope of sound medical judgment, are suitable for use in contact with the tissues of humans and animals without causing excessive toxicity, irritation, allergic reaction or other problems or complications proportionate to a reasonable risk / benefit ratio. Compounds of formula (I) can be provided as amorphous solids or crystalline solids. Freeze-drying can be used to provide compounds of formula (I) as amorphous solids. It should also be understood that solvates (e.g., hydrates) of compounds of formula (I) are also within the scope of this disclosure. The term "solvate" means a physical association of a compound of formula (I) with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain cases, the solvate may be isolated, for example, when one or more solvent molecules are incorporated into the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolable solvates. Examples of solvates include hydrates, ethanolates, methanolates, isopropanolates, acetonitrile solvates, and ethyl acetate solvates. Solvation methods are known in the art. Various forms of prodrugs are well known in the technique, which are described in Rautio, J. et al. Nature Review Drug Discover, 17, 559-587 (2018). Furthermore, compounds of formula (I), after preparation, can be isolated and purified to obtain a composition containing an amount by weight equal to or greater than 99% of a compound of formula (I), respectively ("substantially pure"), which is subsequently used or formulated as described herein. This document also includes such "substantially pure" compounds of formula (I) as part of this disclosure. "Stable compound" and "stable structure" are intended to include a compound that is robust enough to survive isolation to a useful degree of purity from a reaction mixture and formulation into an effective therapeutic agent. This disclosure is intended to include stable compounds."Therapeutically effective amount" is intended to include an amount of a compound of the present invention alone or an amount of the claimed combination of compounds or an amount of a compound of the present disclosure in combination with other active ingredients effective to act as a TLR9 inhibitor, or effective to treat or prevent disorders associated with a fibrotic disease or disorder, bile acid dysregulation, such as pathological fibrosis. As used herein, "treat" or "treatment" covers the treatment of a pathological condition in a mammal, particularly a human, and includes: (a) preventing the occurrence of the pathology in a mammal, particularly when such mammal has a predisposition to the pathology but has not yet been diagnosed with it; (b) inhibiting the pathology, i.e., stopping its development; and / or (c) alleviating the pathology, i.e., causing the regression of the pathology. The compounds of the present disclosure and invention are intended to include all isotopes of the atoms appearing in the present compounds. Isotopes include atoms that have the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium (D) and tritium (T). Carbon isotopes include 13C and 14C. Generally, isotopically labeled compounds of the invention can be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using a suitable isotopically labeled reagent instead of an unlabeled reagent. For example, methyl (-CH3) also includes deuterated methyl groups such as -CD3. Utility The compounds disclosed are useful for inhibiting the TLR9 receptor. It should be understood, even if not explicitly stated herein, that methods for treating a disease, disorder, or condition refer to a substance or composition for use in such method. One instance of the disclosure (not claimed as such) provides a method for treating a disease, disorder, or condition associated with dysregulation of bile acids in a patient in need of such treatment, and the method comprises administering a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable stereoisomer, tautomer, or salt or solvate thereof, to the patient. One instance of the disclosure (not claimed as such) provides a method for treating a disease, disorder, or condition associated with TLR9 receptor activity in a patient in need of such treatment comprising administering a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable stereoisomer, tautomer, or salt or solvate thereof, to the patient. In a method for treating a disease, disorder, or condition, a patient in need of such treatment may be administered a therapeutically effective amount of at least one of the compounds in this disclosure, alone or, optionally, in combination with another compound in this disclosure and / or at least one other type of therapeutic agent. One instance of the disclosure (not claimed as such) provides a method for causing an agonizing effect of the TLR9 receptor in a patient comprising administering a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable stereoisomer, tautomer, or salt or solvate thereof, to the patient. Diseases, disorders, or conditions associated with TLR9 dysfunction include pathological fibrosis, cancer, inflammatory disorders, metabolic disorders, or cholestatic disorders. A compound of the invention, or a pharmaceutical composition of the invention, is provided herein for use in the treatment of pathological fibrosis. The disease, disorder, or condition to be treated under this disclosure may be associated with fibrosis, including hepatic, biliary, renal, cardiac, dermal, ocular, and pancreatic fibrosis. In other cases, the disease, disorder, or condition to be treated in accordance with this disclosure may be associated with cell proliferation disorders, such as cancer. For example, cancer may include solid tumor growth or neoplasia. In another example, cancer may include tumor metastasis. In some examples, cancer may be of the liver, gallbladder, small intestine, large intestine, kidney, prostate, bladder, blood, bone, brain, breast, central nervous system, cervix, colon, endometrium, esophagus, genitals, genitourinary tract, head, larynx, lung, muscle tissue, neck, oral or nasal mucosa, ovary, pancreas, skin, spleen, stomach, testicle, or thyroid. In other examples, cancer may be a carcinoma, sarcoma, lymphoma, leukemia, melanoma, mesothelioma, multiple myeloma, or seminoma. Examples of diseases, disorders, or conditions associated with FXR activity that may be prevented, modulated, or treated in accordance with this disclosure include, but are not limited to, transplant injection, fibrotic disorders (e.g., liver fibrosis, kidney fibrosis), inflammatory disorders (e.g., acute hepatitis, chronic hepatitis, non-alcoholic steatohepatitis (NASH), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD)), as well as cell proliferation disorders (e.g., cancer, myeloma, fibroma, hepatocellular carcinoma, colorectal cancer, prostate cancer, leukemia, Kaposi's sarcoma, solid tumors). Fibrotic disorders, inflammatory disorders, and cell proliferation disorders that are suitable for prevention or treatment by the compounds in this disclosure include, but are not limited to, non-alcoholic fatty liver disease (NAFLD), alcoholic or non-alcoholic steatohepatitis (NASH), acute hepatitis, chronic hepatitis, hepatic cirrhosis, primary biliary cirrhosis, primary sclerosing cholangitis, drug-induced hepatitis, biliary cirrhosis, portal hypertension, regenerative failure, hepatic hypofunction, hepatic blood flow disorder, nephropathy, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), abnormal pancreatic secretion, benign prostatic hyperplasia, neuropathic bladder disease, diabetic nephropathy, focal segmental glomerulosclerosis, IgA nephropathy, drug- or transplant-induced nephropathy, autoimmune nephropathy, lupus nephritis, and hepatic fibrosis.renal fibrosis, chronic kidney disease (CKD), diabetic kidney disease (DKD), skin fibrosis, keloids, systemic sclerosis, scleroderma, virus-induced fibrosis, idiopathic pulmonary fibrosis (IPF), interstitial lung disease, nonspecific interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP), radiation-induced fibrosis, familial pulmonary fibrosis, airway fibrosis, chronic obstructive pulmonary disease (COPD), spinal cord tumor, herniated intervertebral disc, spinal canal stenosis, heart failure, cardiac fibrosis, vascular fibrosis, perivascular fibrosis, foot-and-mouth disease, cancer, myeloma, fibroma, hepatocellular carcinoma, colorectal cancer, prostate cancer, leukemia, chronic lymphocytic leukemia, Kaposi's sarcoma, solid tumors, stroke, cerebral hemorrhage, neuropathic pain, peripheral neuropathy, age-related macular degeneration (AMD) glaucoma,Ocular fibrosis, corneal scarring, diabetic retinopathy, proliferative vitreoretinopathy (PVR), scarring from glaucoma filtration surgery, cicatricial pemphigoid, Crohn's disease, or systemic lupus erythematosus; keloid formation as a result of abnormal wound healing; fibrosis occurring after organ transplantation, myelofibrosis, and fibromas. This disclosure describes a method for treating a fibrotic disorder, an inflammatory disorder, or a cell proliferation disorder, comprising administering to a patient in need of such treatment a therapeutically effective amount of at least one of the compounds in this disclosure, alone or, optionally, in combination with another compound in this disclosure and / or at least one other type of therapeutic agent. In another instance, this disclosure provides a compound of this disclosure for use in therapy. For example, a compound in this disclosure may be used in therapy for the treatment of a fibrotic disorder, an inflammatory disorder, or a cellular proliferative disorder. A method for the treatment of a fibrotic disorder, an inflammatory disorder, or a cell proliferation disorder according to this disclosure may comprise administering to a patient in need a therapeutically effective amount of a first and second therapeutic agent, wherein the first therapeutic agent is a compound of this disclosure. In another embodiment, the present disclosure describes a combined preparation of a compound of the present invention and additional therapeutic agent(s) for simultaneous, separate, or sequential use in therapy. The combined preparation of a compound from this disclosure and additional therapeutic agent(s) may be for simultaneous, separate, or sequential use in the treatment of a fibrotic disorder, an inflammatory disorder, or a proliferative cell disorder. The compounds in this disclosure may be used in combination with additional therapeutic agent(s), such as one or more antifibrotic and / or anti-inflammatory therapeutic agents. Additional therapeutic agents used in combination pharmaceutical compositions, combined methods, or combined uses may be selected from one or more, preferably from one to three, of the following therapeutic agents: TGFP receptor inhibitors (e.g., galunisertib), TGFP synthesis inhibitors (e.g., pirfenidone), vascular endothelial growth factor (VEGF) inhibitors, platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) receptor kinases (e.g., nintedanib), humanized anti-integrin avP6 monoclonal antibody (e.g., 3G9), recombinant human pentraxin-2, recombinant human serum amyloid P, recombinant human antibody against TGFP-1, -2, and -3, endothelin receptor antagonists (e.g., macitentan), interferon gamma, c-Jun amino-terminal kinase inhibitor (JNK) (for example, 4-[[9-[ (3S) - tetrahyd dro-3-furany 1.- 8-[ (2, 4,6-trifluorophenyl)amino]-97 / -purin-2-yl | amino]-trans cyclohexane1, 3-pentylbenzeneacetic acid (PBI-4050), manganese(III)-containing tetra-substituted porphyrin derivative, eotaxin-2-directed monoclonal antibody, interleukin-13 (IL-13) antibody (e.g., lebrikizumab, tralokinumab), bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13), NK1 tachykinin receptor agonist (e.g., Sar9, Met(O2)11-Substance P), Cintredekin Besudotox, human recombinant DNA derivative, IgG1 kappa monoclonal antibody against connective growth factor, and fully human IgG1 kappa antibody selective for CC2 chemokine ligand (e.g., carlumab, CCX140), antioxidants (e.g., N-acetylcysteine), phosphodiesterase 5 (PDE5) inhibitors (e.g., sildenafil), agents for the treatment of obstructive airway diseases such as muscarinic antagonists (e.g.,tiotropium, ipratropium bromide), adrenergic agonists 32 (e.g., salbutamol, salmeterol), corticosteroids (e.g., triamcinolone, dexamethasone, fluticasone), immunosuppressive agents (e.g., tacrolimus, rapamycin, pimecrolimus) and therapeutic agents useful for the treatment of fibrotic conditions, such as hepatic, biliary and renal fibrosis, non-alcoholic fatty liver disease (NALFD), non-alcoholic steatohepatitis (NASH), cardiac fibrosis, idiopathic pulmonary fibrosis (IPF) and systemic sclerosis. Therapeutic agents useful for the treatment of such fibrotic conditions include, but are not limited to, FXR agonists (e.g., oca, GS-9674 and LJN452), LOXL2 inhibitors (e.g., simtuzumab), LPA1 antagonists (e.g., BMS-986020 and SAR 100842), PPAR modulators (e.g., elafibrinor, pioglitazone and saroglitazar, IVA337), SSAO / VAP-1 inhibitors (e.g., PXS-4728A and SZE5302),ASK-1 inhibitors (e.g., GS-4997 or selonsertib), ACC inhibitors (e.g., CP-640186 and NDI-010976 or GS-0976), FGF21 mimetics (e.g., LY2405319 and BMS-986036), caspase inhibitors (e.g., emricasan), N0X4 inhibitors (e.g., GKT137831), MGAT2 inhibitor (e.g., BMS-963272), aV integrin inhibitors (e.g., abituzumab), and bile acid / fatty acid conjugates (e.g., aramchol). FXR agonists of various embodiments of the present invention can also be used in combination with one or more therapeutic agents such as CCR2 / 5 inhibitors (e.g., cenicriviroc), galectin-3 inhibitors (e.g., TD-139, GR-MD-02), leukotriene receptor antagonists (e.g., tipelukast, montelukast), SGLT2 inhibitors (e.g., dapagliflozin, remogliflozin), GLP-1 receptor agonists (e.g., liraglutide and semaglutide), FAK inhibitors (e.g., GSK-2256098),CB1 inverse agonists (e.g., JD-5037), CB2 agonists (e.g., APD-371 and JBT-101), autotaxin inhibitors (e.g., GLPG1690), prolyl tRNA synthetase inhibitors (e.g., halofugenone), FPR2 agonists (e.g., ZK-994), and THR agonists (e.g., MGL:3196). In another embodiment, the additional therapeutic agents used in combination pharmaceutical compositions, combined methods, or combined uses are selected from one or more, preferably from one to three, immunologic agents, such as alemtuzumab, atezolizumab, ipilimumab, nivolumab, ofatumumab, pembrolizumab, and rituximab. When the terms "TLR9-associated condition" or "TLR9-associated disease or disorder" are used herein, each is intended to encompass all of the above-identified conditions as repeated in their entirety, as well as any other condition that is affected by TLR9 inhibition. The aforementioned therapeutic agents, when used in combination with the compounds described herein, may be used, for example, in the amounts indicated in the Physicians' Desk Reference (PDR) or as otherwise determined by a person skilled in the art. In the methods described herein, such other therapeutic agent(s) may be administered before, during, or after the administration of the compounds described herein. This disclosure also describes pharmaceutical compositions capable of treating conditions associated with TLR9. The compositions described herein may contain other therapeutic agents as described above and may be formulated, for example, using conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type suitable to the desired mode of administration (e.g., excipients, binders, preservatives, stabilizers, flavorings, etc.) in accordance with techniques such as those well known in the art of pharmaceutical formulation. Accordingly, this disclosure also includes compositions comprising one or more compounds of formula (I) and a pharmaceutically acceptable carrier. A "pharmaceutically acceptable carrier" refers to means generally accepted in the art for the administration of biologically active agents to animals, particularly mammals. Pharmaceutically acceptable carriers are formulated according to a number of factors well within the scope of those skilled in the art. These include, but are not limited to, the type and nature of the active agent to be formulated; the subject to whom the composition containing the agent is to be administered; the intended route of administration of the composition; and the intended therapeutic indication. Pharmaceutically acceptable carriers include both aqueous and non-aqueous liquid media, as well as a variety of solid and semi-solid dosage forms. Such carriers may include a number of different ingredients and additives in addition to the active agent. These additional ingredients are included in the formulation for a variety of reasons, such as stabilization of the active agent, binding, etc., well known to those skilled in the art.Descriptions of suitable pharmaceutically acceptable carriers, and factors involved in their selection, can be found in a variety of readily available sources such as, for example, Remington: The Science and Practice of Pharmacy, 22nd edition (2013). Compounds according to formula (I) can be administered by any means suitable for the condition to be treated, which may depend on the need for site-specific treatment or the amount of compound of formula (I) to be administered. The compounds of formula (I) can be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to that route and at a dose effective for the desired treatment. The compounds and compositions of this disclosure can, for example, be administered orally, via mucosal routes, or parenterally, including intravascular, intravenous, intraperitoneal, subcutaneous, intramuscular, and intrasternal routes, in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. For example, the pharmaceutical carrier may contain a mixture of mannitol or lactose and microcrystalline cellulose. The mixture may contain additional components such as a lubricating agent, for example, magnesium stearate, and a disintegrating agent such as crospovidone.The carrier mixture can be filled into a gelatin capsule or compressed into a tablet. The pharmaceutical composition can be administered as an oral dosage form or as an infusion, for example. For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, liquid capsule, suspension, or liquid. The pharmaceutical composition is preferably manufactured as a dosage unit containing a particular amount of the active ingredient. For example, the pharmaceutical composition may be provided as a tablet or capsule comprising an amount of active ingredient in the range of approximately 0.1 to 1000 mg, preferably from approximately 0.25 to 250 mg, and more preferably from approximately 0.5 to 100 mg. An appropriate daily dose for a human or other mammal may vary widely depending on the patient's condition and other factors, but can be determined using routine methods. Any pharmaceutical composition covered by this document may, for example, be administered orally by any acceptable and suitable oral preparation. Examples of oral preparations include, but are not limited to, tablets, lozenges, suckling pills, aqueous and oily suspensions, dispersible powders or granules, emulsions, hard and soft capsules, liquid capsules, syrups, and elixirs. Pharmaceutical compositions intended for oral administration may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions intended for oral administration. In order to provide pharmaceutically palatable preparations, a pharmaceutical composition as disclosed may contain at least one agent selected from among sweeteners, flavoring agents, coloring agents, demulcents, antioxidants, and preservatives. A tablet may, for example, be prepared by mixing at least one compound of formula (I) with at least one pharmaceutically acceptable, non-toxic excipient suitable for tablet manufacture. Illustrative excipients include, but are not limited to, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, and sodium phosphate; granulating and disintegrating agents such as microcrystalline cellulose, croscarmellose sodium, maize starch, and alginic acid; binding agents such as starch, gelatin, polyvinylpyrrolidone, and gum arabic; and lubricating agents such as magnesium stearate, stearic acid, and talc.In addition, a tablet may be uncoated or coated using techniques known to mask the unpleasant taste of a drug or to delay the disintegration and absorption of the active ingredient in the gastrointestinal tract, thereby prolonging the effects of the active ingredient. Examples of water-soluble taste-masking materials include, but are not limited to, hydroxypropyl methylcellulose and hydroxypropyl cellulose. Examples of time-delaying materials include, but are not limited to, ethyl cellulose and cellulose acetate butyrate. Hard gelatin capsules can, for example, be prepared by mixing at least one compound of formula (I) with at least one inert solid diluent, such as, for example, calcium carbonate; calcium phosphate and kaolin. Soft gelatin capsules can, for example, be prepared by mixing at least one compound of formula (I) with at least one water-soluble carrier, such as, for example, polyethylene glycol, and at least one oily medium, such as, for example, peanut oil, liquid paraffin, and olive oil. An aqueous suspension can be prepared, for example, by mixing at least one compound of formula (I) with at least one excipient suitable for the manufacture of an aqueous suspension. Excipients suitable for the manufacture of an aqueous suspension include, but are not limited to, suspending agents such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, alginic acid, polyvinylpyrrolidone, tragacanth gum, and gum arabic; dispersing or wetting agents such as a naturally occurring phosphatide, such as lecithin; condensation products of alkylene oxides with fatty acids, such as polyoxyethylene stearate; and condensation products of ethylene oxide with long-chain aliphatic alcohols, such as heptadecaethylene-oxycetanol.Ethylene oxide condensation products with partial esters derived from fatty acids and hexitol, such as, for example, polyoxyethylene sorbitol monooleate, and ethylene oxide condensation products with partial esters derived from fatty acids and hexitol anhydrides, such as, for example, polyethylene sorbitan monooleate. An aqueous suspension may also contain at least one preservative, such as, for example, ethyl and n-propyl p-hydroxybenzoate; at least one colorant; at least one flavoring agent; and / or at least one sweetening agent, including, but not limited to, for example, sucrose, saccharin, and aspartame. Oil suspensions can, for example, be prepared by suspending at least one compound of formula (I) either in a vegetable oil, such as, for example, peanut oil; olive oil; sesame oil and coconut oil or in a mineral oil, such as, for example, liquid paraffin. An oil suspension may also contain at least one thickening agent, such as, for example, beeswax, hard paraffin, and cetyl alcohol. To provide a palatable oil suspension, at least one of the sweetening agents described earlier in this document and / or at least one flavoring agent may be added. An oil suspension may further contain at least one preservative, including, but not limited to, an antioxidant such as, for example, butylated hydroxyanisole and alpha-tocopherol. Dispersible powders and granules may, for example, be prepared by mixing at least one compound of formula (I) with at least one dispersing and / or wetting agent; at least one suspending agent; and / or at least one preservative. Suitable dispersing agents, wetting agents, and suspending agents are as described above. Preservatives include, but are not limited to, antioxidants, such as ascorbic acid. In addition, dispersible powders and granules may also contain at least one excipient, including, but not limited to, sweeteners, flavoring agents, and coloring agents. An emulsion of at least one compound of formula (I) may, for example, be prepared as an oil-in-water emulsion. The oil phase of emulsions comprising compounds of formula (I) may be constituted from known ingredients in a known manner. The oil phase may be provided by, but is not limited to, for example, a vegetable oil, such as olive oil and peanut oil; a mineral oil, such as liquid paraffin; and mixtures thereof. Although the phase may comprise simply an emulsifier, it may also comprise a mixture of at least one emulsifier with a fat or an oil, or with both a fat and an oil.Suitable emulsifying agents include, but are not limited to, for example, naturally occurring phosphatides, such as soybean lecithin; esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate; and condensation products of partial esters with ethylene oxide, such as polyoxyethylsorbitan monooleate. Preferably, a hydrophilic emulsifier is included along with a lipophilic emulsifier that acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s), with or without the stabilizer(s), constitute what is known as the emulsifying wax, and the wax, together with the oil and fat, forms what is known as the emulsifying ointment base, which constitutes the dispersed oil phase of cream formulations.An emulsion may also contain a sweetening agent, a flavoring agent, a preservative, and / or an antioxidant. Emulsifiers and emulsion stabilizers suitable for use in the formulation of this disclosure include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, sodium lauryl sulfate, glyceryl distearate alone or with a wax or other materials well known in the art. The compounds of formula (I) may, for example, also be administered intravenously, subcutaneously, and / or intramuscularly by any pharmaceutically acceptable and suitable injectable form. Examples of injectable forms include, but are not limited to, sterile aqueous solutions comprising acceptable vehicles and solvents, such as water, Ringer's solution, and isotonic sodium chloride solution; sterile oil-in-water microemulsions; and aqueous or oily suspensions. Parenteral formulations may be in the form of sterile, isotonic, aqueous or non-aqueous solutions or suspensions for injection.These solutions and suspensions can be prepared from sterile powders or granules, using one or more of the carriers or diluents mentioned, for use in formulations for oral administration, or using other suitable dispersing or wetting agents and suspending agents. The compounds can be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, tragacanth gum, and / or various buffers. Other adjuvants and modes of administration are well known in pharmaceutical practice. The active ingredient can also be administered by injection in the form of a composition with suitable carriers, including saline solution, dextrose, or water, or with cyclodextrin (i.e., Captisol), co-solvent solubilization (i.e., propylene glycol), or micellar solubilization (i.e., Tween 80). A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic, parenterally acceptable diluent or solvent, for example, a solution in 1,3-butanediol. Acceptable vehicles and solvents include water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, non-volatile oils are commonly used as solvents or suspension mediums. Any mild, non-volatile oil, including synthetic mono- or diglycerides, may be used for this purpose. Furthermore, fatty acids, such as oleic acid, are also used in the preparation of injectables. A sterile oil-in-water microemulsion for injection can, for example, be prepared by 1) dissolving at least one compound of formula (I) in an oily phase, such as, for example, a mixture of soybean seed oil and lecithin; 2) combining the formula (I) containing the oily phase with a mixture of water and glycerol; and 3) processing the combination to form a microemulsion. A sterile aqueous or oily suspension can be prepared according to methods already known in the art. For example, a sterile aqueous solution or suspension can be prepared with a parenterally acceptable, non-toxic diluent or solvent, such as, for example, 1,3-butanediol, and a sterile oily suspension can be prepared with an acceptable, non-toxic, sterile solvent or suspension medium, such as, for example, sterile fixed oils, for example, synthetic mono- or diglycerides and fatty acids, such as, for example, oleic acid. The carriers, adjuvants, and vehicles that may be used in the pharmaceutical compositions of this disclosure include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-alpha-tocopherol succinate polyethylene glycol 1000, surfactants used in pharmaceutical dosage forms such as Tweens, polyethoxylated castor oil such as CREMOPHOR surfactant (BASF), or other similar polymeric delivery matrices, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, mixtures of partial glycerides of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, trisilicate magnesium, polyvinylpyrrolidone, cellulose-based substances,Polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene block polymers, polyoxypropylene, polyethylene glycol, and lanolin. Cyclodextrins such as alpha, beta, and gamma-cyclodextrin or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-cyclodextrins or other solubilized derivatives, can also be advantageously used to enhance the release of compounds from the formulations described herein. The pharmaceutically active compounds in this disclosure can be processed according to conventional pharmacy methods to produce medicinal agents for administration to patients, including humans and other mammals. The pharmaceutical compositions may be subjected to conventional pharmaceutical operations such as sterilization and / or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers, etc. Tablets and lozenges may be further prepared with enteric coatings. Such compositions may also include adjuvants, such as wetting agents, sweeteners, flavorings, and perfumes. The amounts of compounds administered and the dosage regimen for treating a disease with the compounds and / or compositions in this disclosure depend on a variety of factors, including the subject's age, weight, sex, medical condition, type of disease, severity of disease, route and frequency of administration, and the particular compound used. Therefore, the dosage regimen may vary widely but can be routinely determined using standard methods. A daily dose of approximately 0.001 to 100 mg / kg of body weight, preferably between approximately 0.0025 and approximately 50 mg / kg of body weight, and most preferably between approximately 0.005 to 10 mg / kg of body weight, may be appropriate. The daily dose may be administered in one to four doses per day. Other dosage schedules include one dose per week and one dose per two-day cycle. For therapeutic purposes, the active compounds in this disclosure are normally combined with one or more adjuvants appropriate for the indicated route of administration. If administered orally, the compounds may be mixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, alkyl cellulose esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, gum arabic, sodium alginate, polyvinylpyrrolidone, and / or polyvinyl alcohol, and then compressed or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation, which may be provided in a dispersion of the active compound in hydroxypropyl methylcellulose. The pharmaceutical compositions of this disclosure comprise at least one compound of formula (I) and, optionally, an additional agent selected from any pharmaceutically acceptable carrier, adjuvant, and carrier.The alternative compositions in this disclosure comprise a compound of formula (I) described herein, or a prodrug thereof, and a pharmaceutically acceptable excipient, adjuvant, or carrier. This disclosure also covers a manufactured article. As used herein, the manufactured article is intended to include, but is not limited to, kits and packages. The manufactured article of this disclosure comprises: (a) a first container; (b) a pharmaceutical composition located within the first container, wherein the composition comprises: a first therapeutic agent comprising: a compound of this disclosure or a pharmaceutically acceptable salt form thereof; and (c) a package insert indicating that the pharmaceutical composition can be used for the treatment of a cardiovascular disorder, diuresis, and / or natriuresis. In another embodiment, the package insert indicates that the pharmaceutical composition can be used in combination (as defined above) with a second therapeutic agent for the treatment of a cardiovascular disorder, diuresis, and / or natriuresis.The manufactured article may further comprise: (d) a second container, wherein components (a) and (b) are located within the second container and component (c) is located either within or outside the second container. Located within the first and second containers means that the respective container holds the article within its boundaries. The first container is a receptacle used to hold a pharmaceutical composition. This container can be for manufacturing, storage, shipping and / or individual / bulk sale. The first container is intended to cover a bottle, jar, vial, flask, syringe, tube (for example, for a cream preparation) or any other container used to manufacture, contain, store or distribute a pharmaceutical product. The second container is one used to hold the first container and, optionally, the package insert. Examples of the second container include, but are not limited to, boxes (e.g., cardboard or plastic), crates, cartons, bags (e.g., paper or plastic bags), sachets, and sacks. The package insert may be physically attached to the outside of the first container by tape, glue, staples, or another method of attachment, or it may be inside the second container without any physical means of attachment to the first container. Alternatively, the package insert may be located on the outside of the second container. When located on the outside of the second container, it is preferred that the package insert be physically attached by tape, glue, staples, or another method of attachment. Alternatively, it may be adjacent to or in contact with the outside of the second container without being physically attached. The package insert is a label, tag, marker, or other written sheet that provides information regarding the pharmaceutical composition inside the first container. The information listed will generally be determined by the regulatory agency governing the area where the manufactured product will be sold (for example, the U.S. Food and Drug Administration). Preferably, the package insert specifically describes the indications for which the pharmaceutical composition has been approved. The package insert may be made of any material on which a person can read the information contained therein or on it. Preferably, the package insert is a printable material (for example, paper, plastic, cardboard, foil, paper or plastic with adhesive backing, etc.) on which the desired information has been formed (for example, printed or applied). Preparation methods The compounds in this disclosure can be prepared in various ways well known to a person skilled in the art of organic synthesis. These compounds can be synthesized using the methods described below, in conjunction with other known synthetic methods in the art of synthetic organic chemistry, or variations thereof, as deemed appropriate by those skilled in the art. Preferred methods include, but are not limited to, those described below. The reactions and techniques described in this section are carried out in solvents appropriate for the reagents and materials used and are suitable for the transformations performed. Furthermore, in the description of the synthetic methods below, it is understood that all proposed reaction conditions, including the choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment, and preparation procedures, are selected as standard conditions for that reaction and should be readily recognizable by someone skilled in the art. Someone skilled in the art of organic synthesis will understand that the functionality present in various portions of the molecule must be compatible with the proposed reagents and reactions.These restrictions on substituents compatible with the reaction conditions will be readily apparent to a person skilled in the art, and alternative methods must then be used. This will sometimes require an evaluation to modify the order of the synthesis steps or to select one particular process scheme over another to obtain a desired compound from this disclosure. It will also be recognized that another major consideration when planning any synthetic route in this field is the judicious choice of the protecting group used to shield reactive functional groups present in the compounds described herein. An authoritative description outlining the many alternatives for the skilled practitioner is Greene et al. (Protective Groups in Organic Synthesis, Third Edition, Wiley and Sons (1999)). Scheme 1 Scheme 1 describes the synthesis of compounds of formula II-A and II-B, a subset of formula II. The term "halo" in this scheme refers to any halogen that a person skilled in the art would consider suitable for achieving the desired transformation. The term "PG" refers to any suitable amino protecting group, such as an alkyl carbamate, alkylamide, or alkyl group. Ring A, as shown in formula II-A and II-B, is substituted at position 6 with the imidazo[1,2-a]pyridine ring; however, a person skilled in the art can easily modify this synthetic scheme. The compound can be reacted with alpha-halo-ketone Ib in any typical reaction solvent (e.g., EtOH, DMF, DMSO) with or without heating. The reaction can be carried out in the presence of a base such as potassium carbonate or sodium bicarbonate, but it is not required. Compound Ic can be coupled with boronate ester Id under standard Suzuki coupling conditions. The resulting alkene can be reduced by catalytic hydrogenation using a catalyst such as Pd or Pt. The protecting group PG can be removed by a person skilled in the art using appropriate reagents and conditions. Reductive amination of amine If with ketone Ig or Ih can be achieved with a reducing agent such as sodium triacetoxyborohydride or sodium cyanoborohydride, with or without an acid catalyst (i.e., AcOH), to give compounds of formula II-A and II-B. Scheme 2 Scheme 2 describes the synthesis of compounds of formula III-A and III-B, a subset of formula III. The term "PG" refers to any suitable amino protecting group, such as alkyl carbamate, alkylamide, or alkyl. Ring A, as shown in formula III-A and III-B, is substituted at position 6 of the 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine ring; however, a person skilled in the art can easily modify this synthetic scheme. The compound le (see Scheme 1) can be reduced by catalytic hydrogenation using a catalyst such as Pd or Pt, at 1 atm or higher. Reaction times may vary, but are usually greater than 24 h. Reductive amination of amine 2a with ketone 2b or 2c can be achieved with a reducing agent such as sodium triacetoxyborohydride or sodium cyanoborohydride, with or without an acid catalyst (i.e., AcOH), to give compounds of formula III-A and III-B. Examples The compounds of the present disclosure and invention, and the intermediate products used in the preparation of the compounds of the present disclosure and invention, can be prepared by the procedures shown in the following examples and related procedures. The methods and conditions used in these examples, and the actual compounds prepared in these examples, are not intended to be limiting, but are intended to demonstrate how the compounds of the present disclosure and invention can be prepared. The starting materials and reagents used in these examples, when not prepared by a procedure described herein, are generally commercially available or reported in the chemistry literature, or can be prepared using procedures described in the chemistry literature. The disclosure is further defined in the following examples. It should be understood that the examples are provided for illustrative purposes only.Based on the foregoing analysis and examples, a person skilled in the art can determine the essential characteristics of the disclosure and can make various changes and modifications to adapt the disclosure to different uses and conditions. As a result, the present invention is not limited by the illustrative examples set forth below, but is defined by the appended claims. In the given examples, the expression "dried and concentrated" generally refers to drying a solution in an organic solvent, either on sodium sulfate or magnesium sulfate, followed by filtration and removal of the solvent from the filtrate (generally at reduced pressure and at a temperature suitable for the stability of the material being dried and concentrated). Chemical names were determined using ChemDraw Ultra, version 9.0.5 (CambridgeSoft). The following abbreviations are used: aqueous acid saturated aqueous sodium chloride brine DCM dichloromethane DMAP dimethylaminopyridine DMF N,N-dimethylformamide DMSO: dimethyl sulfoxide EtOAc ethyl acetate EtOH ethanol g gram(s) h hour(s) High-performance liquid chromatography by HPLC Liquid chromatography LC-MS-mass spectroscopy MeCN acetonitrile MeOH methanol petroleum ether petroleum ether TEA Trielamin TFA: trifluoroacetic acid THF: tetrahydrofuran Preparation All reagents purchased from commercial sources were used without further purification unless otherwise noted. All reactions involving air- or moisture-sensitive reagents were performed under an inert atmosphere. Proton magnetic resonance spectra were recorded on a Bruker Avance 400 or JEOL Eclipse 500 spectrometer. The CL-MS analyses were performed on the Waters Acquity UPLC system coupled with Waters TUV and SQ mass detector (column: BEH C 182, 1 x 50 mm; mobile phase A: water with 0.05% TFA; mobile phase B: acetonitrile with 0.05% TFA; gradient: 2-98% of B for 1.6 minutes; flow: 0.8 ml / min); HPLC analyses were performed on a Shimadzu LC10-AT HPLC system coupled with an SPD-10AV UV detector (YMC S5 Combiscreen ODS 4 column, 6 x 50 mm; mobile phase A: 5:95 acetonitrile:water with 0.1% TFA; mobile phase B: 95:5 acetonitrile:water with 0.1% TFA; gradient: 0-100% B for 40 minutes, then a 1-minute hold at 100% B; flow: 1 ml / min); preparative HPLC purifications were performed on a Shimadzu LC-8 preparative HPLC system coupled with an SPD 20 UV detector. Detailed conditions are described in the experimental procedures. CL-EM Analytical Methods Method 1: Column: Waters XBridge l8, 2, 1 mm x 50 mm, 1.7 µm particles; mobile phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; mobile phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; temperature: 50 °C; gradient: 0% B to 100% B for 3 min, then a 0.50 min hold at 100% B; flow: 1 ml / min; detection: MS and UV (220 nm). Method 2: Column: Waters XBridge C 18, 2, 1 mm x 50 mm, 1.7 pm particles; mobile phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid; mobile phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid; temperature: 50 °C; gradient: 0% B to 100% B for 3 min, then a 0.50 min hold at 100% B; flow: 1 ml / min; detection: MS and UV (220 nm). Method 3: Column: Waters Acquity BEH C18, 2, 1 x 50 mm, 1.7 pm particles; mobile phase A: 5:95 MeOH:water with 10 mM ammonium acetate; mobile phase B: 95:5 MeOH:water with 10 mM ammonium acetate; temperature: 50 °C; gradient: 0% B to 100% B for 3 min, then a 0.50 min hold at 100% B; flow: 1 ml / min; detection: MS and UV (220, 254 nm). Method 4: Column: Waters Acquity BEH C18, 2, 1 x 50 mm, 1.7 pm particles; mobile phase A: 5:95 acetonitrile:water with 0.05% trifluoroacetic acid; mobile phase B: 95:5 acetonitrile:water with 0.05% trifluoroacetic acid; temperature: 50 °C; gradient: 0% B to 100% B for 3 min, then a hold of 0.50 min at 100% B; flow: 1 ml / min; detection: MS and UV (220, 254 nm). Method 5: Column: Waters Acquity BEH C18, 2, 1 x 50 mm, 1.7 pm particles; mobile phase A: 5:95 acetonitrile:water with 0.05% trifluoroacetic acid; mobile phase B: 95:5 acetonitrile:water with 0.05% trifluoroacetic acid; temperature: 60 °C; gradient: 2% B to 98% B for 1 min, then a hold of 0.50 min at 98% B; flow: 0.8 ml / min; detection: MS and UV (220 nm). Chiral analytical methods of CFS Method 1: Instrument: ShimadzuNexera UC CFS; Column: Chiral OD, 4, 6 x 100 mm, 5 microns; Mobile phase: 55% CO2 / 45% MeOH with 0.1% DEA; Flow conditions: 2 ml / min; Detector wavelength: 220 nm. SFC Method 2: Instrument: ShimadzuNexera UC SFC; Column: Chiral OD, 4, 6 x 100 mm, 5 microns; Mobile phase: 60% CO2 / 40% MeOH with 0.1% DEA; Flow conditions: 2 ml / min; Detector wavelength: 220 nm. SFC Method 3: Instrument: ShimadzuNexera UC SFC; Column: Chiral OD, 4, 6 x 100 mm, 5 microns; Mobile phase: 75% CO2 / 25% IPA-acetonitrile 50-50 with 0.1% DEA; Flow conditions: 2 ml / min; Detector wavelength: 220 nm. SFC Method 4: Instrument: ShimadzuNexera UC SFC; Column: OD chiral, 4, 6 x 100 mm, 5 microns; Mobile phase: 55% CO2 / 45% IPA with 0.1% DEA; Flow conditions: 2 ml / min; Detector wavelength: 220 nm. SFC Method 5: Instrument: Berger SFC; Column: OD chiral 4, 6 x 250 mm, 5 microns; Mobile phase: 70 / 30 CO2 / EtOH-0.1%DEA; Flow conditions: 4 ml / min; Detector wavelength: 220 nm. SFC Method 6: Instrument: Shimadzu Nexera UC SFC; Column: OD chiral, 4.6 x 100 mm, 5 microns; Mobile phase: 65% CO2 / 35% IPA with 0.6% DEA / 0.1% TFA; Flow conditions: 2 ml / min; Detector wavelength: 220 nm. SFC Method 7: Instrument: Shimadzu Nexera UC SFC; Column: Chiral OD, 4, 6 x 100 mm, 5 microns; Mobile phase: 80% CO2 / 20% MeOH with 0.1% DEA; Flow conditions: 2 ml / min; Detector wavelength: 220 nm. SFC Method 8: Instrument: Agilent SFC; Column: Chiralcel OD-H, 4.6 x 250 mm, 5 microns; Mobile phase: 55% CO2 / 40% MeOH-0, 1% DEA; Flow conditions: 2.0 ml / min, 120 bar, TA; Detector wavelength: 220 nm. SFC Method 9: Instrument: Agilent SFC; Column: Chiralcel OD-H, 4.6 x 250 mm, 5 microns; Mobile phase: 65% CO2 / 45% EtOH-0, 1% DEA; Flow conditions: 2.0 ml / min; Detector wavelength: 220 nm. Preparative HPLC Preparation Methods Method 1: Column: XBridge C 18, 200 mm x 19 mm, 5 pm particles; mobile phase A: 5:95 acetonitrile: ammonium acetate water; mobile phase B: 95:5 acetonitrile: ammonium acetate water; gradient: (variable; substrate dependent) %B for 20 minutes, then a 0 minute hold at 100% B; flow rate: 20 ml / min; column temperature: 25 °C. Fraction collection was triggered by MS and UV signals. Preparation method 2: Column: XBridge C 18, 200 mm x 19 mm, 5-pm particles; mobile phase A: 5:95 acetonitrile:water with 0.05% trifluoroacetic acid; mobile phase B: 95:5 acetonitrile:water with 0.05% trifluoroacetic acid; gradient: (variable; substrate-dependent) % B for 20 minutes, then a 0-minute hold at 100% B; flow rate: 20 ml / min; column temperature: 25 °C. Fraction collection was triggered by EM signals. Example 1 6-(1-cyclopropyl-[1,4-bipiperidin]-4-yl)-2-(3,4-dimethoxyphenyl)-8-methylimidazo[1,2-a]pyridine Step A. Intermediate Product 1 A. Preparation of 6-bromo-2-(3,4-dimethoxyphenyl)-8-methylimidazo[1,2-a]pyridine 5-Bromo-3-methylpyridin-2-amine (2.5 g, 13 mmol), 2-bromo-1-(3,4-dimethoxyphenyl)ethan-1-one (4.5 g, 17 mmol), and EtOH (50 mL) were added to a 250 mL round-bottom flask. The reaction mixture was stirred under reflux. After 18 h, a precipitate formed. The reaction mixture was cooled, stored at -20 °C for 1 h, and the precipitate was collected by vacuum filtration. The filter cake was washed with a minimal amount of ether, and the product was vacuum-dried to obtain the title compound (4.6 g, 13 mmol, 99% yield) as a toasted solid. 1H-NMR (500 MHz, methanol-d4) 8, 93-8, 88 (m, 1H) , 8, 41 (s, 1H) , 7, 92-7, 86 (m, 1H) , 7, 55 (s, 2H) , 7, 20-7, 16 (m, 1H) , 3, 98 (s, 3H) , 3, 94 (s, 3H) , 2, 76-2, 72 (m, 3H) . Analytical CL / MS (method 5) : Observed mass: 349.1; Retention time: 0.66 min. Step B. Intermediate Product 1B. Preparation of 4-(2-(3,4-dimethoxyphenyl)-8-methylimidazo[1,2-a]pyridin-6-yl)-3,6-dihydropyridine-1(2H)-tert-butyl carboxylate The intermediate product 1A (2.8 g, 8.0 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-tert-butyl carboxylate (3.0 g, 9.7 mmol), 1,4-dioxane (30 ml) were added to a 200 ml pear-shaped flask, followed by potassium phosphate (5.1 g, 24 mmol) dissolved in water (7 ml). The flask was evacuated and purged with MgSO4 (2x), then 1,1-bis(diphenylphosphino)ferrocene-palladium(II) dichloromethane dichloride complex (0.30 g, 0.37 mmol) was added. The vessel was evacuated, purged again, and stirred at 75 °C. After 18 h, the reaction mixture was cooled, diluted with water (200 mL), and extracted with EtOAc (2 x 100 mL). The organic phase was combined, washed with brine, dried over MgSO4, filtered, and concentrated. The residue was purified by ultrafast column chromatography (120 g silica gel cartridge; A = Hex, B = EtOAc; 30 min gradient; B from 0% to B from 100%; flow rate = 80 mL / min).The pure fractions were combined, concentrated, and vacuum dried to obtain the title compound (3.5 g, 7.8 mmol, 98% yield) as a pale yellow solid. 1H-NMR (500 MHz, methanol-d4) 8, 31-8, 27 (m, 1H), 8, 06 (s, 1H), 7, 62-7, 58 (m, 1H), 7, 51-7, 47 (m, 1H), 7, 33-7, 30 (m, 1H) , 7, 07-7, 02 (m, 1H) , 6, 30-6, 19 (m, 1H) , 4, 16-4, 09 (m, 2H) , 3, 96 (s, 3H) , 3, 90 (s, 3H) , 3, 71-3, 67 (m, 2H) , 2, 66-2, 61 (m, 3H) , 2, 59-2, 53 (m, 2H) , 1, 22 (s, 9H) . Analytical CL / EM (method 5) : Observed mass: 450, 4; Retention time: 0, 81 min. Step C. Intermediate Product 1C. Preparation of 4-(2-(3,4-dimethoxyphenyl)-8-methylimidazo[1,2-a]pyridin-6-yl)piperidine-1-carboxylate tert-butyl Intermediate product IB (3.5 g, 7.8 mmol) and MeOH (150 mL) were added to a 1 L round-bottom flask. The flask was evacuated and purged with N2, then Pd-C (5% on carbon) (1.7 g, 0.78 mmol) was added, and the reaction mixture was evacuated and purged again. The reaction mixture was stirred under hydrogen at 1 atm. After 1 h, 1H-NMR showed complete conversion of the starting material. The reaction mixture was filtered, the filtrate was concentrated, and the product was vacuum-dried to obtain the title compound (3.1 g, 6.9 mmol, 88% yield) as a pale yellow solid. (500 MHz, methanol-d6) 8, 19-8, 16 (m, 1H) , 8, 08 (s, 1H) , 7, 62-7, 58 (m, 1H) , 7, 51-7, 47 (m, 1H) , 7, 18-7, 14 (m, 1H) , 7, 07-7, 03 (m, 1H) , 4, 31-4, 22 (m, 2H) , 3, 96 (s, 3H) , 3, 90 (s, 3H) , 2, 98-2, 86 (m, 2H) , 2, 84-2, 72 (m, 1H) , 2, 62 (s, 3H), 1, 97-1, 88 (m, 2H), 1, 70-1, 59 (m, 2H), 1, 51 (s, 9H).CL / EM analytical (Method 5): Observed mass: 452.4; Retention time: 1.18 min. Step D. Intermediate Product 1D. Preparation of 2-(3,4-dimethoxyphenyl)-8-methyl-6-(piperidin-4-yl)imidazo[1,2-a]pyridine hydrochloride The intermediate product 1C (3.1 g, 6.9 mmol) was added to a 1 L round-bottom flask, along with a minimal amount of MeOH to solubilize it, followed by 4 M HCl in dioxane (150 mL). The reaction mixture was stirred. After 1 h, the solvent was concentrated and the residue was co-evaporated with toluene. The product was vacuum dried to obtain the title compound (2.1 g, 5.4 mmol, 78% yield) as a whitish solid. 1H-NMR (500 MHz, methanol-d4) 8, 60-8, 55 (m, 1H) , 8, 45-8, 40 (m, 1H) , 7, 75-7, 70 (m, 1H) , 7, 58-7, 53 (m, 2H) , 7, 20-7, 15 (m, 1H) , 3, 99 (s, 3H) , 3, 94 (s, 3H) , 3, 62-3, 57 (m, 2H) , 3, 28-3, 20 (m, 2H) , 3, 17-3, 11 (m, 1H) , 2, 74 (s, 3H) , 2, 28-2, 20 (m, 2H) , 2, 10-1, 98 (m, 2H) . Analytical CL / EM (Method 5) : Observed mass: 352.2; Retention time: 0.68 min. Step E. Preparation of example 1 The intermediate product 1D (70 mg, 0.18 mmol), 1-cyclopropylpiperidin-4-one (130 mg, 0.90 mmol), AcOH (0.011 ml, 0.20 mmol), DMF (2 ml), and MgSO4 (220 mg, 1.8 mmol) were added to a 40 ml vial. The reaction mixture was stirred for 20 min, then sodium triacetoxyborohydride (170 mg, 0.80 mmol) was added and the reaction mixture was stirred again. After 24 h, the reaction mixture was filtered and the filter cake was washed with 10% IPA / chloroform (20 ml). The filtrate was washed with 10% aqueous NaOH (10 mL), brine, dried over MgSO4, filtered, and concentrated. The crude material was purified by preparative HPLC (preparation method 1) to obtain the title compound (51 mg, 0.11 mmol, 60% yield).1H-RMN (500 MHz, DMSO-6) 8, 24-8, 21 (m, 1H) , 8, 19-8, 13 (m, 1H) , 7, 57-7, 52 (m, 1H) , 7, 51-7, 46 (m, 1H) , 7, 05-6, 99 (m, (m, 2H) , 1, 89-1, 81 (m, 2H) , 1, 80-1, 74 (m, 2H) , 1, 73-1, 62 (m, 2H) , 1, 62-1, 54 (m, 1H) , 1, 48-1, 36 (m, 2H) , 0, 45-0, 38 (m, 2H), 0, 33-0, 27 (m, 2H) (tres protones oscurecidos). CL / EM analítica (Método 1): Pureza: 99, 2%; Masa observada: 474, 91; Retention time: 1, 38 minutes. (Método 2): Pureza: 98, 9%; Masa observada: 475, 36; Retention time: 0, 99 min. Example 2 2- (3, 4-dimetoxifenil) -6- (1-isopropil-[1, 4-bipiperidin]-4-il) -8-metilimidazo[1, 2-a]piridina Example 2 was synthesized according to the general methods described for the preparation of Example 1 (step E), using intermediate 1D (70 mg, 0.18 mmol) as the starting material and substituting 1-isopropylpiperidin-4-one (130 mg, 0.90 mmol) where appropriate. The crude material was purified by preparative HPLC (preparation method 1) to obtain the title compound (52 mg, 0.11 mmol, 61% yield). 1H-NMR (500 MHz, DMSO-d6) 8, 24-8, 20 (m, 1H) , 8, 20-8, 13 (m, 1H) , 7, 57-7, 52 (m, 1H) , 7, 52-7, 47 (m, 1H) , 7, 06-6, 99 (m, 2H) , 3, 86 (s, 3H) , 3, 80 (s, 3H) , 3, 51-3, 44 (m, 1H) , 3, 06-2, 96 (m, 3H) , 2, 93-2, 85 (m, 1H) , 2, 41-2, 27 (m, 5H), 1, 92 (s, 3H) , 1, 87-1, 80 (m, 4H) , 1, 73-1, 61 (m, 2H) , 1, 60-1, 49 (m, 2H) , 1, 04 (da, .J=6, 4 Hz, 6H) (one obscured proton) . Analytical CL / EM (Method 1) : Purity: 100 %; Observed Mass: 477, 29; Retention Time: 1, 42 min.(Method 2): Purity: 100%; Observed mass: 477.03; Retention time: 0.97 min. Example 3 2-(3,4-dimethoxyphenyl)-6-(1-isobutyl-[1,4-bipiperidin]-4-yl)-8-methylimidazo[1,2-a]pyridine Example 3 was synthesized according to the general methods described for the preparation of Example 1 (step E), using intermediate 1D (70 mg, 0.18 mmol) as the starting material and substituting 1-isobutylpiperidin-4-one (140 mg, 0.90 mmol) where appropriate. The crude material was purified by preparative HPLC (preparation method 1) to obtain the title compound (52 mg, 0.11 mmol, 61% yield). 1H-NMR (500 MHz, DMSO-6) 8.58 (s, 1H) , 8.46 (sa, 1H) , 7.57 (sa, 2H) , 7.52-7.47 (m, 1H) , 7.17-7.13 (m, 1H) , 3.89 (s, 3H) , 3, 85 (s, 3H) , 3, 74-3, 60 (m, 1H) , 3, 25-3, 15 (m, 1H) , 3, 09-2, 91 (m, 4H) , 2, 64 (s, 3H) , 2, 36-2, 27 (m, 2H) , 2, 23-1, 96 (m, 8H) , 1, 01-0, 95 (m, 6H) (5 obscured protons) . Analytical CL / EM (Method 1): Purity: 97%; Observed mass: 491.18; Retention time: 1.51 min. (Method 2): Purity: 100%; Observed mass: 491.27; Retention time: 0.94 min. Example 4 6-(1-cyclopropyl-[1, 4-bipiperidin]-4-yl)-2-(3-fluoro-4-methoxyphenyl)-8-methylimidazo[1, 2-a]pyridine Etapa A. Producto intermedio 4 A. Preparación de 6-bromo-2-(3-fluoro-4-methoxyphenyl)-8-methylimidazo[1, 2-a]pyridine Intermediate product 4A was prepared according to the general methods described for the synthesis of intermediate product 1A, starting from 5-bromo-3-methylpyridin-2-amine (0.76 g, 4.1 mmol) and substituting 2-bromo-1-(3-fluoro-4-methoxyphenyl)ethan-1-one (1.0 g, 4.1 mmol) when appropriate to obtain the title compound (1.0 g, 3.0 mmol, 73% yield) as a roasted solid. 1H-NMR (500 MHz, DMSO-6) 9, 08-9, 02 (m, 1H) , 8, 59 (s, 1H) , 7, 96-7, 90 (m, 1H) , 7, 89-7, 80 (m, 2H) , 7, 44-7, 37 (m, 1H) , 2, 64 (s, 3H) . Analytical CL / EM (Method 5) : Observed mass: 337, 0; Retention time: 0, 75 min. Step B. Intermediate Product 4B. Preparation of 4-(2-(3-fluoro-4-methoxyphenyl)-8-methylimidazo[1,2-a]pyridin-6-yl)-3,6-dihydropyridine-1(2H)-tert-butyl carboxylate Intermediate 4B was prepared according to the general methods described for the synthesis of intermediate 1B, using intermediate 4A (500 mg, 1.5 mmol) as the starting material to obtain the title compound (480 mg, 1.1 mmol, 73% yield) as a pale yellow solid. 1H-NMR (500 MHz, methanol-d4) 8, 32-8, 27 (m, 1H) , 8, 09-8, 05 (m, 1H) , 7, 72-7, 66 (m, 2H) , 7, 36-7, 30 (m, 1H) , 7, 21-7, 14 (m, 1H) , 6, 27-6, 20 (m, 1H) , 4, 19-4, 08 (m, 2H), 3, 94 (s, 3H), 3, 73-3, 65 (m, 2H), 2, 64-2, 60 (m, 3H), 2, 59-2, 53 (m, 2H), 1, 52 (s, 9H). Analytical LC / MS (Method 5) : Observed mass: 438.4; Retention time: 0. 88 min. Stage C. Intermediate product 4C. 2-(3-fluoro-4-methoxyphenyl)-8-methyl-6-(piperidin-4-yl)imidazo[1,2-a]pyridine hydrochloride Intermediate product 4C was prepared according to the general methods described for the synthesis of intermediate product 1D (steps CD), using intermediate product 4B (480 mg, 1.1 mmol) as a starting material to obtain the title compound (410 mg, 1.1 mmol, 100% yield) as a roasted solid. 1H-NMR (500 MHz, methanol-d4) 8, 64-8, 60 (m, 1H), 8, 49-8, 45 (m, 1H), 7, 83-7, 80 (m, 1H), 7, 80-7, 74 (m, 2H), 7, 39-7, 33 (m, 1H) , 4, 00 (s, 3H) , 3, 79-3, 73 (m, 1H) , 3, 73-3, 65 (m, 2H) , 3, 63-3, 55 (m, 2H) , 2, 75 (s, 3H) , 2, 28-2, 21 (m, 2H), 2, 10-2, 01 (m, 2H) . Analytical CL / EM (Method 5) : Observed mass: 340, 2; Retention time: 0, 58 min. Stage D. Preparation of example 4 Example 4 was synthesized according to the general methods described for the preparation of Example 1 (step E), using intermediate product 4C (60 mg, 0.15 mmol) as the starting material. The crude material was purified by preparative HPLC (preparation method 1) to obtain the title compound (40 mg, 0.086 mmol, 57% yield). 1H-NMR (500 MHz, DMSO-6) 7, 99 (s, 1H) , 7, 92 (s, 1H) , 7, 49 (da, .J=2, 7 Hz, 2H) , 7, 01-6, 95 (m, 1H) , 6, 81-6, 75 (m, 1H) , 3, 63 (s, 3H) , 2, 80-2, 65 (m, 2H) , 2, 30 (s, 3H) , 1, 95-1, 83 (m, 2H) , 1, 65-1, 54 (m, 2H) , 1, 54-1, 36 (m, 4H) , 1, 36-1, 29 (m, 1H) , 1, 26-1, 09 (m, 2H) , 0, 20-0, 11 (m, 2H) , 0, 08-0, 01 (m, 2H) (6 obscured protons) . Analytical CL / EM (Method 1) : Purity: 100 %; Observed Mass: 463, 14; Retention Time: 1, 53 min. (Method 2) : Purity: 100 %; Observed Mass: 463, 16; Retention Time: 0, 99 min. Example 5 2-(3-fluoro-4-methoxyphenyl)-6-(1-isopropyl-[1, 4-bipiperidin]-4-yl)-8-methylimidazo[1, 2-a]pyridine Example 5 was synthesized according to the general methods described for the preparation of Example 1 (step E) using intermediate product 4C (60 mg, 0.15 mmol) as the starting material and substituting 1-isopropylpiperidin-4-one (110 mg, 0.78 mmol) where appropriate. The crude material was purified by preparative HPLC (preparation method 1) to obtain the title compound (49 mg, 0.11 mmol, 73% yield). 1H-NMR (500 MHz, DMSO-6) 8, 24 (s, 1H), 8, 18-8, 15 (m, 1H), 7, 77-7, 70 (m, 2H), 7, 26-7, 19 (m, 1H), 7, 06-7, 01 (m, 1H), 3, 88 (s, 3H) , 3, 03-2, 97 (m, 2H) , 2, 97-2, 90 (m, 1H) , 2, 56-2, 53 (m, 1H) , 2, 51 (s, 3H) , 2, 49-2, 44 (m, 1H) , 2, 38-2, 21 (m, 4H) , 1, 86-1, 76 (m, 4H) , 1, 71-1, 60 (m, 2H) , 1, 56-1, 43 (m, 2H) , 1, 07-0, 97 (m, 6H) (two obscured protons) . Analytical CL / EM: (Method 1) : Purity: 100 %; Observed Mass: 465.01; Retention Time: 1.54 min.(Method 2): Purity: 100%; Observed mass: 465.29; Retention time: 1.04 min. Example 6 2-(3-fluoro-4-methoxyphenyl)-6-(1-isobutyl-[1,4-bipiperidin]-4-yl)-8-methylimidazo[1,2-a]pyridine Example 6 was synthesized according to the general methods described for the preparation of Example 1 (step E) using intermediate product 4C (60 mg, 0.15 mmol) as the starting material and substituting 1-isobutylpiperidin-4-one (120 mg, 0.77 mmol) where appropriate. The crude material was purified by preparative HPLC (preparation method 1) to obtain the title compound (40 mg, 0.084 mmol, 56% yield). 1H-NMR (500 MHz, DMSO-6) 8, 26 (s, 1H) , 8, 19 (s, 1H) , 7, 79-7, 72 (m, 2H) , 7, 28-7, 22 (m, 1H) , 7, 07-7, 03 (m, 1H) , 3, 90 (s, 3H) , 3, 42-3, 35 (m, 1H) , 3, 21-3, 17 (m, 1H) , 3, 14-3, 02 (m, 2H) , 3, 00-2, 88 (m, 2H) , 2, 44-2, 35 (m, 2H) , 2, 12-2, 04 (m, 2H) , 1, 91-1, 85 (m, 2H) , 1, 83-1, 75 (m, 3H) , 1, 74-1, 61 (m, 3H) , 1, 60-1, 45 (m, 3H) , 0, 87 (ad, .J=6, 4 Hz, 6H) (three obscured protons) . Analytical CL / EM (Method 1): Purity: 100%; Observed Mass: 479.13; Retention Time: 1.77 min.(Method 2): Purity: 98.8%; Observed mass: 479.05; Retention time: 1.04 min. Example 7 6-(1-cyclopropyl-[1,4-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine Step A. Intermediate Product 7A. Preparation of 6-bromo-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine Intermediate 7A was prepared according to the general methods described for the synthesis of intermediate 1A, starting from 5-bromo-3-methylpyridin-2-amine (0.60 g, 3.2 mmol) and substituting 2-bromo-1-(4-(methylsulfonyl)phenyl)ethan-1-one (0.89 g, 3.2 mmol) when appropriate to obtain the title compound (1.0 g, 2.7 mmol, 84% yield) as a roasted solid.1H-NMR (500 MHz, methanol-d4) 9.01-8.95 (m, 1H) , 8.66 (s, 1H) , 8.24-8.17 (m, 4H) , 7.98-7.92 (m, 1H) , 3, 25-3, 22 (m, 3H) , 2, 78-2, 74 (m, 3H) . Analytical CL / EM (Method 5) : Observed mass: 367, 1; Retention time: 0, 72 min. Step B. Intermediate Product 7B. Preparation of 4-(8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridin-6-yl)-3,6-dihydropyridin-1(2H)-tert-butyl carboxylate Intermediate product 7B was prepared according to the general methods described for the synthesis of intermediate product IB, using intermediate product 7A (1.0 g, 2.7 mmol) as a starting material to obtain the title compound (1.2 g, 2.6 mmol, 96% yield) as a pale yellow solid. 1H-NMR (500 MHz, methanol-d4) 8, 37-8, 32 (m, 2H), 8, 24-8, 19 (m, 2H), 8, 07-8, 01 (m, 2H), 7, 42-7, 36 (m, 1H), 6, 32-6, 24 (m, 1H), 4, 19-4, 09 (m, 2H), 3, 72-3, 65 (m, 2H), 3, 19 (s, 3H), 2, 64 (s, 3H), 2, 61-2, 53 (m, 2H), 1, 53 (s, 9H). CL / EM analytical (Method 5): Observed mass: 468.4; Retention time: 0.81 min. Step C. Intermediate Product 7C. Preparation of 8-methyl-2-(4-(methylsulfonyl)phenyl)-6-(piperidin-4-yl)imidazo[1,2-a]pyridine hydrochloride Intermediate product 7C was prepared according to the general methods described for the synthesis of intermediate product ID (steps CD), using intermediate product 7B (1.2 g, 2.5 mmol) as a starting material to provide the title compound (1.0 g, 2.5 mmol, 100% yield) as a tan-colored solid. 1H-NMR (500 MHz, methanol-d4) 8.74 (s, 1H) , 8.72-8.69 (m, 1H) , 8.22 (d, J=10.2 Hz, 4H) , 7.91-7.87 (m, 1H) , 3.71-3.67 (m, 1H), 3, 63-3, 61 (m, 1H), 3, 61-3, 58 (m, 1H), 3, 28-3, 24 (m, 2H), 3, 23 (s, 3H), 2, 78 (s, 3H), 2, 29-2, 22 (m, 2H) , 2, 12-2, O2 (m, 2H) . CL / EM analytical (Method 5) : Observed mass: 370.4; Retention time: 0.51 min. Stage D. Preparation of example 7 Example 7 was synthesized according to the general methods described for the preparation of Example 1 (step E), using intermediate product 7C (70 mg, 0.16 mmol) as the starting material. The crude material was purified by preparative HPLC (preparation method 1) to obtain the title compound (61 mg, 0.12 mmol, 75% yield). 1H-NMR (500 MHz, DMSO-d6) 8, 48 (s, 1H) , 8, 21 (da, J=8, 6 Hz, 3H) , 8, 01-7, 94 (m, 2H) , 7, 11-7, 07 (m, 1H) , 3, 25-3, 22 (m, 1H), 3, 02-2, 94 (m, 2H), 2, 53 (s, 3H), 2, 40-2, 25 (m, 2H), 2, 18-2, 09 (m, 2H), 1, 88-1, 81 (m, 2H), 1, 77-1, 70 (m, 2H) , 1, 69-1, 61 (m, 2H) , 1, 60-1, 54 (m, 1H) , 1, 46-1, 35 (m, 2H) , 0, 42-0, 37 (m, 2H) , 0, 30-0, 25 (m, 2H) (6 obscured protons). Analytical CL / MS (Method 1): Purity: 96.8%; Observed mass: 493.14; Retention time: 1.45 min. (Method 2): Purity: 94.9%; Observed mass: 493.15; Retention time: 0.90 min. Example 8 6-(1-isopropyl-[1, 4-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine Example 8 was synthesized according to the general methods described for the preparation of Example 1 (step E) using intermediate 7C (70 mg, 0.16 mmol) as the starting material and substituting 1-isopropylpiperidin-4-one (110 mg, 0.78 mmol) where appropriate. The crude material was purified by preparative HPLC (preparation method 1) to obtain the title compound (49 mg, 0.10 mmol, 63% yield). 1H-NMR (500 MHz, DMSO-d6) 8, 48 (s, 1H) , 8, 22 (da, J=8, 9 Hz, 3H) , 7, 98 (da, J=8, 5 Hz, 2H) , 7, 13-7, 08 (m, 1H) , 3, 26-3, 22 (m, 2H), 3, 02-2, 95 (m, 2H), 2, 87-2, 81 (m, 2H), 2, 72-2, 64 (m, 1H), 2, 53 (s, 3H), 2, 49-2, 44 (m, 1H), 2, 29-2, 17 (m, 3H) , 2, 16-2.05(m,2H) 2H), 1.00-0.93 (m, 6H). Analytical LC / MS (Method 1): Purity: 94.4%; Observed mass: 494.90; Retention time: 1.19 min.(Method 2): Purity: 95%; Observed mass: 495.17; Retention time: 0.90. Example 9 6-(1-isobutyl-[1,4-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine Example 9 was synthesized according to the general methods described for the preparation of Example 1 (step E) using intermediate 7C (70 mg, 0.16 mmol) as the starting material and substituting 1-isobutylpiperidin-4-one (120 mg, 0.77 mmol) where appropriate. The crude material was purified by preparative HPLC (preparation method 1) to obtain the title compound (62 mg, 0.12 mmol, 75% yield). 1H-NMR (500 MHz, DMSO-d6) 8, 49 (s, 1H) , 8, 23 (da, J=8, 9 Hz, 3H) , 8, 00 (s, 2H) , 7, 15-7, 08 (m, 1H) , 3, 28-3, 23 (m, 1H) , 3, 05-2, 97 (m, 2H), 2, 92-2, 83 (m, 2H), 2, 54 (sa, 4H), 2, 34-2, 23 (m, 3H), 2, 06-1, 99 (m, 2H), 1, 90-1, 81 (m, 4H), 1, 79-1, 71 (m, 3H) , 1, 71-1, 59 (m, 3H) , 1, 55-1, 43 (m, 2H) , 0, 86 (da, .J=6, 4 Hz, 6H) (one obscured proton) . Analytical CL / EM (Method 1) : Purity: 100 %; Observed Mass: 509, 17; Retention Time: 1, 38 min.(Method 2): Purity: 99.3%; Observed mass: 509.18; Retention time: 0.94 min. Example 10 6-(1-cyclopropyl-[1,4'-bipiperidin]-4-yl)-2-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyridine Step A. Intermediate Product 10A. Preparation of 6-bromo-2-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyridine Intermediate product 10A was prepared according to the general methods described for the synthesis of intermediate product 1A, substituting 5-bromopyridin-2-amine (5.0 g, 29 mmol) when appropriate to provide the title compound (9.5 g, 29 mmol, 100% yield) as a roasted solid. 1H-NMR (500 MHz, methanol-d4) 9, 10-9, 08 (m, 1H) , 8, 48 (s, 1H) , 8, 09-8, 05 (m, 1H) , 7, 87-7, 83 (m, 1H) , 7, 52-7, 47 (m, 2H) , 7, 20-7, 16 (m, 1H) , 3, 98 (s, 3H) , 3, 94 (s, 3H) . CL / EM analytical (Method 5) : Observed mass: 335.2; Retention time: 0.62 min. Step B. Intermediate Product 10B. Preparation of 4-(2-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyridin-6-yl)-3,6-dihydropyridin-1(2H)-tert-butyl carboxylate Intermediate product 10B was prepared according to the general methods described for the synthesis of intermediate product IB, using intermediate product 10A (2.5 g, 7.5 mmol) as a starting material to obtain the title compound (3.2 g, 7.4 mmol, 99% yield) as a yellow solid. 1H-NMR (500 MHz, methanol-d4) 8.40-8.36 (m, 1H) , 8.05 (s, 1H) , 7.55-7.53 (m, 1H) , 7.51-7.48 (m, 2H) , 7.47-7.43 (m, 1H) , 7.05-7.00 (m, 1H) , 6.26-6.18 (m, 1H) , 4, 14-4, 09 (m, 2H), 3, 94 (s, 3H), 3, 89 (s, 3H), 3, 70-3, 66 (m, 2H), 2, 59-2, 53 (m, 2H), 1, 54-1, 51 (m, 9H). Analytical LC / MS (Method 5) : Observed mass: 436.4; Retention time: 0. 78 min. Step C. Intermediate Product 10C. Preparation of 4-(2-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyridin-6-yl)piperidin-1-carboxylate tert-butyl The intermediate product 10B (3.2 g, 7.4 mmol) and MeOH (40 mL) were added to a 100 mL pear-shaped flask. The flask was evacuated and purged with N2 (2x), then platinum(IV) oxide (0.68 g, 3.0 mmol) was added and the reaction mixture was stirred in hydrogen at 1 atm. After 1 h, the catalyst was filtered and the filtrate was concentrated. The residue was purified by ultrafast column chromatography (80 g silica gel cartridge; A = Hex, B = EtOAc; 30 min gradient; B from 0% to B100%; flow rate = 60 mL / min). The pure fractions were combined, concentrated, and vacuum dried to obtain the title compound (1.0 g, 2.3 mmol, 31% yield) as a white solid.1H-NMR (500 MHz, methanol-d4) 8, 31-8, 28 (m, 1H), 8, 10-8, 07 (m, 1H), 7, 58-7, 55 (m, 1H), 7, 52-7, 46 (m, 2H), 7, 31-7, 27 (m, 1H) , 7, 06-7, 02 (m, 1H) , 4, 30-4, 24 (m, 2H) , 3, 95 (s, 3H) , 3, 90 (s, 3H) , 2, 99-2, 87 (m, 2H) , 2, 84-2, 77 (m, 1H), 1, 97-1, 90 (m, 2H) , 1, 71-1, 61 (m, 2H) , 1, 51 (s, 9H) . Analytical CL / EM (Method 5) : Observed mass: 438, 4; Retention time: 0, 78 min. Step D. Intermediate Product 10D. Preparation of 2-(3,4-dimethoxyphenyl)-6-(piperidin-4-yl)imidazo[1,2a]pyridine2,2,2-trifluoroacetate Intermediate product 10C (1.0 g, 2.3 mmol) was added to a 100 ml pear-shaped flask, DCM (5 ml) and TFA (5 ml). After stirring for 1 h, the solvent was concentrated, the residue was co-evaporated with toluene, and the product was vacuum-dried to obtain the title compound (1.0 g, 2.2 mmol, 96% yield) as a roasted solid. 1H-NMR (500 MHz, methanol-d4) 8, 74-8, 70 (m, 1H) , 8, 49-8, 46 (m, 1H) , 7, 99-7, 94 (m, 1H) , 7, 93-7, 89 (m, 1H) , 7, 52-7, 46 (m, 2H) , 7, 20-7, 16 (m, 1H) , 3, 98 (s, 3H) , 3, 94 (s, 3H) , 3, 63-3, 58 (m, 2H) , 3, 27-3, 23 (m, 2H) , 2, 30-2, 22 (m, 2H) , 2, 08-1, 98 (m, 2H) (one obscured proton) . Analytical CL / EM (Method 5) : Observed mass: 338.3; Retention time: 0.50 min. Stage E. Preparation of example 10 Example 10 was synthesized according to the general methods described for the preparation of Example 1 (step E) using intermediate product 10D (70 mg, 0.16 mmol) as the starting material. The crude material was purified by preparative HPLC (preparation method 1) to obtain the title compound (25 mg, 0.054 mmol, 34% yield). 1H-NMR (500 MHz, DMSO-6) 8, 33 (s, 1H) , 8, 25 (s, 1H) , 7, 55 (s, 1H) , 7, 53-7, 46 (m, 2H) , 7, 23-7, 18 (m, 1H) , 7, 05-7, 01 (m, 1H) , 3, 86 (s, 3H) , 3, 81 (s, 3H) , 3, 14-3, 05 (m, 1H) , 3, 04-2, 97 (m, 2H) , 2, 61-2, 55 (m, 1H) , 2, 49-2, 35 (m, 2H), 2, 21-2, 13 (m, 2H) , 1, 92-1, 84 (m, 2H) , 1, 82-1, 75 (m, 2H) , 1, 75-1, 65 (m, 2H) , 1, 64-1, 56 (m, 1H) , 1, 50-1, 38 (m, 2H) , 0, 45-0, 39 (m, 2H) , 0, 32-0, 26 (m, 2H) (two obscured protons). Analytical CL / MS (Method 1): Purity: 95.9%; Observed Mass: 461.27; Retention Time: 1.35 min.(Method 2) : Purity: 96.7%; Observed mass: 460.99; Retention time: 1.02 min. Example 11 2-(3,4-dimethoxyphenyl)-6-(r-isopropyl-[1,4-bipiperidin]-4-yl)imidazo[1,2-a]pyridine Example 11 was synthesized according to the general methods described for the preparation of Example 1 (step E) using intermediate product 10D (70 mg, 0.16 mmol) as the starting material and substituting 1-isopropylpiperidin-4-one (110 mg, 0.78 mmol) where appropriate. The crude material was purified by preparative HPLC (preparation method 1) to obtain the title compound (43 mg, 0.093 mmol, 58% yield). 1H-NMR (500 MHz, DMSO-6) 8, 33-8, 29 (m, 1H) , 8, 22 (s, 1H) , 7, 55-7, 51 (m, 1H) , 7, 47 (s, 2H) , 7, 23-7, 18 (m, 1H) , 7, 03-6, 97 (m, 1H) , 3, 84 (s, 3H) , 3, 78 (s, 3H) , 3, 01-2, 94 (m, 2H) , 2, 90-2, 81 (m, 2H) , 2, 76-2, 65 (m, 1H) , 2, 29-2, 19 (m, 3H) , 2, 18-2, 07 (m, 2H) , 1, 85-1, 72 (m, 4H) , 1, 69-1, 59 (m, 2H) , 1, 50-1.37 (m, 2H), 0.97 (d, J=6.6 Hz, 6H) (one darkened proton). Analytical CL / EM (Method 1): Purity: 100%; Observed mass: 463.29; Retention time: 1.33 min. (Method 2) : Purity: 100%; Observed mass: 463.16; Retention time: 0.96 min. Example 12 2-(3,4-dimethoxyphenyl)-6-(1'-isobutyl-[1,4'-bipiperidin]-4-yl)imidazo[1,2-a]pyridine Example 12 was synthesized according to the general methods described for the preparation of Example 1 (step E) using intermediate product 10D (70 mg, 0.16 mmol) as the starting material and substituting 1-isobutylpiperidin-4-one (120 mg, 0.77 mmol) where appropriate. The crude material was purified by preparative HPLC (preparation method 1) to obtain the title compound (23 mg, 0.050 mmol, 31% yield). 1H-NMR (500 MHz, DMSO-6) 8, 33 (s, 1H) , 8, 25 (s, 1H) , 7, 56-7, 53 (m, 1H) , 7, 53-7, 46 (m, 2H) , 7, 25-7, 19 (m, 1H) , 7, 05-7, 00 (m, 1H) , 3, 85 (s, 3H) , 3, 80 (s, 3H) , 3, 60-3, 49 (m, 1H) , 3, 20-3, 17 (m, 1H) , 3, 13-3, 05 (m, 2H) , 2, 99-2, 89 (m, 2H) , 2, 46-2, 36 (m, 3H) , 2, 14-2, 06 (m, 2H) , 2, 00-1, 94 (m, 1H) , 1, 91-1.85 (m, 2H), 1.84-1.75 (m, 3H), 1.75-1.64 (m, 2H), 1.59-1.49 (m, 2H), 0.86 (s, 6H) (one protonated). Analytical LC / MS (Method 1) : Purity: 100%; Observed mass: 477.03; Retention time: 1.39 min.(Method 2): Purity: 100%; Mass observed: 477, 02; Retention time: 1, 04 min. Example 13 2- (3, 4-dimethoxyphenyl) -6- (1- (2-isopropyl-2-azaspiro[3.3]heptan-6-yl) piperidin-4-yl) -8- methylimidazo[1, 2-a]pyridine Etapa A. Producto intermedio 13A. Preparación de diclorhidrato de 6- (1- (2-azaspiro[3.3]heptan-6-il) piperidin-4-il) -2- (3, 4-dimetoxifenil) -8-metilimidazo[1, 2-a]piridina The intermediate product ID (0.50 g, 1.3 mmol), tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate (0.82 g, 3.9 mmol), AcOH (0.081 ml, 1.4 mmol), magnesium sulfate (2.3 g, 19 mmol), and DMF (10 ml) were added to a 40 ml vial. The reaction mixture was stirred for 20 min, then sodium triacetoxyborohydride (0.82 g, 3.9 mmol) was added and the reaction mixture was stirred. After 20 h, the reaction mixture was adsorbed onto Celite and the product was purified by ultrafast column chromatography (100 g reversed-phase GOLD C18 silica gel cartridge; A = water MeCN:TFA 90:10:0.05%, B = water:MeCN:TFA 10:90:0.05%; 20 min gradient; 0% B to 50% B; flow rate = 80 mL / min). The pure fractions were combined, concentrated, and the intermediate was dissolved in a minimal amount of MeOH and diluted with 4 M HCl in dioxane (10 mL). After stirring for 1.5 h, the solvent was concentrated.The resulting solid was ground with MeOH and the product was collected by vacuum filtration and vacuum dried to provide the title compound (0.40 g, 0.77 mmol, 59% yield) as a white solid. 1H-NMR (500 MHz, methanol-d6) 8, 58-8, 51 (m, 1H) , 8, 43-8, 36 (m, 1H) , 7, 77-7, 66 (m, 1H) , 7, 58-7, 52 (m, 2H) , 7, 19-7, 14 (m, 1H) , 4, 25-4, 21 (m, 2H) , 4, 19-4, 15 (m, 2H) , 3, 99 (s, 3H) , 3, 94 (s, 3H) , 3, 74-3, 70 (m, 1H) , 3, 68-3, 62 (m, 2H) , 3, 18-3, 10 (m, 1H) , 3, 08-2, 98 (m, 2H) , 2, 85-2, 80 (m, 3H) , 2, 73 (s, 3H) , 2, 28-2, 20 (m, 4H) (one obscured proton) . Analytical CL / EM (Method 5) : Observed mass: 447.4; Retention time: 0.50 min. Stage B. Preparation of example 13 Intermediate product 13A (70 mg, 0.14 mmol), propan-2-one (80 mg, 1.4 mmol), AcOH (8.4 mg, 0.14 mmol), magnesium sulfate (220 mg, 1.8 mmol), and DMF (2 mL) were added to a 40 mL vial. The reaction mixture was stirred for 20 min, then sodium triacetoxyborohydride (87 mg, 0.41 mmol) was added, and the reaction mixture was stirred again. After stirring for 24 h, the reaction mixture was filtered, and the filter cake was washed with 10% IPA / chloroform (20 mL). The filtrate was washed with 10% aqueous NaOH (10 mL), brine, dried over MgSCU, filtered, and concentrated. The raw material was purified by preparative HPLC (preparation method 1) to obtain the title compound (36 mg, 0.074 mmol, 53% yield).1H-RMN (500 MHz, DMSO-6) 8, 21 (s, 1H) , 8, 17-8, 13 (m, 1H) , 7, 54-7, 51 (m, 1H) , 7, 50-7, 46 (m, 1H) , 7, 03-6, 98 (m, 2H) , 3, 85-3, 82 (m, 3H) , 3, 79- 3, 77 (m, 3H) , 3, 70-3, 64 (m, 2H) , 3, 18-3, 15 (m, 1H) , 2, 92-2, 85 (m, 2H) , 2, 65-2, 59 (m, 1H) , 2, 56-2, 53 (m, 2H) , 2, 49-2, 44 (m, 2H) , 2, 28-2, 21 (m, 2H) , 1, 97-1, 91 (m, 2H) , 1, 86- 1, 77 (m, 4H) , 1, 67-1, 57 (m, 2H), 0, 97-0, 92 (m, 6H) (dos protones oscurecidos). CL / EM analysis (Método 1): Pure: 100%; Masa observada: 489, 07; Retention time: 1, 2 minutes. (Método 2): Pureza: 95, 2%; Masa observada: 489, 29; Retention time: 0, 98 min. Example 14 6- (1- (2-ciclobutil-2-azaspiro[3.3]heptan-6-il) piperidin-4-il) -2- (3, 4-dimetoxifenil) - 8-metilimidazo[1, 2-a]piridina Example 14 was synthesized according to the general methods described for the preparation of Example 13 (step B) using intermediate product 13 A (70 mg, 0.14 mmol) as the starting material and substituting cyclobutanone (98 mg, 1.4 mmol) where appropriate. The crude material was purified by preparative HPLC (preparation method 1) to obtain the title compound (48 mg, 0.096 mmol, 69% yield). 1H-NMR (500 MHz, DMSO-6) 8, 32-8, 22 (m, 1H) , 8, 18-8, 14 (m, 1H) , 7, 57-7, 47 (m, 2H) , 7, 04-6, 98 (m, 2H) , 4, 00-3, 95 (m, 1H) , 3, 90-3, 87 (m, 1H) , 3, 86 (s, 3H) , 3, 79 (s, 3H) , 3, 69-3, 61 (m, 1H) , 3.58–3.48 (m, 1H) , 3.09–2.98 (m, 1H) , 2.57–2.54 (m, 3H) , 2.49–2.39 (m, 2H) , 2.24–2.09 (m, 6H) , 2.07–1.87 (m, 4H) , 1.84–1.66 (m, 4H) (4 obscured protons). Analytical CL / MS (Method 1): Purity: 96.7%; Observed mass: 501.22; Retention time: 1.31 min. (Method 2): Purity 95.2%; Observed mass: 501.21; Retention time: 0.95 min. Example 15 2- (3, 4-dimethoxyphenyl) -6- (1- (2-isobutyl-2-azaspiro[3.3]heptan-6-yl) piperidin-4-yl) -8- methylimidazo[1, 2-a]pyridine Example 15 was synthesized according to the general methods described for the preparation of Example 13 (step B) using intermediate product 13 A (90 mg, 0.17 mmol) as the starting material and substituting isobutyraldehyde (63 mg, 0.87 mmol) where appropriate. The crude material was purified by preparative HPLC (preparation method 1) to obtain the title compound (32 mg, 0.064 mmol, 38% yield). 1H-NMR (500 MHz, DMSO-6) 8, 21 (s, 1H) , 8, 17-8, 13 (m, 1H) , 7, 52 (d, J=1, 7 Hz, 1H) , 7, 51-7, 45 (m, 1H) , 7, 00 (da, J=1, 2 Hz, 2H) , 3, 85 (s, 3H) , 3, 79 (s, 3H) , 2, 93-2, 85 (m, 2H) , 2, 62-2, 57 (m, 1H) , 2, 55 (s, 4H), 2, 48-2, 43 (m, 1H), 2, 41-2, 33 (m, 2H), 2, 27-2, 20 (m, 2H), 2, 16-2, 02 (m, 1H), 1, 94 (sa, 2H), 1, 80 (da, J=11, 4 Hz, 4H) , 1.67-1.54 (m, 3H) , 0.90-0.87 (m, 1H) , 0.84 (d, J=6.7 Hz, 6H) (one darkened proton) .CL / EM analytical (Method 1): Purity: 99.2%; Observed mass: 502.96; Retention time: 1.46 min. (Method 2): Purity: 100%; Observed mass: 502.96; Retention time: 1.03 min. Example 16 6-(1-(2-(cyclopropylmethyl)-2-azaspiro[3.3]heptan-6-yl)piperidin-4-yl)-2-(3,4-dimethoxyphenyl)-8-methylimidazo[1,2-a]pyridine Example 16 was synthesized according to the general methods described for the preparation of Example 13 (step B) using intermediate 13A (90 mg, 0.17 mmol) as the starting material and substituting cyclopropanecarbaldehyde (61 mg, 0.87 mmol) where appropriate. The crude material was purified by preparative HPLC (preparation method 1) to obtain the title compound (49 mg, 0.098 mmol, 58% yield). 1H-NMR (500 MHz, DMSO-6) 8, 29 (s, 1H) , 8, 21 (sa, 1H) , 7, 30 (sa, 2H) , 7, 28-7, 24 (m, 1H) , 6, 91-6, 86 (m, 1H) , 4, 04-3, 95 (m, 1H) , 3, 92-3, 80 (m, 3H) , 3, 63 (s, 3H) , 3, 58 (s, 3H) , 3, 39-3, 20 (m, 1H) , 2, 80-2, 73 (m, 3H) , 2, 70-2, 59 (m, 2H), 2, 52-2, 44 (m, 1H), 2, 37 (s, 3H), 2, 35-2, 29 (m, 2H), 1, 94-1, 86 (m, 2H), 1, 69-1, 56 (m, 2H), 0, 72-0, 61 (m, 1H), 0.34-0.28 (m, 2H), 0.10-0.03 (m, 2H) (three protons darkened).CL / EM analytical (Method 1): Purity: 100%; Observed mass: 501.25; Retention time: 1.01 min. (Method 2): Purity: 100%; Observed mass: 501.28; Retention time: 1.52 min. Example 17 6-(1-(2-cyclopropyl-2-azaspiro[3.3]heptan-6-yl)piperidin-4-yl)-2-(3,4-dimethoxyphenyl)-8-methylimidazo[1,2-a]pyridine Intermediate product 13A (100 mg, 0.19 mmol), (1-ethoxycyclopropoxy)trimethylsilane (100 mg, 0.58 mmol), activated molecular sieves 3A (500 mg), and MeOH (5 ml) were added to a 40 ml vial. The reaction mixture was washed thoroughly with N2 and stirred at 80 °C for 1 h, cooled to room temperature, then sodium cyanoborohydride (36 mg, 0.58 mmol) was added, the container was washed thoroughly with N2, and the reaction mixture was stirred at 40 °C. After 18 h, the vessel was cooled, replenished with (1-ethoxycyclopropoxy)trimethylsilane (100 mg, 0.58 mmol), AcOH (0.066 mL, 1.2 mmol), sodium cyanoborohydride (36 mg, 0.58 mmol), and additional 3A molecular sieves. The vessel was rinsed with N2, heated to 50 °C, and stirred. After 18 h, the reaction mixture was cooled, filtered, and concentrated.The raw material was purified by preparative HPLC (preparation method 1) to obtain the title compound (10 mg, 0.021, 11% yield). 1H-NMR (500 MHz, DMSO-6) 8, 08-8, 04 (m, 1H) , 7, 96-7, 93 (m, 1H) , 7, 32 (da, J=1, 7 Hz, 2H) , 7, 30-7, 26 (m, 1H) , 6, 82-6, 80 (m, 1H) , 3, 64 (s, 3H) , 3, 58 (s, 3H) , 3, 08-3, 04 (m, 1H) , 2, 97-2, 94 (m, 1H) , 2, 76-2, 68 (m, 2H) , 2, 35-2, 34 (m, 3H), 2, 09-2, 06 (m, 1H) , 2, 02-1, 95 (m, 3H) , 1, 90-1, 85 (m, 2H) , 1, 72-1, 65 (m, 4H) , 1, 63-1, 58 (m, 2H) , 1, 47-1, 40 (m, 2H), 0.27-0.20 (m, 1H), 0.12-0.09 (m, 2H), 0.03-0.02 (m, 2H). Analytical LC / MS (Method 1): Purity: 84.9%; Observed mass: 487.23; Retention time: 1.5 min. (Method 2): Purity: 100%; Observed mass: 487.22; Retention time: 1.0 min. Examples 18 and 19 2-(3,4-dimethoxyphenyl)-6-(1-(8-isobutyl-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-8-methylimidazo[1,2-a]pyridine Step A. Intermediate Product 18A. Preparation of bis(2,2,2-trifluoroacetate) of 6-(1-(8-azabicyclo[3.2.l]octan-3-yl)piperidin-4-yl)-2-(3,4-dimethoxyphenyl)-8-methylimidazo[1,2-a]pyridine The intermediate product 1D (400 mg, 1.0 mmol), tert-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (700 mg, 3.1 mmol), AcOH (0.065 ml, 1.1 mmol), magnesium sulfate (1900 mg, 16 mmol), and DMF (10 ml) were added to a 40 ml vial. The reaction mixture was stirred for 20 min, then sodium triacetoxyborohydride (660 mg, 3.1 mmol) was added, and the reaction mixture was stirred again. After 18 h, the reaction mixture was diluted with DCM / MeOH and filtered. Water (0.5 ml) was added to the filtrate, and then the mixture was concentrated. The remaining DMF solution was filtered and the crude product was purified by ultrafast column chromatography (100 g reversed-phase GOLD C18 silica gel cartridge; A = water:MeCN:TFA 90:10:0.05%, B = water:MeCN:TFA 10:90:0.05%; 20 min gradient; 0% B to 40% B; flow rate = 60 ml / min). The fractions corresponding to the intermediate product were combined and concentrated.The resulting residue was dissolved in THF (20 mL) and TFA (20 mL) and stirred. After 3 h, the solvent was concentrated and the residue was purified by ultrafast column chromatography (100 g reversed-phase GOLD C18 silica gel cartridge; A = water:MeCN:TFA 90:10:0.05%, B = water:MeCN:TFA 10:90:0.05%; 20 min gradient; 0% B to 40% B; flow rate = 60 mL / min). The desired fractions were combined, concentrated, and the product was vacuum dried to obtain the title compound (120 mg, 0.26 mmol, 26% yield) as a colorless residue. 1H-NMR (500 MHz, methanol-d4) 8.55-8.50 (m, 1H) , 8.41 (s, 1H) , 7.75-7.69 (m, 1H) , 7.48 (sa, 2H) , 7.10-7.04 (m, 1H) , 4. 31-4, 19 (m, 2H) , 3, 93 (s, 3H) , 3, 89 (s, 3H) , 3, 83-3, 77 (m, 2H) , 3, 35-3, 32 (m, 1H) , 3, 31-3, 22 (m, 2H) , 3, 18-3, 08 (m, 1H) , 2, 70 (s, 3H) , 2, 44-2, 36 (m, 2H) , 2, 31-2, 18 (m, 8H) , 2, 15-2, 09 (m, 2H) .CL / EM analytical (Method 5): Observed mass: 461.3; Retention time: 0.50 min. Stage B. Preparation of example 18 and example 19 The intermediate product 18A (40 mg, 0.058 mmol), isobutyraldehyde (21 mg, 0.29 mmol), AcOH (3.8 mg, 0.064 mmol), magnesium sulfate (220 mg, 1.8 mmol), and DMF (2 mL) were added to a 40 mL vial. The reaction mixture was stirred for 20 min, then sodium triacetoxyborohydride (36 mg, 0.17 mmol) was added, and the reaction mixture was stirred again. After 18 h, the reaction mixture was filtered, the filter cake was washed with MeOH, and the filtrate was concentrated. The crude isomeric mixture was purified by preparative HPLC under the following conditions: Column: XBridge Cl 8, 200 mm x 19 mm, 5-pm particles; Mobile phase A: 5:95 acetonitrile: water with ammonium acetate; Mobile phase B: 95:5 acetonitrile: water with ammonium acetate; Gradient: a hold of 0 minutes at 15% B, 15-70% B for 20 minutes, then a hold of 0 minutes at 100% B; Flow rate: 20 ml / min; Column temperature: 25 °C.The collection of fractions was activated by EM signals. The fractions containing the respective desired products were combined and dried by centrifugal evaporation. Example 18 (12 mg, 0.023 mmol, 40% yield) was isolated as the 1st elution isomer. 1H-NMR (500 MHz, DMSO-6) 8, 23 (s, 1H) , 8, 16 (s, 1H) , 7, 54 (d, J=1, 2 Hz, 1H) , 7, 52-7, 48 (m, 1H) , 7, 05-6, 99 (m, 2H) , 3, 86 (s, 3H) , 3, 81 (s, 3H) , 3, 07-3, 01 (m, 1H) , 2, 69-2, 60 (m, 1H) , 2, 50-2, 44 (m, 1H) , 2, 31-2, 12 (m, 4H) , 1, 94-1, 91 (m, 1H) , 1, 91-1, 80 (m, 4H) , 1, 75-1, 50 (m, 9H) , 0, 91 (d, .J=6, 4 Hz, 6H) (5 obscured protons) . Analytical CL / EM (Method 1): Purity: 97.7%; Observed mass: 516.90; Retention time: 1.59 min. (Method 2): Purity: 96.1%; Observed mass: 517.24; Retention time: 1.09 min. Example 19 (3.6 mg, 0.0070 mmol, 12% yield) was isolated as the 2nd elution isomer. 1H-NMR (500 MHz, DMSO-6) 8, 22 (s, 1H), 8, 20-8, 16 (m, 1H), 7, 56-7, 53 (m, 1H), 7, 52-7, 47 (m, 1H), 7, 02 (s, 2H), 3, 87 (s, 3H) , 3, 81 (s, 3H) , 3, 27-3, 20 (m, 1H) , 3, 11-3, 05 (m, 2H) , 2, 57 (s, 3H) , 2, 49-2, 43 (m, 1H) , 2, 42-2, 36 (m, 1H), 2, 04-1, 98 (m, 2H) , 1, 97-1, 92 (m, 2H) , 1, 88-1, 80 (m, 6H) , 1, 78-1, 72 (m, 2H) , 1, 70-1, 57 (m, 5H) , 0, 89 (d, J=6, 4 Hz, 6H) (one obscured proton). Analytical CL / EM (Method 1): Purity: 98.9%; Observed Mass: 517.01; Retention Time: 1.69 min. (Method 2): Purity: 100%; Observed Mass: 517.33; Retention Time: 1.1 min. Examples 20 and 21 6-(1-(8-(cyclopropylmethyl)-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-2-(3,4-dimethoxyphenyl)-8-methylimidazo[1,2-a]pyridine Examples 20 and 21 were synthesized according to the general methods described for the synthesis of Examples 18 and 19, using intermediate 18A (40 mg, 0.058 mmol) as starting material 1 and substituting cyclopropanecarbaldehyde (20 mg, 0.29 mmol) where appropriate. The crude isomeric mixture was purified by preparative HPLC under the following conditions: Column: X Bridge Cl 8, 200 mm x 19 mm, 5-pm particles; Mobile phase A: 5:95 acetonitrile:ammonium acetate water; Mobile phase B: 95:5 acetonitrile:ammonium acetate water; Gradient: a 0-minute hold at 13% B, 13–53% B for 20 minutes, then a 0-minute hold at 100% B; Flow rate: 20 mL / min. Column temperature: 25 °C. Fraction collection was activated by EM signals. The fractions containing the respective desired products were combined and dried by centrifugal evaporation. Example 20 (7.5 mg, 0.015 mmol, 26% yield) was isolated as the first elution isomer. 1H-NMR (500 MHz, DMSO-6) 8.05 (s, 1H) , 8.01-7.97 (m, 1H) , 7.36 (s, 1H) , 7.35-7.30 (m, 1H) , 6.85 (s, 2H) , 3.69 (s, 3H), 3, 63 (s, 3H), 2, 88-2, 78 (m, 2H), 2, 58-2, 46 (m, 1H), 2, 31-2, 19 (m, 3H), 2, 09-2, 00 (m, 2H), 1, 75 (s, 3H) , 1, 70-1, 62 (m, 2H) , 1, 45 (da, J=8, 9 Hz, 8H) , 1, 21-1, 03 (m, 1H) , 0, 79-0, 68 (m, 1H) , 0, 33 (da, J=7, 0 Hz, 2H) , 0, 01 (da, J=4, 3 Hz, 2H) (three obscured protons) . Analytical CL / EM (Method 1): Purity: 95.9%; Observed Mass: 514.94; Retention Time: 1.52 min. (Method 2): Purity: 96.2%; Observed Mass: 514.33; Retention Time: 1.08 min. Example 21 (4.1 mg, 0.0080 mmol, 14% yield) was isolated as the second elution isomer.1H-RMN (500 MHz, DMSO-6) 8, 05 (s, 1H) , 8, 02-7, 97 (m, 1H) , 7, 36 (s, 1H) , 7, 35-7, 31 (m, 1H) , 6, 85 (s, 2H) , 3, 69 (s, 3H) , 3, 63 (s, 3H) , 2, 87-2, 79 (m, 2H) , 2, 57-2, 46 (m, 1H) , 2, 33-2, 20 (m, 3H) , 2, 09-2, 00 (m, 2H) , 1, 75 (s, 3H) , 1, 69-1, 61 (m, 2H) , 1, 45 (da, J=8, 9 Hz, 8H) , 0, 79-0, 69 (m, 1H) , 0, 37-0, 28 (m, 2H) , 0, 05-0, 03 (m, 2H) (cuatro protones oscurecidos). CL / EM analysis (Método 1): Pure: 100%; Masa observada:515, 25; Retention time: 1, 74 minutes. (Método 2): Pureza: 96, 1%; Masa observada: 515, 41; Retention time: 1, 08 minutes. Example 22 2- (3, 4-dimetoxifenil) -6- (1- (8-isopropil-8-azabiciclo[3.2.1]octan-3-il) piperidin-4-il) -8-metilimidazo[1, 2-a]piridina Examples 22 and 23 were synthesized according to the general methods described for the synthesis of Examples 18 and 19, using intermediate 18A (40 mg, 0.058 mmol) as starting material 1 and substituting propan-2-one (17 mg, 0.29 mmol) where appropriate. The crude isomeric mixture was purified by preparative LC / MS under the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 pm particles; Mobile phase A: 5:95 acetonitrile:ammonium acetate water; Mobile phase B: 95:5 acetonitrile:ammonium acetate water; Gradient: 0 min hold at 15% B, 15–60% B for 20 min, then 0 min hold at 100% B; Flow rate: 20 mL / min. Column temperature: 25 °C. Fraction collection was activated by EM signals. The fractions containing the respective desired products were combined and dried by centrifugal evaporation. Example 22 (5.3 mg, 0.011 mmol, 19% yield) was isolated as the first elution isomer. 1H-NMR (500 MHz, DMSO-6) 8, 23 (s, 1H), 8, 18-8, 14 (m, 1H), 7, 56-7, 53 (m, 1H), 7, 52-7, 48 (m, 1H), 7, 02 (da, J=1, 2 Hz, 2H) , 3, 87 (s, 3H) , 3, 81 (s, 3H) , 3, 05-2, 97 (m, 2H) , 2, 86-2, 77 (m, 1H) , 2, 70-2, 61 (m, 1H) , 2, 58-2, 56 (m, 1H) , 2, 50-2, 41 (m, 1H) , 2, 24-2, 13 (m, 2H) , 1, 95-1, 90 (m, 1H) , 1, 87-1, 78 (m, 4H) , 1, 73-1, 53 (m, 6H) , 1, 52-1, 45 (m, 2H) , 1, 05 (a, J=5, 8 Hz, 6H) (three obscured protons). Analytical CL / EM (Method 1): Purity: 100%; Observed Mass: 503.18; Retention Time: 1.39 min. (Method 2): Purity: 100%; Observed Mass: 503.21; Retention Time: 1.00 min. Example 23 (2.6 mg, 0.0052 mmol, 9.0% yield) was isolated as the second elution isomer.1H-NMR (500 MHz, DMSO-6) 8, 22 (s, 1H) , 8, 20-8, 17 (m, 1H) , 7, 57-7, 52 (m, 1H) , 7, 52-7, 47 (m, 1H) , 7, 05-7, 00 (m, 2H) , 3, 87 (s, 3H) , 3, 81 (s, 3H) , 3, 35-3, 24 (m, 1H) , 2, 72-2, 62 (m, 1H) , 2, 49-2, 43 (m, 1H) , 2, 40-2, 32 (m, 1H) , 1, 92 (sa, 13H) , 1, 70-1, 60 (m, 2H) , 1, 04 (da, J=5, 8 Hz, 6H) (5 obscured protons) . Analytical CL / EM (Method 1): Purity: 97%; Observed mass: 502.90; Retention time: 1.65 min. (Method 2): Purity: 98.6%; Observed mass: 503.16; Retention time: 1.07 min. Example 24 6-(8-(1-cyclopropylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-2-(3,4-dimethoxyphenyl)-8-methylimidazo[1,2-a]pyridine (isomeric mixture) Step A. Intermediate product 24 A. Preparation of 3-(2-(3,4-dimethoxyphenyl)-8-methylimidazo[1,2-a]pyridin-6-yl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate tert-butyl To a 40 ml vial were added intermediate product 1 A (260 mg, 0.75 mmol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate tert-butyl (250 mg, 0.75 mmol), XPhos Pd G3, 95% (63 mg, 0.075 mmol), 1,4-dioxane (15 ml), followed by tribasic potassium phosphate (550 mg, 2.6 mmol) dissolved in water (3 ml). The container was washed thoroughly with N2, capped, and the reaction mixture was stirred at 85 °C. After 18 h, the reaction mixture was cooled, diluted with water (100 ml), and extracted with EtOAc (2 x 50 ml). The organic phase was combined, washed with brine, dried over MgSCU, filtered, and concentrated. The residue was purified by ultrafast column chromatography (120 g silica gel cartridge; A = Hex, B = EtOAc; 30 min gradient; B from 0% to B from 100%; flow rate = 80 ml / min).The pure fractions were combined, concentrated, and vacuum dried to obtain the title compound (270 mg, 0.56 mmol, 75% yield) as a pale yellow solid. 1H-NMR (500 MHz, methanol-d4) 8.27 (s, 1H) , 8.06 (s, 1H) , 7.60 (s, 1H) , 7.52-7.45 (m, 1H) , 7.30 (s, 1H) , 7.08-7.01 (m, 1H) , 6.65-6.57 (m, 1H) , 4.57-4.53 (m, 1H) , 4.53-4.48 (m, 1H) , 3.96 (s, 3H) , 3, 90 (s, 3H) , 3, 16-3, 03 (m, 1H) , 2, 62 (s, 3H) , 2, 38-2, 22 (m, 2H) , 2, 10-2, 00 (m, 2H) , 1, 86-1, 75 (m, 1H), 1, 49 (s, 9H). Analytical LC / MS (Method 5) : Observed mass: 476.4; Retention time: 0. 88 min. Step B. Intermediate Product 24B. Preparation of 6-(8-azabicyclo[3.2.1]octan-3-yl)-2-(3,4-dimethoxyphenyl)-8-methylimidazo[1,2-a]pyridine hydrochloride Intermediate product 24A (270 mg, 0.57 mmol) and MeOH (30 mL) were added to a 100 mL pear-shaped flask. The flask was evacuated and purged with N2, then Pd-C (10% on carbon) (60 mg, 0.057 mmol) was added, and the reaction mixture was stirred in hydrogen at 1 atm. After 18 h, the catalyst was filtered, and 4 M HCl in dioxane (30 mL) was added to the filtrate. After stirring for 30 min, the solvent was concentrated, the residue was co-evaporated with toluene (2x), and the product was vacuum-dried to obtain the title compound (230 mg, 0.56 mmol, 98% yield) as a toasted solid. 1H-NMR (500 MHz, methanol-d4) 8, 83-8, 59 (m, 1H), 8, 46 (s, 1H), 7, 80 (s, 1H), 7, 56 (s, 2H), 7, 21-7, 15 (m, 1H), 4, 25-4, 14 (m, 2H), 3, 98 (s, 3H), 3, 94 (s, 3H), 3, 78-3, 58 (m, 2H), 3, 48-3, 40 (m, 1H), 2, 77-2, 72 (m, 3H), 2, 25 (sa, 4H) , 2, 16-2, 08 (m, 2H) . CL / EM analytical (Method 5) : Observed mass: 378.3; Retention time: 0.58 min. Stage C. Preparation of Example 24 Intermediate product 24B (70 mg, 0.16 mmol), 1-cyclopropylpiperidin-4-one (110 mg, 0.79 mmol), AcOH (10 mg, 0.17 mmol), magnesium sulfate (220 mg, 1.8 mmol), and DMF (2 mL) were added to a 40 mL vial. The reaction mixture was stirred for 20 min, then sodium triacetoxyborohydride (99 mg, 0.47 mmol) was added, and the reaction mixture was stirred again. After 18 h, the reaction mixture was filtered and partitioned into 10% NaOH (20 mL) and extracted with 10% IPA / chloroform (3 x 10 mL). The organic phase was combined, dried over Na₂SO₄, filtered, and concentrated. The raw material was purified by preparative HPLC (preparation method 1) to obtain the title compound (57 mg, 0.11 mmol, 69% yield).1H-RMN (500 MHz, DMSO-6) 8, 01-7, 94 (m, 2H), 7, 32-7, 22 (m, 2H), 6, 83-6, 75 (m, 2H), 3, 62 (s, 3H), 3, 56 (s, 3H), 2, 82-2, 66 (m, 3H), 2, 66-2, 58 (m, 1H), 2, 24-2, 15 (m, 1H), 2, 11-2, 02 (m, 1H), 2, 02-1, 90 (m, 2H), 1, 58 (sa, 9H), 1, 50-1, 30 (m, 4H) , 1, 29-1, 20 (m, 1H) , 1, 15-1, 01 (m, 2H) , 0, 23-0, 14 (m, 2H) , 0, 10-0, 02 (m, 2H) . CL / EM analítica (Método 1): Pureza: 98, 9%; Masa observada: 501, 17; Retention time: 1, 52 minutes. (Método 2): Pureza: 100%; Masa observada: 500, 96; Retention time: 1, 16 minutes. Examples 25 and 26 6- (8- (1-ciclopropilpiperidin-4-il) -8-azabiclo[3.2.1]octan-3-il) -2- (3, 4-dimetoxifenil) -8-metilimidazo[1, 2-a]piridina The individual isomers of example 25 and example 26 were obtained by separating the isomeric mixture of example 24 (21 mg, 0.041 mmol) under the following conditions: Instrument: Waters 100 Prep SFC; Column: Chiral OD, 30 x 250 mm, 5 microns; Mobile phase: 55% CO2 / 45% IPA with 0.1% DEA; Flow conditions: 100 ml / min; Detector wavelength: 220 nm; Injection details: 600 µl, 21 mg dissolved in 3 ml of MeOH. Example 25 (5.6 mg, 0.011, 27% yield) was isolated as the first elution isomer. 1H-NMR (500 MHz, DMSO-6) 7.95 (s, 1H) , 7.94-7.90 (m, 1H) , 7.30-7.26 (m, 1H) , 7.25-7.19 (m, 1H) , 6.76 (sa, 2H) , 3.60 (s, 3H) , 3.54 (s, 3H) , 3.36-3.19 (m, 1H) , 2.76-2.62 (m, 3H) , 1.98-1.89 (m, 2H) , 1.67-1.52 (m, 6H) , 1.51-1.42 (m, 2H) , 1.35-1.25 (m, 3H) , 1.07-0.95 (m, 2H) , 0.17-0.11 (m, 2H) , 0.07-0.00 (m, 2H) (5 obscured protons). Analytical CL / MS (Method 1): Purity: 99.3%; Observed Mass: 501.21; Retention Time: 1.46 min. (Method 2): Purity: 100%; Observed Mass: 500.98; Retention Time: 1.01 min. Chiral analysis (SFC 4 method): Chiral purity > 95%. Retention time: 2.2 min. Example 26 (4.1 mg, 0.0082 mmol, 20% yield) was isolated as the second elution isomer. 1H-NMR (500 MHz, DMSO-6) 8.42-8.35 (m, 1H) , 8.21 (s, 1H) , 7.52 (d, J=1, 9 Hz, 1H) , 7.48 (dd, J=8, 2, 1, 8 Hz, 1H) , 7.07 (s, 1H) , 7.02 (d, J=8, 5 Hz, 1H) , 3.85 (s, 3H) , 3.79 (s, 3H) , 3.13-3.01 (m, 1H) , 3.00-2, 89 (m, 2H) , 2.51 (dd, J=3, 8, 1, 9 Hz, 6H) , 2, 43-2, 30 (m, 2H) , 2, 24-2, 13 (m, 2H) , 1, 93-1, 82 (m, 5H) , 1, 62-1, 49 (m, 4H), 1, 46-1, 33 (m, 2H), 0, 43-0, 38 (m, 2H), 0, 32-0, 28 (m, 2H). Analytical LC / MS (Method 1) : Purity: 100%; Observed mass: 500, 93; Retention time: 1.46 min. (Method 2): Purity: 98.6%; Observed mass: 500.96; Retention time: 0.99 min. Chiral analysis (SFC method 4): Chiral purity > 95%. Retention time: 4.2 min. Example 27 2-(3, 4-dimethoxyphenyl)-6-(8-(1-isobutylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-8-methylimidazo[1, 2-a]pyridine (isomeric mixture) Example 27 was prepared according to the general methods described for the synthesis of Example 24 (step C), using intermediate 24C (70 mg, 0.16 mmol) as starting material 1 and substituting 1-isobutylpiperidin-4-one (120 mg, 0.77 mmol) where appropriate. The crude material was purified by preparative HPLC (preparation method 1) to obtain the title compound (76 mg, 0.15 mmol, 94% yield). 1H-NMR (500 MHz, DMSO-d6) 8, 23 (s, 2H) , 7, 55-7, 52 (m, 1H) , 7, 51-7, 46 (m, 1H) , 7, 07-6, 99 (m, 2H) , 3, 86 (s, 3H) , 3, 80 (s, 3H) , 3, 69-3, 62 (m, 1H) , 3, 05-2, 94 (m, 1H) , 2, 88-2, 79 (m, 2H) , 2, 56 (s, 4H) , 2, 33-2, 23 (m, 1H) , 2, 06-2, 01 (m, 2H) , 1, 89-1, 72 (m, 6H) , 1, 66-1, 55 (m, 2H) , 1, 49-1, 30 (m, 3H) , 0, 88-0, 85 (m, 6H) (4 obscured protons) . Analytical CL / MS (Method 1): Purity: 97.9%; Observed Mass: 516.97; Retention Time: 1.59 min. (Method 2): Purity: 100%; Observed Mass: 516.96; Retention Time: 1.1 min. Examples 28 and 29 2-(3,4-dimethoxyphenyl)-6-(8-(1-isobutylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-8-methylimidazo[1,2-a]pyridine The individual isomers of example 28 and example 29 were obtained by separating the isomeric mixture of example 27 (50 mg, 0.097 mmol) under the following conditions: Instrument: Berger SFC; Column: OD 30 x 250 mm ID, 5pm; Temperature: 40 °C; Flow rate: 85.0 ml / min; Mobile phase: 75 / 25 CO2 / EtOH-0.1 %DEA; Detector wavelength: 220 nm; Injection volume: 500 µl; Sample preparation: 50 mg of the sample dissolved in 3 ml of MeOH. Example 28 (22 mg, 0.043 mmol, 44% yield) was isolated as the first elution isomer. 1H-NMR (400 MHz, methanol-d4) 8,12-8,07 (m, 1H) , 8,01 (s, 1H) , 7,61-7,58 (m, 1H) , 7,49-7,44 (m, 1H) , 7,09-7,05 (m, 1H) , 7,04-6,98 (m, 1H) , 3,95 (s, 3H) , 3,88 (s, 3H) , 3,69-3,61 (m, 2H) , 3,35-3,32 (m, 1H) , 3, 05-2, 89 (m, 3H) , 2, 59 (s, 3H) , 2, 56-2, 49 (m, 1H) , 2, 11 (s, 2H) , 2, 05-1, 89 (m, 4H) , 1, 86-1, 76 (m, 3H), 1.68-1.47 (m, 4H), 1.29 (s, 3H), 0.93 (d, J=6.7 Hz, 6H). Analytical LC / MS (Method 3) : Purity: 96.9%; Observed mass: 517.55; Retention time: 2.27 min. (Method 4): Purity: 98.0%; Observed mass: 517.20; Retention time: 1.25 min. Chiral analysis (SFC method 5): Chiral purity > 99%. Retention time: 11.58 min. Example 29 (12 mg, 0.010 mmol, 23% yield) was isolated as the second elution isomer. 1H-NMR (400 MHz, methanol-d4) 8, 42-8, 37 (m, 1H), 8, 08-8, 05 (m, 1H), 7, 62-7, 59 (m, 1H), 7, 52-7, 46 (m, 1H), 7, 19-7, 15 (m, 1H) , 7, 07-7, 02 (m, 1H) , 3, 96 (s, 3H) , 3, 90 (s, 3H) , 3, 68-3, 64 (m, 1H) , 3, 52-3, 48 (m, 1H) , 3, 40-3, 36 (m, 1H), 3, 17-3.05 (m, 4H) , 2.63 (s, 3H) , 2.54-2.44 (m, 4H) , 2.39-2.35 (m, 1H) , 2.12-2.01 (m, 6H) , 1.78-1.64 (m, 5H) , 0.98-0.97 (m, 3H) , 0.97-0.95 (m, 3H) . Analytical CL / EM (Method 3): Purity: 98.5%; Observed mass: 517.50; Retention time: 2.28 min. (Method 4): Purity 96.1%; Observed mass: 517.20; Retention time: 1.18 min. Chiral analysis (SFC 5 method): Chiral purity > 99%. Retention time: 19.81 min. Example 30 2-(3, 4-dimethoxyphenyl)-6-(8-(1-isopropylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-8-methylimidazo[1, 2-a]pyridine (isomeric mixture) Example 30 was prepared according to the general methods described for the synthesis of Example 24 (step C), using intermediate 24C (70 mg, 0.16 mmol) as starting material 1 and substituting 1-isopropylpiperidin-4-one (110 mg, 0.78 mmol) where appropriate. The crude material was purified by preparative HPLC (preparation method 1) to obtain the title compound (44 mg, 0.088 mmol, 55% yield). 1H-NMR (500 MHz, DMSO-6) 8, 23-8, 18 (m, 2H), 7, 56-7, 52 (m, 1H), 7, 51-7, 47 (m, 1H), 7, 05-6, 99 (m, 2H), 3, 86 (s, 3H), 3, 80 (s, 3H) , 3, 62-3, 40 (m, 1H) , 3, 02-2, 91 (m, 1H) , 2, 88-2, 80 (m, 2H) , 2, 76-2, 67 (m, 1H) , 2, 56 (s, 3H) , 2, 49-2, 40 (m, 1H) , 2, 24-2, 16 (m, 2H) , 1, 91-1, 70 (m, 8H) , 1, 59-1, 51 (m, 2H) , 1, 38-1, 29 (m, 2H) , 0, 99 (s, 6H) (one obscured proton) . Analytical CL / EM (Method 1) : Purity: 100 %; Observed Mass: 502, 90; Retention Time: 1, 41 min.(Method 2): Purity: 100%; Observed mass: 502.96; Retention time: 1.08 min. Example 31 2- (3, 4-dimethoxyphenyl) -6- (1-isobutyl-[1, 4-bipiperidin]-4-yl) -5, 6, 7, 8-tetrahydroimidazo[1, 2-a]pyridine (racemic mixture) Step A. Intermediate product 31 A. Preparation of 4-(2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-6-yl) piperidin-1-tert-butyl carboxylate Intermediate product 10B (2.5 g, 5.7 mmol) and MeOH (350 mL) were added to a 100 mL pear-shaped flask. The flask was evacuated and purged with N2, then Pd-C (10% on carbon) (1.2 g, 0.57 mmol) was added and the reaction mixture was stirred in hydrogen at 1 atm. After stirring for 96 h, the catalyst was filtered and the filtrate was concentrated. The crude residue was purified by ultrafast column chromatography (120 g silica gel cartridge; A = DCM, B = MeOH; 30 min gradient; 0% B to 10% B; flow rate = 80 mL / min). The pure fractions were combined, concentrated, and vacuum dried to obtain the title compound (2.1 g, 4.8 mmol, 84% yield) as a pale yellow solid.1H-RMN (500 MHz, methanol-d6) 7, 34 (d, J=1, 9 Hz, 1H) , 7, 26-7, 23 (m, 1H) , 7, 22 (s, 1H) , 6, 97-6, 93 (m, 1H) , 4, 20-4, 13 (m, 3H) , 3, 90 (s, 3H) , 3, 85 (s, 3H) , 3, 79-3, 71 (m, 1H) , 3, 05-2, 97 (m, 1H) , 2, 85-2, 72 (m, 3H) , 2, 24-2, 15 (m, 1H) , 1, 93-1, 85 (m, 2H), 1, 83-1, 75 (m, 1H), 1, 71-1, 54 (m, 2H), 1, 49-1, 46 (m, 9H), 1, 34-1, 24 (m, 2H). CL / EM analítica (Método 5): Masa observada: 442, 5; Retention time: 0, 78 min. Etapa B. Producto intermedio 31B. Preparation of clorhydration of 2- (3, 4-dimetoxifenil) -6- (piperidin-4-il) -5, 6, 7, 8-tetrahidroimidazo[1, 2-a]piridina The intermediate product 31A (2.1 g, 4.8 mmol), THF (10 ml), and 4 M HCl in dioxane (20 ml) were added to a 200 ml pear-shaped flask. After shaking for 18 h, the solvent was concentrated and the residue was co-evaporated with toluene. The product was vacuum dried to obtain the title compound (1.8 g, 4.8 mmol, 100% yield) as a light tan solid. 1H-NMR (500 MHz, methanol-d6) 7.70 (s, 1H) , 7.27-7.26 (m, 1H) , 7.30-7.26 (m, 1H) , 7.11-7.08 (m, 1H) , 4.43-4.37 (m, 1H) , 4.01-3.94 (m, 1H) , 3.93 (s, 3H) , 3.90 (s, 3H) , 3.63-3.58 (m, 4H) , 3.53-3.47 (m, 2H) , 3, 30-3, 26 (m, 1H) , 3, 25-3, 22 (m, 1H) , 3, 11-3, 03 (m, 3H) , 2, 34-2, 27 (m, 1H) , 2, 19-2, 04 (m, 2H) . Analytical CL / EM (Method 5) : Observed mass: 342.4; Retention time: 0.50 min. Stage C. Preparation of example 31 To a 40 mL vial were added the intermediate product 3IB (120 mg, 0.27 mmol), 1-isobutylpiperidin-4-one (220 mg, 1.4 mmol), AcOH (0.017 mL, 0.3 mmol), magnesium sulfate (490 mg, 4.1 mmol), and DMF (5 mL). The reaction mixture was stirred for 20 min, then sodium triacetoxyborohydride (170 mg, 0.81 mmol) was added, and the reaction mixture was stirred again. After 24 h, the reaction mixture was filtered, and the filter cake was washed with 10% IPA / chloroform (20 mL). The filtrate was washed with 10% aqueous NaOH (10 mL), brine, dried over MgSCU, filtered, and concentrated. The crude material was purified by preparative HPLC (preparation method 1) to obtain the title compound (69 mg, 0.14 mmol, 52% yield). Analytical LC / MS (Method 1): Purity: 96.8%; Observed mass: 481.23; Retention time: 1.38 min. (Method 2): Purity: 97.6%; Observed mass: 481.22; Retention time: 0.91 min. Examples 32 and 33 2-(3,4-dimethoxyphenyl)-6-(1-isobutyl-[1,4-bipiperidin]-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine The individual enantiomers of example 32 and example 33 were obtained by separating the racemic mixture of example 31 (68 mg, 0.14 mmol) under the following conditions: Instrument: Waters 100 Prep SFC; Column: Chiral OD, 30 x 250 mm, 5 microns; Mobile phase: 55% CO2 / 45% MeOH with 0.1% DEA; Flow conditions: 100 ml / min; Detector wavelength: 220 nm; Injection details: 1000 µl, 68 mg dissolved in 3 ml of MeOH. Example 32 (21 mg, 0.044 mmol, 31% yield) was isolated as the 1st elution enantiomer. 1H-NMR (500 MHz, DMSO-6) 7, 58-7, 48 (m, 1H) , 7, 34-7, 29 (m, 1H) , 7, 28-7, 21 (m, 1H) , 7, 00-6, 93 (m, 1H) , 4, 18-4, 09 (m, 1H), 3, 81 (s, 3H), 3, 78 (s, 3H), 3, 00-2, 89 (m, 9H), 2, 84-2, 76 (m, 1H), 2, 05 (sa, 4H), 1, 89 (sa, 5H), 1, 68-1, 45 (m, 5H), 0.93-0.89 (m, 6H) (three obscured protons). Analytical CL / MS (Method 1): Purity: 98.2%; Observed mass: 481.18; Retention time: 1.38 min. (Method 2): Purity: 97.1%; Observed mass: 480.98; Retention time: 1.05 min. Chiral analysis (SFC method 1): Chiral purity > 95%. Retention time: 1.89 min. Example 33 (11 mg, 0.023 mmol, 16% yield) was isolated as the 2nd elution enantiomer.1H-NMR (500 MHz, DMSO-6) 7, 35 (s, 1H) , 7, 30 (d, J=1, 2 Hz, 1H) , 7, 21 (s, 1H) , 6, 92 (d, J=8, 2 Hz, 1H) , 4, 11-4, 01 (m, 1H) , 3, 79 (s, 3H) , 3, 76 (s, 3H) , 3, 69-3, 60 (m, 1H) , 3, 05-2, 98 (m, 2H) , 2, 91-2, 83 (m, 3H) , 2, 72-2, 63 (m, 1H) , 2, 40-2, 30 (m, 1H) , 2, 28-2, 18 (m, 2H) , 2, 09-1, 99 (m, 3H) , 1, 92-1, 81 (m, 3H) , 1, 79-1, 68 (m, 5H), 1, 59-1, 43 (m, 3H), 1, 38-1, 24 (m, 3H), 0, 85 (d, .J=6, 4 Hz, 6H). Analytical LC / MS (Method 1) : Purity: 100%; Observed mass: 481.17; Retention time: 1.38 min. (Method 2): Purity: 97.2%; Observed mass: 481.01; Retention time: 1.05 min. Chiral analysis (SFC method 1): Chiral purity > 95%. Retention time: 5.19 min. Example 34 2-(3, 4-dimethoxyphenyl)-6-(1-isopropyl-[1, 4-bipiperidin]-4-yl)-5, 6, 7, 8-tetrahydroimidazo[1, 2-a]pyridine (racemic mixture) Example 34 was prepared according to the general methods described for the synthesis of Example 31 (step C), using intermediate 3 IB (120 mg, 0.27 mmol) as the starting material and substituting 1-isopropylpiperidin-4-one (190 mg, 1.3 mmol) where appropriate. The crude material was purified by preparative HPLC (preparation method 1) to obtain the title compound (70 mg, 0.15 mmol, 56% yield). 1H-NMR (500 MHz, DMSO-d6) 7.34 (s, 1H) , 7.30 (d, J=1, 8 Hz, 1H) , 7.21 (dd, J=8, 2, 1, 8 Hz, 1H) , 6.91 (d, J=8, 2 Hz, 1H) , 4.09-4.01 (m, 1H) , 3.79 (s, 3H) , 3.75 (s, 3H) , 3.70-3.59 (m, 1H) , 2.95-2.86 (m, 2H), 2, 86-2, 79 (m, 2H), 2, 73-2, 61 (m, 2H), 2, 19-2, 13 (m, 1H), 2, 08 (sa, 5H), 1, 80-1, 64 (m, 5H), 1, 58-1, 47 (m, 1H), 1.45-1.34 (m, 2H), 1.32-1.18 (m, 3H), 0.96 (d, J=6.7 Hz, 6H) (one darkened proton). Analytical LC / MS (Method 1) : Purity: 90.7%; Observed mass: 467.13; Retention time: 1.2 min.(Method 2): Purity: 95.1%; Observed mass: 467.65; Retention time: 0.64 min. Examples 35 and 36 2-(3,4-dimethoxyphenyl)-6-(1-isopropyl-[1,4-bipiperidin]-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine The individual enantiomers of example 35 and example 36 were obtained by separating the racemic mixture of example 34 (26 mg, 0.056 mmol) under the following conditions: Instrument: Waters 100 Prep SFC; Column: Chiral OD, 30 x 250 mm, 5 microns; Mobile phase: 55% CO2 / 45% MeOH with 0.1% DEA; Flow conditions: 100 ml / min; Detector wavelength: 220 nm; Injection details: 1000 µl, 26 mg dissolved in 3 ml of MeOH. Example 35 (6.4 mg, 0.014 mmol, 25% yield) was isolated as the 1st elution enantiomer. 1H-NMR (500 MHz, DMSO-6) 7, 32 (s, 1H) , 7, 29 (d, J=1, 7 Hz, 1H) , 7, 19 (s, 1H) , 6, 90 (d, J=8, 4 Hz, 1H) , 4, 08-3, 98 (m, 1H) , 3, 77 (s, 3H) , 3, 73 (s, 3H) , 2, 94-2, 88 (m, 2H) , 2, 87-2, 79 (m, 3H) , 2, 73-2, 60 (m, 2H) , 2, 21-1, 98 (m, 6H) , 1, 79-1, 70 (m, 4H) , 1, 69-1, 61 (m, 1H) , 1, 57-1, 46 (m, 1H) , 1, 45-1, 34 (m, 2H) , 1, 33-1, 19 (m, 3H) , 0, 95 (d, J=6, 5 ​​Hz, 6H) (one obscured proton) . Analytical CL / MS (Method 1): Purity: 97.7%; Observed Mass: 467.21; Retention Time: 1.25 min. (Method 2): Purity: 100%; Observed Mass: 467.19; Retention Time: 0.97 min. Chiral Analytical (Method SFC 1): Chiral purity > 95%. Retention time: 1.85 min. Example 36 (7.4 mg, 0.016 mmol, 29% yield) was isolated as the 2nd elution enantiomer. 1H-NMR (500 MHz, DMSO-6) 7, 34 (s, 1H) , 7, 30 (s, 1H) , 7, 23-7, 18 (m, 1H) , 6, 94-6, 89 (m, 1H) , 4, 10-4, 02 (m, 1H) , 3, 78 (s, 3H) , 3, 74 (s, 3H) , 3, 71-3, 61 (m, 1H) , 2, 98-2, 86 (m, 4H) , 2, 80-2, 71 (m, 1H) , 2, 70-2, 61 (m, 1H) , 2, 29-2, 08 (m, 6H), 2.07-2.00 (m, 1H) , 1.83-1.65 (m, 5H) , 1.57-1.39 (m, 3H) , 1.36-1.21 (m, 3H) , 1.01-0.98 (m, 6H) . CL / EM analytical (Method 1): Purity: 100%; Observed mass: 467.21; Retention time: 1.25 min. (Method 2): Purity: 98.4%; Observed mass: 467.19; Retention time: 0.97 min. Chiral analytical (method SFC 1): Chiral purity > 95%. Retention time: 3.68 min. Examples 37 and 38 6- (1-cyclopropyl-[1, 4-bipiperidin]-4-yl) -2- (3, 4-dimethoxyphenyl) -5, 6, 7, 8-tetrahydroimidazo[1, 2-a]pyridine The racemic mixture was prepared according to the general methods described for the synthesis of Example 31 (step C), using the intermediate product 3 IB (300 mg, 0.62 mmol) as the starting material and substituting 1-cyclopropylpiperidin-4-one (430 mg, 3.1 mmol) where appropriate. The crude material was purified by preparative HPLC (Preparation Method 1) to provide the racemic mixture (65 mg, 0.14 mmol, 23% yield). The individual enantiomers of example 37 and example 38 were obtained by separating the racemic mixture (65 mg, 0.14 mmol) under the following conditions: Instrument: Waters 100 Prep SFC; Column: AD chiral, 30 x 250 mm, 5 microns; Mobile phase: 60% CO2 / 40% MeOH with 0.1% DEA; Flow conditions: 100 ml / min; Detector wavelength: 220 nm; Injection details: 1200 ul, 65 mg dissolved in 3 ml of MeOH. Example 37 (25 mg, 0.054 mmol, 39% yield) was isolated as the 1st elution enantiomer. 1H-NMR (500 MHz, DMSO-6) 7.08 (s, 1H) , 7.04 (d, J=1.8 Hz, 1H) , 6.97-6.94 (m, 1H) , 6.66 (s, 1H) , 3.82-3.77 (m, 1H) , 3. 53 (s, 3H) , 3, 49 (s, 3H) , 3, 43-3, 36 (m, 1H) , 2, 75-2, 69 (m, 3H) , 2, 63-2, 57 (m, 1H) , 2, 45-2, 36 (m, 1H) , 2, 15-2, 04 (m, 1H) , 2, 02-1, 91 (m, 2H) , 1, 91-1, 81 (m, 2H) , 1, 81-1, 74 (m, 1H) , 1, 57-1, 42 (m, 5H) , 1, 34-1, 23 (m, 2H) , 1, 19-0, 96 (m, 6H), 0.17-0.11 (m, 2H), 0.05-0.03 (m, 2H). Analytical LC / MS (Method 1) : Purity: 100%; Observed mass: 465.28; Retention time: 1.37 min. (Method2) : Purity: 100%; Observed mass: 465.28; Retention time: 0.95 min. Chiral analysis (SFC 2 method): Chiral purity > 95%. Retention time: 3.60 min. Example 38 (23 mg, 0.043 mmol, 31% yield) was isolated as the 2nd elution enantiomer. 1H-NMR (500 MHz, DMSO-6) 7, 08 (s, 1H) , 7.04 (d, J=1, 9 Hz, 1H) , 6, 97-6, 94 (m, 1H) , 6, 65 (d, J=8, 5 Hz, 1H) , 3, 84-3, 76 (m, 1H) , 3, 53 (s, 3H) , 3, 49 (s, 3H) , 3, 43-3, 34 (m, 1H) , 2, 77-2, 68 (m, 4H) , 2, 65-2, 56 (m, 1H), 2, 45-2, 36 (m, 1H), 2, 15-2, 05 (m, 1H), 2, 01-1, 91 (m, 2H), 1, 90-1, 82 (m, 2H), 1, 81-1, 74 (m, 1H), 1.57-1.42 (m, 5H), 1.34-1.24 (m, 2H), 1.18-0.98 (m, 5H), 0.17-0.11 (m, 2H), 0.04-0.02 (m, 2H). Analytical LC / MS (Method 1) : Purity: 100%; Observed mass: 465.29; Retention time: 1.37 min. (Method 2): Purity: 87.7%; Observed mass: 465.29; Retention time: 0.95 min. Chiral analysis (SFC 2 method): Chiral purity > 95%. Retention time: 5.58 min. Example 39 1- (4- (2- (3,4-dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-6-yl)-[1,4'-bipiperidin]-1-yl)-2-methylpropan-1-one (racemic mixture) Step A. Intermediate Product 39A. Preparation of 6-([1,4'-bipiperidin]-4-yl)-2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine dihydrochloride To a 40 mL vial were added the intermediate product 3 IB (600 mg, 1.6 mmol), tert-butyl 4-oxopiperidine-1-carboxylate (950 mg, 4.8 mmol), AcOH (0.10 mL, 1.7 mmol), magnesium sulfate (2900 mg, 24 mmol), and DMF (15 mL). The reaction mixture was stirred for 20 min, then sodium triacetoxyborohydride (1000 mg, 4.8 mmol) was added, and the reaction mixture was stirred again. After 24 h, the reaction mixture was filtered, and the filter cake was washed with 10% MeOH / DCM (20 mL). The filtrate was concentrated, and the crude product was purified by ultrafast column chromatography (100 g GOLD C18 reversed-phase silica gel cartridge; A = water MeCN:TFA 90:10:0.05%, B = water:MeCN:TFA 10:90:0.05%; 20 min gradient; 0% B to 400% B; flow rate = 60 mL / min). The pure fractions were combined and concentrated. The resulting residue was dissolved in THF (20 mL) and 4 M HCl in dioxane (20 mL) and stirred.After 3 h, the solvent was concentrated, the residue was co-evaporated with toluene, and the product was vacuum-dried to yield the title compound (790 mg, 1.6 mmol, 100% yield) as a yellow solid. Analytical CL / MS (Method 5): Observed mass: 425.4; Retention time: 0.48 min. Stage B. Preparation of example 39 To a 40 ml vial were added the intermediate product 39A (200 mg, 0.22 mmol), isobutyric acid (39 mg, 0.44 mmol), TEA (0.062 ml, 0.44 mmol), HOBt (85 mg, 0.44 mmol) and DMF (2 ml). To this mixture was added EdC (85 mg, 0.44 mmol), the vial was capped and the reaction mixture was shaken. After 18 h, the crude reaction mixture was purified by preparative HPLC (preparation method 2) to obtain the title compound (30 mg, 0.061 mmol, 28% yield). 1H-NMR (500 MHz, DMSO-6) 7, 93 (s, 1H) , 7, 36 (s, 2H) , 7, 11 (da, J=8, 5 Hz, 1H) , 4, 62-4, 52 (m, 1H) , 4, 29-4, 21 (m, 1H) , 4, 17-4, 08 (m, 1H) , 3, 92-3, 87 (m, 1H) , 3, 86-3, 83 (m, 3H) , 3, 83-3, 80 (m, 3H) , 3, 58-3, 50 (m, 1H) , 3, 20-2, 86 (m, 6H) , 2, 14-2, 02 (m, 4H) , 1, 99-1, 91 (m, 2H) , 1, 74-1, 38 (m, 7H) , 1, 04-0, 99 (m, 6H) (two obscured protons) . Analytical CL / EM (Method 1) : Purity: 98.6%; Observed Mass: 495.19; Retention Time: 1.25 min.(Method 2): Purity: 98.8%; Observed mass: 495.16; Retention time: 1.05 min. Examples 40 and 41. 1-(4-(2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-6-yl)-1,4'-bipiperidin]-1'-yl)-2-methylpropan-1-one The individual enantiomers of example 40 and example 41 were obtained by separating the racemic mixture of example 39 (14 mg, 0.028 mmol) under the following conditions: Instrument: Waters 100 Prep SFC; Column: Chiral OD, 30 x 250 mm, 5 microns; Mobile phase: 55% CO2 / 45% MeOH-ACN-50-50; Flow conditions: 100 ml / min; Detector wavelength: 220 nm; Injection details: 2000 µl, 14 mg dissolved in 3 ml of MeOH. Example 40 (3.7 mg, 0.0075 mmol, 27% yield) was isolated as the 1st elution enantiomer. 1H-NMR (500 MHz, DMSO-6) 7, 34 (s, 1H) , 7, 30 (s, 1H) , 7, 24-7, 19 (m, 1H) , 6, 94-6, 89 (m, 1H) , 4, 49-4, 38 (m, 1H) , 4, 09-4, 03 (m, 1H) , 4, 01-3, 93 (m, 1H) , 3, 79 (s, 3H) , 3, 75 (s, 3H) , 3, 70-3, 61 (m, 1H) , 3, 04-2, 90 (m, 3H) , 2, 90-2, 82 (m, 2H), 2.72–2.60 (m, 1H) , 2.22–2.13 (m, 2H) , 2.07–2.01 (m, 1H) , 1.85–1.72 (m, 4H) , 1.71–1.65 (m, 1H) , 1.59–1.48 (m, 1H) , 1.39–1.17 (m, 6H) , 0.99 (s, 6H) (one obscured protonated sample). Analytical CL / MS (Method 1): Purity: 95.3%; Observed mass: 495.15; Retention time: 1.28 min. (Method 2): Purity: 97.2%; Observed mass: 495.13; Retention time: 1.06 min. Chiral analysis (SFC method 1): Chiral purity > 95%. Retention time: 1.25 min. Specimen 41 (3.8 mg, 0.0077 mmol, 28% yield) was isolated as the 2 or elution enantiomer.1H-NMR (500 MHz, DMSO-6) 7, 36-7, 33 (m, 1H) , 7, 32-7, 29 (m, 1H) , 7, 24-7, 19 (m, 1H) , 6, 94-6, 89 (m, 1H) , 4, 47-4, 39 (m, 1H), 4, 10-4, 02 (m, 1H), 4, 00-3, 93 (m, 1H), 3, 78 (s, 3H), 3, 75 (s, 3H), 3, 69-3, 61 (m, 1H), 3, 54-3, 44 (m, 1H) , 3, 02-2, 94 (m, 1H), 2, 94-2, 83 (m, 4H), 2, 72-2, 60 (m, 1H), 2, 50-2, 43 (m, 2H), 2, 07-2, 00 (m, 1H), 1, 84-1, 71 (m, 4H), 1.70-1.65 (m, 1H), 1.57-1.48 (m, 1H), 1.36-1.14 (m, 6H), 0.99 (ta, J=7.2 Hz, 6H). Analytical LC / MS (Method 1) : Purity: 96%; Observed mass: 495.16; Retention time: 1.28 min. (Method 2): Purity: 96.7%; Observed mass: 495.12; Retention time: 1.06 min. Chiral analysis (SFC Method 1): Chiral purity > 95%. Retention time: 3.40 min. Example 42 cyclopropyl (4-(2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-6-yl)-[1,4'-bipiperi din]-1-yl) m ethanone (racemic mixture) To a 40 mL vial were added the intermediate product 39A (200 mg, 0.22 mmol), TEA (0.34 mL, 2.4 mmol), DMAP (98 mg, 0.80 mmol), and DCM (2 mL). To this mixture, cyclopropanecarbonyl chloride (0.073 mL, 0.80 mmol) was added, the vial was capped, and the reaction mixture was shaken. After 2 h, the solvent was concentrated, and the crude material was purified by preparative HPLC (preparation method 1) to obtain the title compound (59 mg, 0.12 mmol, 55% yield). 1H-NMR (500 MHz, DMSO-6) 7, 34-7, 32 (m, 1H) , 7, 30-7, 28 (m, 1H) , 7, 22-7, 18 (m, 1H) , 6, 92-6, 88 (m, 1H) , 4, 45-4, 35 (m, 1H), 4, 33-4, 24 (m, 1H), 4, 09-4, 01 (m, 1H), 3, 77 (s, 3H), 3, 74 (s, 3H), 3, 09-2, 94 (m, 3H), 2, 91-2, 81 (m, 1H) , 2, 72-2, 60 (m, 2H), 2, 30-2, 18 (m, 2H), 2, 07-2, 00 (m, 1H), 1, 98-1, 93 (m, 1H), 1, 91-1, 66 (m, 6H), 1, 58-1, 47 (m, 1H), 1, 44-1, 19 (m, 6H), 0, 69 (br d, J=7, 3 Hz, 4H). CL / EM analytical (Method 1): Purity: 100%; Observed mass: 493.08; Retention time: 1.14 min. (Method 2): Purity: 100%; Observed mass: 493.28; Retention time: 1.02 min. Examples 43 and 44 cyclopropyl (4-(2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-6-yl)-[1,4'-bipiperidin]-1'-yl)methanone The individual enantiomers of example 43 and example 44 were obtained by separating the racemic mixture of example 42 (59 mg, 0, 12 mmol) under the following conditions: Instrument: Waters 100 Prep SFC; Column: Chiral DO, 30 x 250 mm, 5 microns; Mobile phase: 75% CO2 / 25% IPA-ACN 50-50 with 0.1% DEA; Flow conditions: 100 ml / min; Detector wavelength: 220 nm; Injection details: 1000 µl, 59 mg dissolved in 3 ml of MeOH. Sample 43 (21 mg, 0.043 mmol, 36% yield) was isolated as the 1st elution enantiomer. 1H-NMR (500 MHz, DMSO-6) 7, 34 (s, 1H) , 7, 30 (s, 1H) , 7, 21 (da, , J=8, 2 Hz, 1H) , 6, 91 (da, J=8, 2 Hz, 1H) , 4, 42-4, 33 (m, 1H) , 4, 32-4, 24 (m, 1H) , 4, 10-4, 02 (m, 1H) , 3, 78 (s, 3H) , 3, 74 (s, 3H) , 3, 68-3, 57 (m, 2H) , 3, 46-3, 37 (m, 1H) , 3, 09-2, 98 (m, 1H) , 2, 94-2, 81 (m, 3H) , 2, 70-2, 60 (m, 1H) , 2, 11 (da, J=2, 7 Hz, 3H) , 2, 07-2, 01 (m, 1H) , 1, 99-1, 92 (m, 2H) , 1, 84-1, 62 (m, 2H) , 1, 59-1, 47 (m, 2H) , 1, 29-1, 23 (m, 2H) , 1, 19 (sa, 3H) , 0, 70 (da, J=6, 7 Hz, 4H) . Analytical LC / MS (Method 1): Purity: 95.4%; Observed mass: 493.14; Retention time: 1.24 min. (Method 2): Purity: 97.3%; Observed mass: 493.13; Retention time: 1.03 min. Chiral analysis (Method SFC 3): Chiral purity > 95%. Retention time: 5.99 min. Sample 44 (22 mg, 0.0045 mmol, 38% yield) was isolated as the 2nd elution enantiomer. 1H-NMR (500 MHz, DMSO-6) 7, 34 (s, 1H) , 7, 30 (s, 1H) , 7, 21 (da, , J=7, 9 Hz, 1H) , 6, 91 (d, J=8, 5 Hz, 1H) , 4, 43-4, 34 (m, 1H) , 4, 33-4, 23 (m, 1H) , 4, 09-4, 01 (m, 1H) , 3, 78 (s, 3H) , 3, 74 (s, 3H) , 3, 59-3, 53 (m, 1H) , 3, 47-3, 36 (m, 1H) , 3, 09-2, 99 (m, 1H), 2, 96-2, 90 (m, 2H), 2, 89-2, 83 (m, 1H), 2, 70-2, 61 (m, 1H), 2, 16 (s, 2H), 2, 08-2, 01 (m, 2H), 1.99-1.93 (m, 2H), 1.86-1.66 (m, 4H), 1.56-1.49 (m, 1H), 1.27 (sa, 2H), 1.22-1.10 (m, 3H), 0.73-0.68 (m, 4H). Analytical LC / MS (Method 1) : Purity: 100%; Observed mass: 493.34; Retention time: 1.24 min. (Method 2): Purity: 95.9%; Observed mass: 493.13; Retention time: 1.04 min. Chiral analysis (SFC method 3): Chiral purity > 95%. Retention time: 7.30 min. Example 45 2- (3, 4-dimethoxyphenyl) -6- (1- (2-isopropyl-2-azaspiro[3.3]heptan-6-yl) piperidin-4-yl) -5, 6, 7, 8-tetrahidroimidazo[1, 2-a]piridina (mezcla racémica) Etapa A. intermediate product 45 A. Preparation of 6- (1- (2-azaspiro[3.3]heptan-6-yl) piperidin-4-yl) -2- (3, 4-dimethoxyphenil) -5, 6, 7, 8-tetrahidroimidazo[1, 2-a]pyridine bis (2, 2, 2-tri fluoroacetate) The intermediate product 31A (1.0 g, 2.7 mmol), tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate (1.7 g, 7.9 mmol), AcOH (0.17 mL, 2.9 mmol), magnesium sulfate (4.8 g, 40 mmol), and DMF (20 mL) were added to a 250 mL round-bottom flask. The reaction mixture was stirred for 20 min, then sodium triacetoxyborohydride (1.7 g, 7.9 mmol) was added, and the reaction mixture was stirred again. After 18 h, the reaction mixture was filtered, the filter cake was washed with DCM / MeOH, and the filtrate was concentrated. The remaining crude DMF solution was purified by ultrafast column chromatography (275 g reverse-flow GOLD Cl 8 silica gel cartridge; A = water:MeCN:TFA 90:10:0.05%, B = water:MeCN:TFA 10:90:0.05%; 20 min gradient; 10% B to 100% B; flow rate = 125 mL / min). The pure fractions were combined and concentrated. The resulting residue was dissolved in DCM (20 mL) and TFA (20 mL).After stirring for 2 h, the solvent was concentrated under reduced pressure at 35 °C, the residue was co-evaporated with toluene, and the product was vacuum dried to obtain the title compound (1.3 g, 2.0 mmol, 74% yield) as a pale yellow solid. 1H-NMR (500 MHz, methanol-d4) 7.69-7.66 (m, 1H) , 7.27 (s, 2H) , 7.11-7.07 (m, 1H) , 4.40-4.33 (m, 1H) , 3.98-3.94 (m, 1H) , 3.92 (s, 3H) , 3.90 (s, 3H) , 3.67-3.54 (m, 3H) , 3, 28-3, 20 (m, 1H) , 3, 10-3, 01 (m, 1H) , 2, 82-2, 75 (m, 3H) , 2, 70-2, 61 (m, 3H) , 2, 32-2, 25 (m, 1H) , 2, 16-2, 06 (m, 3H) , 1, 85-1, 66 (m, 4H) . Analytical CL / EM (Method 5) : Observed mass: 437.5; Retention time: 0.58 min. Stage B. Preparation of example 45 To a 40 mL vial were added intermediate product 45A (320 mg, 0.48 mmol), acetone (140 mg, 2.4 mmol), AcOH (0.030 mL, 0.53 mmol), magnesium sulfate (870 mg, 7.2 mmol), and DMF (5 mL). The reaction mixture was stirred for 20 min, then sodium triacetoxyborohydride (310 mg, 1.5 mmol) was added, and the reaction mixture was stirred again. After 18 h, the reaction mixture was filtered, the filter cake was washed with 10% MeOH / DCM, and the filtrate was concentrated. The crude product was purified by preparative HPLC (preparation method 1) to obtain the title compound (180 mg, 0.21 mmol, 44% yield) .1H-NMR (500 MHz, DMSO-6) 7, 33 (s, 1H) , 7.29 (d, J=1, 7 Hz, 1H) , 7, 23-7, 18 (m, 1H) , 6, 90 (d, J=8, 5 Hz, 1H) , 4, 09-4, 01 (m, 1H) , 3, 78 (s, 3H) , 3, 74 (s, 3H) , 3, 69-3, 59 (m, 1H) , 3, 33-3, 15 (m, 1H) , 2, 88-2, 77 (m, 3H) , 2, 70-2, 61 (m, 1H) , 2, 47-2, 37 (m, 1H) , 2, 21-2, 13 (m, 2H) , 2, 06-1, 99 (m, 1H) , 1, 89-1, 83 (m, 2H) , 1, 79-1, 70 (m, 2H) , 1, 68-1, 59 (m, 3H) , 1, 58-1, 47 (m, 1H) , 1, 30-1, 17 (m, 3H), 0, 87 (d, J=6, 1 Hz, 6H) (4 protones oscurecidos). CL / EM analítica: (Método 1): Pureza: 95, 4%; Masa observada: 479, 26; Retention time: 1, 2 minutes. (Método 2): Pureza: 97, 5%; Masa observada: 478, 90; Retention time: 0, 98 min. Examples 46 and 47 2- (3, 4-dimetoxifenil) -6- (1- (2-isopropil-2-azaspiro[3.3]heptan-6-il) piperidin-4-il) -5, 6, 7, 8-tetrahidroimidazo[1, 2-a]piridina The individual enantiomers of example 46 and example 47 were obtained by separating the racemic mixture of example 45 (130 mg, 0.27 mmol) under the following conditions: Instrument: Waters 100 Prep SFC; Column: Chiral OD, 30 x 250 mm, 5 microns; Mobile phase: 55% CO2 / 45% MeOH with 0.1% DEA; Flow conditions: 100 ml / min; Detector wavelength: 220 nm; Injection details: 300 µl, 130 mg dissolved in 3 ml of MeOH. Example 46 (59 mg, 0.12 mmol, 44% yield) was isolated as the 1st elution enantiomer.1H-NMR (500 MHz, DMSO-6) 8, 38-8, 22 (m, 1H) , 7, 91-7, 81 (m, 1H) , 7, 36-7, 24 (m, 1H) , 7, 08 (da, J=8, 5 Hz, 1H) , 4, 27-4, 19 (m, 1H) , 4, 15-4, 04 (m, 2H) , 4, 02-3, 94 (m, 1H) , 3, 88-3, 84 (m, 1H) , 3, 82 (s, 3H) , 3, 80 (s, 3H) , 3, 74-3, 63 (m, 2H) , 3, 44-3, 30 (m, 1H) , 3, 25-3, 07 (m, 1H) , 3, 02-2, 88 (m, 4H) , 2, 79-2, 61 (m, 2H) , 2, 49-2, 46 (m, 1H) , 2, 46-2, 35 (m, 1H) , 2, 15-1, 88 (m, 3H) , 1, 76-1, 55 (m, 2H) , 1, 55-1, 34 (m, 1H) , 1, 30-1, 22 (m, 1H), 1.09 (da, J=6, 3 Hz, 6H) (two obscured protons). Analytical CL / MS (Method 1): Purity: 100%; Observed mass: 479.26; Retention time: 1.29 min. (Method 2): Purity: 100%; Observed mass: 478.94; Retention time: 0.94 min. Chiral analysis (Method SFC 1): Chiral purity > 95%. Retention time: 1.41 min. Example 47 (22 mg, 0.046 mmol, 17% yield) was isolated as the 2nd elution enantiomer. 1H-NMR (500 MHz, DMSO-6) 7, 34-7, 32 (m, 1H) , 7, 31-7, 28 (m, 1H) , 7, 22-7, 18 (m, 1H) , 6, 90 (d, J=8, 5 Hz, 1H) , 4, 08-4, 01 (m, 1H) , 3, 77 (s, 3H) , 3, 74 (s, 3H) , 3, 67-3, 60 (m, 1H) , 3, 35-3, 17 (m, 2H) , 2, 89-2, 76 (m, 3H) , 2, 69-2, 61 (m, 1H), 2, 48-2, 41 (m, 1H) , 2, 19-2, 13 (m, 2H) , 2, 06-1, 99 (m, 1H) , 1, 90-1, 84 (m, 2H) , 1, 79-1, 70 (m, 2H) , 1, 69-1, 59 (m, 3H), 1.57-1.47 (m, 1H), 1.31-1.16 (m, 3H), 0.87 (da, J=6.2 Hz, 6H) (three protons darkened). Analytical LC / MS (Method 1) : Purity: 100%; Observed mass:479, 26; Retention time: 1.29 (Method 2): Purity: 100%; Observed mass: 479.26; Retention time: 0.94 min. Chiral analysis (SFC Method 1): Chiral purity > 95%. Retention time: 4.05 min. Example 48 6- (1- (2-cyclobutil-2-azaspiro[3.3]heptan-6-yl) piperidin-4-yl) -2- (3, 4-dimethoxyphenyl) -5, 6, 7, 8-tetrahidroimidazo[1, 2a]piridina (mezcla racémica) Example 48 was prepared according to the general methods described for the synthesis of Example 45 (step B), using intermediate product 45 A (320 mg, 0.48 mmol) as the starting material and substituting cyclobutanone (170 mg, 2.4 mmol) where appropriate. The crude product was purified by preparative HPLC (preparation method 1) to obtain the title compound (170 mg, 0.35 mmol, 73% yield). 1H-NMR (500 MHz, DMSO-6) 7, 37-7, 32 (m, 1H) , 7, 31-7, 27 (m, 1H) , 7, 23-7, 18 (m, 1H) , 6, 92-6, 88 (m, 1H) , 4, 15-4, 02 (m, 1H) , 3, 77 (s, 3H) , 3, 74 (s, 3H) , 3, 48-3, 43 (m, 3H) , 3, 06-2, 93 (m, 3H) , 2, 88-2, 76 (m, 3H), 2, 72-2, 61 (m, 3H), 2, 49-2, 43 (m, 1H), 2, 17-1, 92 (m, 6H), 1, 87-1, 82 (m, 2H), 1, 77-1, 72 (m, 2H) , 1, 70-1, 47 (m, 5H) , 1, 30-1, 15 (m, 3H) . Analytical LC / MS (Method 1): Purity: 93.6%; Observed mass: 491.22; Retention time: 1.19 min.(Method 2): Purity: 96.3%; Observed mass: 491.26; Retention time: 1.04 min. Examples 49 and 50 6-(1-(2-cyclobutyl-2-azaspiro[3.3]heptan-6-yl)piperidin-4-yl)-2-(3,4-dimethoxyphenyl)-5, 6, 7, 8-tetrahydroimidazo[1, 2-a]pyridine The individual enantiomers of example 49 and example 50 were obtained by separating the racemic mixture of example 48 (77 mg, 0.16 mmol) under the following conditions: Instrument: Waters 100 Prep SFC; Column: Chiral OD, 30 x 250 mm, 5 microns; Mobile phase: 55% CO2 / 45% MeOH with 0.1% DEA; Flow conditions: 100 ml / min; Detector wavelength: 220 nm; Injection details: 300 µl, 77 mg dissolved in 3 ml of MeOH. Example 49 (13 mg, 0.026 mmol, 16% yield) was isolated as the 1st elution enantiomer. 1H-NMR (500 MHz, DMSO-6) 7, 34-7, 31 (m, 1H) , 7, 30-7, 27 (m, 1H) , 7, 22-7, 17 (m, 1H) , 6, 92-6, 88 (m, 1H) , 4, 07-4, 00 (m, 1H) , 3, 77 (s, 3H) , 3, 73 (s, 3H) , 3, 11 (s, 2H) , 3, 00 (s, 3H) , 2, 89-2, 82 (m, 1H) , 2, 81-2, 75 (m, 2H) , 2, 70-2, 59 (m, 1H), 2, 49-2, 44 (m, 1H) , 2, 16-2, 10 (m, 2H) , 2, 05-1, 97 (m, 1H) , 1, 89-1, 80 (m, 4H) , 1, 77-1, 47 (m, 11H) , 1, 30-1, 15 (m, 3H) . CL / EM analytical (Method 1): Purity: 98.5%; Observed mass: 491.19; Retention time: 1.31 min. (Method 2): Purity: 95.8%; Observed mass: 491.21; Retention time: 0.99 min. Chiral analytical (Method SFC 1): Chiral purity > 95%. Retention time: 1.80 min. Sample 50 (11 mg, 0.022 mmol, 14% yield) was isolated as the 2nd elution enantiomer. 1H-NMR (500 MHz, DMSO-6) 7, 33-7, 31 (m, 1H) , 7, 30-7, 27 (m, 1H) , 7, 21-7, 17 (m, 1H) , 6, 91-6, 88 (m, 1H) , 4, 07-4, 01 (m, 1H) , 3, 77 (s, 3H) , 3, 73 (s, 3H) , 3, 72-3, 68 (m, 2H) , 3, 61-3, 60 (m, 1H) , 3, 03-2, 99 (m, 1H), 2, 87-2, 82 (m, 1H), 2, 80-2, 73 (m, 2H), 2, 69-2, 59 (m, 1H), 2, 49-2, 43 (m, 1H), 2, 16-2, 09 (m, 2H), 2.05-1.97 (m, 1H), 1.88-1.79 (m, 4H), 1.78-1.47 (m, 11H), 1.30-1.15 (m, 3H) (one darkened proton). Analytical LC / MS (Method 1) : Purity: 100%; Observed mass: 491.10; Retention time: 1.32 min. (Method 2): Purity: 100%; Observed mass: 491.19; Retention time: 0.98 min. Chiral analysis (Method SFC 1): Chiral purity > 95%. Retention time: 5.30 min. Example 51 6- (1- (2- (cyclopropylmethyl) -2-azaspiro[3.3]heptan-6-yl) piperidin-4-yl) -2- (3, 4-dimethoxyphenyl) -5, 6, 7, 8-tetrahidroimidazo[1, 2-a]piridina (mezcla racémica) Example 51 was prepared according to the general methods described for the synthesis of Example 45 (step B), using intermediate 45 A (320 mg, 0.48 mmol) as the starting material and substituting cyclopropanecarbaldehyde (170 mg, 2.4 mmol) where appropriate. The crude product was purified by preparative HPLC (preparation method 1) to obtain the title compound (190 mg, 0.39 mmol, 81% yield). 1H-NMR (500 MHz, DMSO-6) 7, 27-7, 25 (m, 1H) , 7, 24-7, 21 (m, 1H) , 7, 16-7, 11 (m, 1H) , 6, 86-6, 81 (m, 1H) , 4, 00-3, 94 (m, 1H) , 3, 71 (s, 3H) , 3, 67 (s, 3H) , 3, 61-3, 54 (m, 1H) , 3, 23-3, 18 (m, 1H) , 3, 12-3, 07 (m, 1H) , 2, 82-2, 68 (m, 3H) , 2, 63-2, 54 (m, 1H) , 2, 43-2, 39 (m, 1H) , 2, 25-2, 20 (m, 2H) , 2, 13-2, 07 (m, 2H) , 1, 98-1, 92 (m, 1H) , 1, 82-1, 75 (m, 2H) , 1, 72-1, 63 (m, 2H) , 1, 61-1, 52 (m, 3H) , 1, 50-1, 41 (m, 1H) , 1, 24-1, 10 (m, 3H), 0.68-0.59 (m, 1H), 0.33-0.29 (m, 2H), 0.01 (da, .J=4, 6 Hz, 2H) (two obscured protons). Analytical CL / EM (Method 1): Purity: 96.3%; Observed mass: 491.20; Retention time: 1.2 min. (Method 2): Purity: 97.3%; Observed mass: 491.19; Retention time: 0.98 min. Example 52 2- (3, 4-dimethoxyphenyl) -6- (1- (2-isobutyl-2-azaspiro[3.3]heptan-6-yl) piperidin-4-yl) - 5, 6, 7, 8-tetrahydroimidazo[1, 2-a]pyridine (racemic mixture) Example 52 was prepared according to the general methods described for the synthesis of Example 45 (step B), using intermediate product 45 A (320 mg, 0.48 mmol) as the starting material and substituting isobutyraldehyde (170 mg, 2.4 mmol) where appropriate. The crude product was purified by preparative HPLC (preparation method 1) to obtain the title compound (190 mg, 0.39 mmol, 81% yield). 1H-NMR (500 MHz, DMSO-6) 7, 33 (s, 1H) , 7, 29 (d, J=1, 8 Hz, 1H) , 7, 23-7, 18 (m, 1H) , 6, 93-6, 87 (m, 1H) , 4, 08-4, 02 (m, 1H) , 3, 78 (s, 3H) , 3, 74 (s, 3H) , 3, 68-3, 61 (m, 1H) , 3, 31-3, 15 (m, 1H) , 2, 88-2, 77 (m, 3H) , 2, 71-2, 60 (m, 1H) , 2, 32-2, 22 (m, 2H) , 2, 21-2, 14 (m, 2H) , 2, 11-2, 05 (m, 1H) , 2, 04-1, 98 (m, 1H), 1.89-1.84 (m, 2H), 1.79-1.71 (m, 2H), 1.69-1.60 (m, 3H), 1.57-1.47 (m, 2H), 1.32-1.16 (m, 3H), 0.82 (d, J=6, 6 Hz, 6H) (three obscured protons) .Purity: 97.6%; Observed mass: 493.20; Retention time: 1.24 min. (Method 2): Purity: 97.5%; Observed mass: 493.22; Retention time: 0.99 min. Examples 53 and 54 2-(3,4-dimethoxyphenyl)-6-(1-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)piperidin-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine The individual enantiomers of example 53 and example 54 were obtained by separating the racemic mixture of example 52 (94 mg, 0.19 mmol) under the following conditions: Instrument: Waters 100 Prep SFC; Column: Chiral OD, 30 x 250 mm, 5 microns; Mobile phase: 55% CO2 / 45% MeOH with 0.1% DEA; Flow conditions: 100 ml / min; Detector wavelength: 220 nm; Injection details: 600 L, 94 mg dissolved in 3 ml of MeOH. Sample 53 (17 mg, 0.035 mmol, 18% yield) was isolated as the 1st elution enantiomer. 1H-NMR (500 MHz, DMSO-6) 7.32 (s, 1H), 7.29 (s, 1H), 7.22-7.17 (m, 1H), 6.91 (s, 1H), 4.09-3.99 (m, 1H), 3.77 (s, 3H) , 3, 73 (s, 3H) , 3, 13 (s, 2H) , 3, 02 (s, 2H) , 2, 88-2, 80 (m, 1H) , 2, 80-2, 73 (m, 2H) , 2, 70-2, 58 (m, 1H) , 2, 49-2, 41 (m, 1H) , 2, 18-2, 09 (m, 4H) , 2, 06-1, 98 (m, 1H) , 1, 90-1, 80 (m, 2H) , 1, 78-1, 69 (m, 2H) , 1, 67-1, 56 (m, 3H) , 1, 55-1, 43 (m, 2H) , 1, 30-1, 15 (m, 3H) , 0, 80 (d, J=6, 6 Hz, 6H) (one obscured proton) . Analytical CL / EM (Method 1): Purity: 97.8%; Observed Mass: 493.21; Retention Time: 1.29 min. (Method 2): Purity: 97.6%; Observed mass: 493.23; Retention time: 0.98 min. Chiral analysis (Method SFC 1): Chiral purity > 95%. Retention time: 1.45 min. Sample 54 (16 mg, 0.032 mmol, 17% yield) was isolated as the 2nd elution enantiomer. 1H-NMR (500 MHz, DMSO-6) 67, 33-7, 31 (m, 1H), 7, 30-7, 27 (m, 1H), 7, 21-7, 17 (m, 1H), 6, 92-6, 87 (m, 1H), 4, 07-3, 99 (m, 1H) , 3, 76 (s, 3H) , 3, 74 (s, 3H) , 3, 18-3, 13 (m, 2H) , 3, 06-3, 00 (m, 2H) , 2, 88-2, 81 (m, 1H) , 2, 80-2, 74 (m, 2H), 2, 67-2, 58 (m, 1H) , 2, 49-2, 42 (m, 1H) , 2, 18-2, 10 (m, 4H) , 2, 06-1, 97 (m, 1H) , 1, 87-1, 79 (m, 2H) , 1, 76-1, 69 (m, 2H), 1.65-1.57 (m, 3H), 1.54-1.43 (m, 2H), 1.30-1.17 (m, 3H), 0.79 (d, J=6.6 Hz, 6H) (one darkened proton). Analytical LC / MS (Method 1) : Purity: 100%; Observed mass: 492.90; Retention time: 1.35 min. (Method 2): Purity: 100%; Observed mass: 493.22; Retention time: 1.00 min. Chiral analysis (Method SFC 1): Chiral purity > 95%. Retention time: 4.10 min. Example 55 6-(1-(cyclopropylmethyl)-[1,4-bipiperidin]-4-yl)-2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (racemic mixture) To a 40 mL vial were added intermediate product 39A (380 mg, 0.42 mmol), cyclopropanecarbaldehyde (150 mg, 2.1 mmol), AcOH (0.026 mL, 0.46 mmol), magnesium sulfate (760 mg, 6.3 mmol), and DMF (5 mL). The reaction mixture was stirred for 20 min, then sodium triacetoxyborohydride (270 mg, 1.3 mmol) was added, and the reaction mixture was stirred again. After 18 h, the reaction mixture was filtered, the filter cake was washed with 10% MeOH / DCM (20 mL), and the filtrate was concentrated. The crude product was purified by preparative HPLC (preparation method 1) to obtain the title compound (100 mg, 0.21 mmol, 50% yield). 1H-NMR (500 MHz, DMSO-6) 7, 32-7, 28 (m, 1H) , 7, 27-7, 23 (m, 1H) , 7, 18-7, 13 (m, 1H) , 6, 89-6, 83 (m, 1H) , 4, 05-3, 95 (m, 1H) , 3, 73 (s, 3H) , 3, 70 (s, 3H) , 3, 01-2, 93 (m, 2H) , 2, 91-2, 84 (m, 2H) , 2, 84-2, 77 (m, 1H), 2, 66-2, 56 (m, 1H), 2, 10 (ad, .J=6, 3 Hz, 3H), 2, 07-1, 95 (m, 3H), 1, 89-1, 80 (m, 3H), 1, 65 (da, J=13, 6 Hz, 5H), 1, 53-1, 44 (m, 1H), 1, 40 (sa, 2H), 1, 21 (sa, 3H), 0, 83-0, 70 (m, 1H), 0, 44-0, 37 (m, 2H), 0, 01 (da, J=4, 3 Hz, 2H). CL / EM analítica (Método 1) :Pureza: 98 %; Masa observada: 479, 12; Retention time: 1, 22 minutes. (Método 2): Pureza: 97, 1%; Masa observada: 478, 97; Retention time: 1, 03 minutes. Examples 56 and 57 6- (1- (ciclopropilmetil)-[1, 4-bipiperidin]-4-il) -2- (3, 4-dimetoxifenil) -5, 6, 7, 8- tetrahidroimidazo[1, 2-a]piridina The individual enantiomers of example 56 and example 57 were obtained by separating the racemic mixture of example 55 (68 mg, 0.14 mmol) under the following conditions: Instrument: Waters 100 Prep SFC; Column: Chiral OD, 30 x 250 mm, 5 microns; Mobile phase: 55% CO2 / 45% MeOH with 0.1% DEA; Flow conditions: 100 ml / min; Detector wavelength: 220 nm; Injection details: 1500 µl, 68 mg dissolved in 2 ml of MeOH. Sample 56 (2.7 mg, 0.0056 mmol, 4.0% yield) was isolated as the 1st elution enantiomer. 1H-NMR (500 MHz, DMSO-6) 7.25-7.22 (m, 1H) , 7.21-7.17 (m, 1H) , 7.13-7.09 (m, 1H) , 6.82-6.78 (m, 1H) , 3.99-3.91 (m, 1H) , 3.68 (s, 3H) , 3.64 (s, 3H) , 3.60-3.49 (m, 1H) , 3.04-2.97 (m, 1H) , 2, 94-2, 86 (m, 1H) , 2, 80-2, 72 (m, 1H) , 2, 60-2, 51 (m, 1H) , 2, 30-2, 24 (m, 1H) , 2, 23-2, 16 (m, 2H) , 2, 15-2, 07 (m, 2H) , 2, 04-1, 89 (m, 3H) , 1, 75-1, 64 (m, 4H) , 1, 64-1, 57 (m, 1H) , 1, 51-1, 37 (m, 3H) , 1, 28-1, 13 (m, 3H) , 0, 79-0, 70 (m, 1H), 0.41-0.35 (m, 2H), 0.05-0.03 (m, 2H) (two obscured protons). Analytical CL / MS (Method 1): Purity: 91.1%; Observed mass: 479.21; Retention time: 1.26 min. (Method 2): Purity: 93.1%; Observed mass: 479.20; Retention time: 0.89 min. Chiral analysis (Method SFC 1): Chiral purity > 95%. Retention time: 2.20 min. Example 57 (2.4 mg, 0.0050 mmol, 3.6% yield) was isolated as the 2nd elution enantiomer. 1H-NMR (500 MHz, DMSO-6) 7, 24-7, 21 (m, 1H) , 7, 20-7, 16 (m, 1H) , 7, 12-7, 07 (m, 1H) , 6, 81-6, 77 (m, 1H) , 3, 99-3, 89 (m, 1H), 3, 66 (s, 3H), 3, 62 (s, 3H), 3, 58- 3, 50 (m, 1H), 3, 05-3, 00 (m, 1H), 2, 88 (s, 2H), 2, 78-2, 71 (m, 1H), 2, 59-2, 49 (m, 1H) , 2, 34-2, 27 (m, 1H) , 2, 25-2, 19 (m, 2H) , 2, 17-2, 08 (m, 2H) , 2, 07-1, 98 (m, 2H) , 1, 96-1, 87 (m, 1H) , 1, 75-1.56 (m, 5H) , 1.43 (sa, 3H) , 1.19 (sa, 3H) , 0.80-0.70 (m, 1H) , 0.37 (da, J=8, 0 Hz, 2H) , 0.01 (da, .J=4.6 Hz, 2H) (a darkened proton). CL / EM analysis (Method 1): Purity: 96.6%; Observed mass: 479.22; Retention time: 1.26 min. (Method 2): Purity: 95.7%; Observed mass: 479.20; Retention time: 0.90 min. Chiral analysis (Method SFC 1): Chiral purity > 95%. Retention time: 4.70 min. Example 58 2- (3, 4-dimethoxyphenyl) -7- (r-isopropyl-[1, 4-bipiperidin]-4-yl) -5, 6, 7, 8-tetrahydroimidazo[1, 2-a]pyridine (racemic mixture) Step A. Intermediate Product 58A. Preparation of 7-bromo-2-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyridine Intermediate product 58A was prepared according to the general methods described for the synthesis of intermediate product 1A, substituting 4-bromopyridin-2-amine (500 mg, 2.9 mmol) when appropriate to provide the title compound (0.98 g, 2.9 mmol, 100% yield) as a blank solid. 1H-NMR (500 MHz, DMSO-6) 8, 75 (d, J=7, 2 Hz, 1H) , 8, 70 (s, 1H) , 8, 16 (d, J=1, 7 Hz, 1H) , 7, 62-7, 57 (m, 1H) , 7, 56-7, 53 (m, 1H) , 7, 56-7, 50 (m, 1H) , 7, 18 (s, 1H) , 3, 89 (s, 3H) , 3, 85 (s, 3H) . Analytical CL / EM (Method 5) : Observed mass: 333, 0; Retention time: 0, 62 min. Step B. Intermediate Product 58B. Preparation of 4-(2-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyridin-7-yl)-3,6-dihydropyridine-1(2H)-tert-butyl carboxylate Intermediate product 58B was prepared according to the general methods described for the synthesis of intermediate product IB, using intermediate product 58A (0.98 g, 2.9 mmol) as the starting material to provide the title compound (1.2 g, 2.8 mmol, 97% yield) as a white solid. 1H-NMR (500 MHz, methanol-d4) 8.35-8.31 (m, 1H) , 8.09 (s, 1H) , 7.56 (d, J=1, 9 Hz, 1H) , 7.48 (s, 2H) , 7.16-7.11 (m, 1H) , 7.06-7.02 (m, 1H) , 6.45-6.33 (m, 1H) , 4, 19-4.12 (m, 2H) , 3.95 (s, 3H) , 3.90 (s, 3H) , 3.74-3.67 (m, 2H) , 2.65-2.57 (m, 2H) , 1.53 (s, 9H) . Analytical LC / MS (method 5) : Mass observed: 436, 2; Retention time: 0. 79 min. Step C. Intermediate Product 58C. Preparation of tert-butyl 4-(2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-7-yl)piperidin-1-carboxylate Intermediate product 58C was prepared according to the general methods described for the synthesis of intermediate product 31A, using intermediate product 58B (1.2 g, 2.8 mmol) as the starting material to provide the title compound (0.56 g, 1.3 mmol, 46% yield) as a white solid. 1H-NMR (400 MHz, methanol-d4) 7.35-7.32 (m, 1H) , 7.22 (s, 2H) , 6.97-6.92 (m, 1H) , 4.20-4.12 (m, 3H) , 3.97-3.91 (m, 1H) , 3.90 (s, 3H) , 3.85 (s, 3H) , 3.06-2, 98 (m, 1H) , 2, 85-2, 68 (m, 2H) , 2, 61-2, 49 (m, 1H) , 2, 26-2, 14 (m, 1H) , 1, 92-1, 69 (m, 4H) , 1, 57-1, 50 (m, 1H) , 1, 48 (s, 9H) , 1, 26 (s, 2H) . Analytical CL / EM (Method 5) : Observed mass: 442.4; Retention time: 0.77 min. Step D. Intermediate Product 58D. Preparation of 2-(3,4-dimethoxyphenyl)-7-(piperidin-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine hydrochloride Intermediate product 58D was prepared according to the general methods described for the synthesis of intermediate product 31B, using intermediate product 58C (0.56 g, 1.3 mmol) as a starting material to obtain the title compound (420 mg, 1.1 mmol, 85% yield) as a pale yellow solid. 1H-NMR (500 MHz, methanol-d4) 7.72 (s, 1H) , 7.30 (s, 2H) , 7.12-7.06 (m, 1H) , 4.42-4.33 (m, 1H) , 4.20-4.11 (m, 1H) , 3.93 (s, 3H) , 3.90 (s, 3H) , 3.54-3.48 (m, 2H), 3, 31-3, 25 (m, 1H), 3, 10-3, 02 (m, 2H), 2, 89-2, 81 (m, 1H), 2, 36-2, 30 (m, 1H), 2, 19-2, 13 (m, 1H), 2, 12-2, 01 (m, 2H), 1, 94-1, 84 (m, 1H), 1, 84-1, 75 (m, 1H), 1, 71-1, 56 (m, 2H). Analytical LC / MS (Method 5) : Observed mass: 342.4; Retention time: 0. 49 min. Stage E. Preparation of example 58 The intermediate product 58D (110 mg, 0.29 mmol), 1-isopropylpiperidin-4-one (120 mg, 0.85 mmol), AcOH (0.017 mL, 0.31 mmol), magnesium sulfate (220 mg, 1.8 mmol), and DMF (1 mL) were added to a 2-drachm vial. The reaction mixture was stirred for 20 min, then sodium triacetoxyborohydride (180 mg, 0.83 mmol) was added, and the reaction mixture was stirred again. After 18 h, the reaction mixture was filtered, the filter cake was washed with 10% MeOH / DCM (10 mL), and the filtrate was concentrated. The crude product was purified by preparative HPLC (preparation method 1) to obtain the title compound (15 mg, 0.032 mmol, 11% yield).1H-RMN (500 MHz, DMSO-6) 7, 37 (s, 1H) , 7, 29 (s, 1H) , 7, 23-7, 18 (m, 1H) , 6, 92-6, 88 (m, 1H) , 4, 10-4. 87-3, 80 (m, 1H) , 3, 78 (s, 3H) , 3, 74 (s, 3H) , 3, 05-2, 96 (m, 3H) , 2, 94-2, 84 (m, 2H) , 2, 47-2, 30 (m, 4H) , 2, 29-2, 19 (m, 2H) . CL / EM analítica (Método 1): Pure: 95%; Masa observada: 467, 20; Retenciation time: 1, 21 minutes. (Método 2): Pureza: 100%; Masa observada: 467, 20; Retention time: 0, 98 min. Example 59 2- (3, 4-dimetoxifenil) -7- (1-isobutil-[1, 4-pipiperidin]-4-il) -5, 6, 7, 8-tetrahidroimidazo[1, 2-a]piridina (mezcla racemica) Example 59 was synthesized according to the general methods described for the preparation of Example 58 (step E), using intermediate product 58D (110 mg, 0.29 mmol) as the starting material and substituting 1-isobutylpiperidin-4-one (130 mg, 0.84 mmol) where appropriate. The crude product was purified by preparative HPLC (preparation method 1) to obtain the title compound (15 mg, 0.031 mmol, 11% yield). 1H-NMR (500 MHz, DMSO-6) 7.37 (s, 1H) , 7.31 (d, J=1, 5 Hz, 1H) , 7.25-7.20 (m, 1H) , 6.92 (d, J=8, 5 Hz, 1H) , 4.12-4.03 (m, 1H) , 3.88-3.81 (m, 1H) , 3.79 (s, 3H) , 3.75 (s, 3H) , 3.50-3.40 (m, 1H) , 3. 01-2, 90 (m, 2H) , 2, 90-2, 83 (m, 2H) , 2, 46-2, 38 (m, 1H) , 2.27-2.21 (m, 1H) , 2.20-2.12 (m, 2H) , 2, 11-2, 04 (m, 1H) , 2.00 (s, 2H) , 1.91-1.56 (m, 9H) , 1.49-1.40 (m, 2H) , 1.24 (sa, 3H) , 0.85 (d, .J=6.4 Hz, 6H) . Analytical LC / MS (Method 1): Purity: 97.4%; Observed mass: 480.99; Retention time: 1.31 min.(Method 2): Purity: 92.7%; Observed mass: 481.03; Retention time: 1.03 min. Example 60 2-(3,4-dimethoxyphenyl)-7-(1-isopropyl-[1,4-bipiperidin]-4-yl)-[1,2,4]triazolo[1,5-a]pyridine Step A. Intermediate Product 60A. Preparation of 7-bromo-2-(3,4-dimethoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridine To a 50 mL three-necked flask were added 4-bromopyridin-2-amine (1.0 g, 5.8 mmol), 3,4-dimethoxybenzonitrile (1.1 g, 6.7 mmol), copper(I) bromide (0.041 g, 0.29 mmol), zinc iodide (0.18 g, 0.56 mmol), 1,10-phenanthroline (0.052 g, 0.29 mmol), and 1,2-dichlorobenzene (12 mL). Air was gently bubbled through the mixture, the system was closed, and the reaction mixture was heated to 130 °C and stirred. After 18 h, the reaction mixture was cooled, diluted with DCM, filtered, and the filter cake was washed with copious amounts of DCM. The filtrate was concentrated, and the residue was purified by ultrafast column chromatography (80 g silica gel cartridge; A = Hex, B = EtOAc; 30 min gradient; 0% B to 100% B; flow rate = 60 mL / min). The pure fractions were combined, concentrated, and vacuum dried to obtain the title compound (1.4 g, 4.2 mmol, 72% yield) as a pale yellow solid.1H-NMR (500 MHz, methanol-d4) 8, 73-8, 69 (m, 1H) , 8, 00-7, 98 (m, 1H) , 7, 86-7, 83 (m, 1H) , 7, 82-7, 81 (m, 1H) , 7, 37-7, 31 (m, 1H) , 7, 13-7, 10 (m, 1H) , 3, 96 (s, 3H) , 3, 93 (s, 3H) . Analytical CL / EM (Method 5) : Observed mass: 335.9; Retention time: 0.86 min. Step B. Intermediate Product 60B. Preparation of 4-(2-(3,4-dimethoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-3,6-dihydropyridine-1(2H)-tert-butyl carboxylate The intermediate product 60A (0.66 g, 2.0 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-tert-butyl carboxylate (0.73 g, 2.4 mmol) were added to a 40 ml vial, followed by 1,4-dioxane (10 ml) and potassium phosphate (1.3 g, 6.1 mmol) dissolved in water (2 ml). The vial was purged with N2, then 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloromethane dichloride complex (0.081 g, 0.099 mmol) was added. The vial was purged again with N2 and the reaction was stirred at 70 °C. After 18 h, the reaction mixture was cooled, diluted with water (100 ml) and extracted with EtOAc (2 x 50 ml). The organic phase was combined, washed with brine, dried over MgSCU, filtered and concentrated. The residue was purified by ultrafast column chromatography (80 g silica gel cartridge; A = Hex, B = EtOAc; 30 min gradient; B from 0% to B from 100%; flow rate = 60 ml / min).The pure fractions were combined, concentrated, and vacuum dried to obtain the title compound (0.61 g, 1.4 mmol, 70% yield) as a pale yellow solid. Analytical CL / MS (Method 5): Observed mass: 437.1; Retention time: 0.96 min. Step C. Intermediate product 60C. Preparation of tert-butyl 4-(2-(3,4-dimethoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl)piperidine-1-carboxylate In a 100 mL pear-shaped flask, the intermediate product 60B (0.61 g, 1.4 mmol) and MeOH (20 mL) were added. The flask was evacuated and purged with N2, then Pd-C (10% on carbon) (0.15 g, 0.14 mmol) was added, and the reaction mixture was stirred in hydrogen at 1 atm. After 2 h, the catalyst was filtered out, and the filtrate was concentrated. The product was dried under vacuum to obtain the title compound (0.61 g, 1.4 mmol, 99% yield) as a white solid. Analytical CL / MS (Method 5): Observed mass: 439.1; Retention time: 0.94 min. Step D. Intermediate product 60D. Preparation of 2-(3,4-dimethoxyphenyl)-7-(piperidin-4-yl)-[1,2,4]triazolo[1,5-a]pyridine hydrochloride Intermediate product 60C (610 mg, 1.4 mmol), THF (2 mL), and 4 M HCl in dioxane (5 mL) were added to a 100 mL pear-shaped flask. A white precipitate formed immediately. The suspension was stirred. After 18 h, the solvent was concentrated, and the solid was purified by trituration from MeOH. The product was collected by vacuum filtration and vacuum dried to obtain the title compound (520 mg, 1.4 mmol, 100% yield) as a whitish solid. 1H-NMR (500 MHz, DMSO-6) 8.93 (s, 1H) , 7.81-7.76 (m, 1H) , 7.73 (s, 1H) , 7.65-7.63 (m, 1H) , 7.12 (s, 2H) , 3.87 (s, 3H), 3, 84 (s, 3H), 3, 44-3, 38 (m, 2H), 3, 11-2, 98 (m, 3H), 2, 11-2, 04 (m, 2H), 2, 01-1, 89 (m, 2H). Analytical LC / MS (Method 5) : Observed mass: 339.0; Retention time: 0.60 in. Stage E. Preparation of example 60 The intermediate product 60D (60 mg, 0.16 mmol), 1-isopropylpiperidin-4-one (68 mg, 0.48 mmol), AcOH (0.010 mL, 0.18 mmol), magnesium sulfate (220 mg, 1.8 mmol), and DMF (2 mL) were added to a 40 mL vial. The reaction mixture was stirred for 20 min, then sodium triacetoxyborohydride (100 mg, 0.48 mmol) was added, and the reaction mixture was stirred again. After 18 h, the reaction mixture was filtered, the filter cake was washed with 10% MeOH / DCM (20 mL), and the filtrate was concentrated. The crude product was purified by preparative HPLC (preparation method 1) to obtain the title compound (71 mg, 0.15 mmol, 94% yield).1H-RMN (500 MHz, DMSO-6) 8, 83 (d, , J=7, 0 Hz, 1H) , 7, 76 (dd, J=8, 2, 1, 8 Hz, 1H) , 7, 71 (s, 1H) , 7, 62 (s, 1H) , 7, 15-7, 08 (m, 2H) , 3, 86 (s, 3H) , 3, 83 (s, 3H) , 3, 55-3, 48 (m, 3H) , 3, 20-3, 16 (m, 1H) , 3, 15-3, 02 (m, 3H) , 2, 75- 2, 67 (m, 1H), 2, 40-2, 29 (m, 3H) , 1, 94-1, 86 (m, 3H) , 1, 76-1, 65 (m, 3H) , 1, 64-1, 52 (m, 2H) , 1, 10 (da, J=5, 8 Hz, 6H). CL / EM analysis (Método 1): Pure: 100%; Masa observada: 464, 31; Retention time: 1, 26 minutes. (Método 2): Pureza: 100%; Masa observada: 464, 15; Retention time: 1, 07 minutes. Example 61 2- (3, 4-dimetoxifenil) -7- (1-isobutil-[1, 4-bipiperidin]-4-il) -[1, 2, 4]triazolo[1, 5-a]piridina Example 61 was synthesized according to the general methods described for the preparation of Example 60 (step E), using intermediate product 60D (60 mg, 0.16 mmol) as the starting material and substituting 1-isobutylpiperidin-4-one (75 mg, 0.48 mmol) where appropriate. The crude product was purified by preparative HPLC (preparation method 1) to obtain the title compound (54 mg, 0.11 mmol, 69% yield). 1 H-NMR (500 MHz, DMSO-d6) 8, 86-8, 78 (m, 1H) , 7, 79-7, 75 (m, 1H) , 7, 71 (d, J=1, 8 Hz, 1H) , 7, 61 (s, 1H) , 7, 12 (s, 2H) , 3, 86 (s, 3H) , 3, 83 (s, 3H) , 3, 57-3, 50 (m, 2H) , 3, 13-3, 05 (m, 1H) , 2, 97-2, 90 (m, 1H) , 2, 78-2, 68 (m, 1H) , 2, 44-2, 34 (m, 2H) , 2, 15-2, 02 (m, 2H) , 1, 98-1, 87 (m, 3H) , 1, 83-1, 64 (m, 5H) , 1, 58-1, 47 (m, 2H) , 0, 86 (d, .J=6, 4 Hz, 6H) (two obscured protons) . Analytical CL / EM (Method 1) : Purity: 99.3%; Observed mass: 478.17; Retention time: 1.39 min.(Method 2): Purity: 97%; Observed mass: 478.17; Retention time: 1.1 min. Examples 62 and 63 6-(1-(8-isopropyl-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine Step A. Intermediate Product 62A. Preparation of 6-(1-(8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine dihydrochloride Intermediate 7C (0.58 g, 1.4 mmol), MeOH (50 mL), and DOWEX 550A anion exchange resin (10 g) were added to a 250 mL round-bottom flask. The mixture was stirred for 15 min, the resin was filtered out, and the filtrate was concentrated. The resulting free amine was dissolved in DCE (15 mL) and DME (15 mL), then tert-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (1.3 g, 5.7 mmol) was added, followed by titanium(IV) isopropoxide (2.1 mL, 7.1 mmol). The reaction mixture was stirred at 40 °C under N2. After 18 h, the mixture was cooled to room temperature, then sodium triacetoxyborohydride (1.2 g, 5.7 mmol) was added and the reaction continued. After 3 h, the reaction mixture was partitioned into 1 M KOH (saturated with solid NaCl) (150 mL) and 10% IPA / chloroform (150 mL). The phases were separated, the aqueous phase was extracted with 10% IPA / chloroform (75 mL), the organic phase was combined, washed with brine, dried over MgSO4, filtered, and concentrated.The residue was purified by ultrafast column chromatography (120 g silica gel cartridge; A = DCM, B = MeOH; 30 min gradient; 0% to 15% B, flow rate = 80 mL / min). The product fractions were combined, concentrated, and vacuum dried. The resulting residue was dissolved in MeOH (20 mL) and 4 M HCl in dioxane (10 mL) and stirred. After 0.5 h, the solvent was concentrated, and the residue was co-evaporated with toluene (2x). The product was vacuum dried to obtain the title compound (0.47 g, 0.85 mmol, 61% yield) as a whitish solid. 1H-NMR (500 MHz, methanol-d4) 8, 70-8, 66 (m, 1H) , 8, 22 (da, J=6, 8 Hz, 4H) , 7, 92-7, 84 (m, 1H) , 7, 19-7, 15 (m, 1H) , 4, 31-4, 18 (m, 3H) , 4, 11-3, 98 (m, 3H) , 3, 89-3, 79 (m, 3H) , 3, 23 (s, 3H) , 2, 78 (s, 3H) , 2, 50-2, 42 (m, 2H) , 2, 17-2, 13 (m, 3H), 2, 01 (da, J=8, 5 Hz, 6H) . Analytical CL / EM (Method 4) : Observed mass: 479.1; Retention time: 0.832 min. Stage B. Examples 62 and 63 The intermediate product 62A (90 mg, 0.16 mmol), propan-2-one (47 mg, 0.82 mmol), AcOH (10 µL, 0.18 mmol), magnesium sulfate (300 mg, 2.5 mmol), and DMF (2 mL) were added to a 40 mL vial. The reaction mixture was stirred for 10 min, then sodium triacetoxyborohydride (170 mg, 0.82 mmol) was added, and the reaction mixture was stirred again. After 18 h, the reaction mixture was diluted with 10% IPA (40 mL) and filtered. The filtrate was partitioned into 10% KOH (aq, saturated with solid NaCl) (20 mL), and the phases were separated. The aqueous phase was extracted with 10% IPA (10 ml), the organic phase was combined, washed with brine, dried over MgSO4, filtered and concentrated.The raw material was purified by preparative LC / MS under the following conditions: Column: X Bridge Cl 8, 200 mm x 19 mm, 5-pm particles; mobile phase A: 5:95 acetonitrile:ammonium acetate water; mobile phase B: 95:5 acetonitrile:ammonium acetate water; gradient: a 0-minute hold at 5% B, 5-55% B for 20 minutes, then a 0-minute hold at 100% B; flow rate: 20 mL / min; column temperature: 25 °C. Fraction collection was triggered by MS and UV signals. The fractions corresponding to the respective desired products were combined and dried by centrifugal evaporation. Example 62 (11 mg, 0.021 mmol, 13% yield) was isolated as the 1st elution isomer. 1H-NMR (500 MHz, DMSO-6) 8, 51-8, 44 (m, 1H), 8, 25-8, 14 (m, 3H), 8, 02-7, 93 (m, 2H), 7, 14-7, 04 (m, 1H), 3, 23 (s, 2H), 3.00 (s, 2H) , 2.83-2.75 (m, 1H) , 2.69-2.59 (m, 1H) , 2.52 (da, J=1.8 Hz, 5H) , 2.17 (sa, 2H) , 1.81 (da, J=11.0 Hz, 4H) , 1, 70-1, 52 (m, 6H) , 1, 51-1, 42 (m, 2H) , 1, 03 (d, J=6, 1 Hz, 6H) (two obscured protons) . Analytical CL / EM (Method 1): Purity: 98.2%; Observed mass: 521.01; Retention time: 0.84 min. (Method 2): Purity: 98%; Observed mass: 520.95; Retention time: 1.28 min. Example 63 (11 mg, 0.021 mmol, 13% yield) was isolated as the 2nd elution isomer. 1H-NMR (500 MHz, DMSO-6) 8, 52-8, 43 (m, 1H), 8, 29-8, 17 (m, 3H), 8, 03-7, 91 (m, 2H), 7, 13-7, 05 (m, 1H), 3, 49-3, 37 (m, 1H), 3, 24 (s, 3H), 2, 62-2, 45 (m, 7H), 2, 39-2, 29 (m, 1H), 1, 94-1, 58 (m, 15H), 1, 00 (da, J=6, 1 Hz, 6H). CL / EM analytical (Method 1): Purity: 97.9%; Observed mass: 521.32; Retention time: 0.84 min. (Method 2): Purity: 96.7%; Observed mass: 521.31; Retention time: 1.35 min. Example 64 2-(3,4-dimethoxyphenyl)-8-methyl-6-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyridine Step A. Intermediate product 64 A. Preparation of 4-(4-(2-(3,4-dimethoxyphenyl)-8-methylimidazo[1,2-a]pyridin-6-yl)phenyl) piperazin-1-carboxylate tert-butyl To a 40 ml vial, intermediate product 1A (500 mg, 1.4 mmol), 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-carboxylate tert-butyl (620 mg, 1.6 mmol), XPhos Pd G3 (120 mg, 0.14 mol), 1,4-dioxane (20 ml) was added, followed by tribasic potassium phosphate (1100 mg, 5.0 mmol) dissolved in water (3 ml). The container was washed thoroughly with N2, capped, and the reaction mixture was stirred at 85 °C. After 18 h, the reaction mixture was cooled, diluted with water (100 ml), and extracted with EtOAc (2 x 50 ml). The organic phase was combined, washed with brine, dried over MgSCU, filtered, and concentrated. The residue was purified by ultrafast column chromatography (120 g silica gel cartridge; A = Hex, B = EtOAc; 30 min gradient; B from 0% to B from 100%; flow rate = 80 ml / min).The fractions corresponding to the desired product were combined, concentrated, and vacuum dried to obtain the title compound (610 mg, 1.2 mmol, 86% yield) as a pale yellow solid. 1H-NMR (500 MHz, chloroform-d) 8, 18-8, 05 (m, 1H) , 7, 86-7, 79 (m, 1H) , 7, 67-7, 59 (m, 1H) , 7, 54-7, 47 (m, 3H) , 7, 26-7, 19 (m, 1H) , 7, 07-7, 01 (m, 2H) , 7, 00-6, 94 (m, 1H) , 4, 05 (s, 3H) , 3, 96 (s, 3H) , 3, 70-3, 60 (m, 4H) , 3, 30-3, 17 (m, 4H) , 2, 74 (s, 3H) , 1, 52 (s, 9H) . Analytical CL / EM (Method 5) : Observed mass: 529, 3; Retention time: 0, 86 min. Step B. Intermediate Product 64B. Preparation of 2-(3,4-dimethoxyphenyl)-8-methyl-6-(4-(piperazin-1-yl)phenyl)imidazo[1,2-a]pyridinedihydrochloride To a 200 mL pear-shaped flask, the intermediate product 64A (610 mg, 1.2 mmol) was added, followed by MeOH (10 mL) and then 4 M HCl in dioxane (10 mL). After shaking for 30 min, the solvent was concentrated, the residue was co-evaporated with toluene, and the product was vacuum-dried to obtain the title compound (600 mg, 1.2 mmol, 100% yield) as a toasted solid. 1H-NMR (500 MHz, DMSO-6) 9, 49-9, 44 (m, 1H) , 9, 03-8, 97 (m, 1H) , 8, 70-8, 64 (m, 1H) , 8, 16-8, 12 (m, 1H) , 7, 88-7, 81 (m, 1H), 7, 77-7, 71 (m, 2H), 7, 70-7, 66 (m, 1H), 7, 21-7, 15 (m, 3H), 3, 94 (s, 3H), 3, 86 (s, 3H), 3, 75-3, 65 (m, 1H) , 3, 56-3, 48 (m, 3H) , 3, 29-3, 20 (m, 4H) , 2, 81 (s, 3H) . Analytical CL / EM (Method 5) : Observed mass: 429.3; Retention time: 0.57 min. Stage C. Example 64 The intermediate product 64B (60 mg, 0.12 mmol), oxetan-3-one (43 mg, 0.60 mmol), AcOH (7.5 µl, 0.13 mmol), magnesium sulfate (220 mg, 1.8 mmol), and DMF (2 mL) were added to a 40 mL vial. The reaction mixture was stirred for 10 min, then sodium triacetoxyborohydride (130 mg, 0.60 mmol) was added, and the reaction mixture was stirred again. After 18 h, the reaction mixture was diluted with 10% IPA (40 mL) and filtered. The filtrate was partitioned into 10% KOH (aq, saturated with solid NaCl) (20 mL), and the phases were separated. The aqueous phase was extracted with 10% IPA (10 ml), the organic phase was combined, washed with brine, dried over MgSO4, filtered and concentrated. The crude material was purified by preparative HPLC (preparation method 1) to provide the title compound (33 mg, 0.068 mmol, 57% yield).1H-NMR (500 MHz, DMSO-6) 8, 67-8, 58 (m, 1H) , 8, 34-8, 30 (m, 1H) , 7, 63-7, 55 (m, 3H) , 7, 54-7, 50 (m, 1H) , 7, 48-7, 42 (m, 1H), 7, 11-7, 01 (m, 3H), 4, 66-4, 59 (m, 2H), 4, 58-4, 49 (m, 2H), 3, 87 (s, 3H), 3, 81-3, 76 (m, 3H), 3, 61-3, 46 (m, 1H) , 3, 36-3, 23 (m, 2H) , 2, 60 (s, 5H) , 2, 51 (sa, 4H) . Analytical CL / EM (Method 1): Purity: 100%; Observed mass: 485.17; Retention time: 1.12 min. (Method 2): Purity: 100%; Observed mass: 485.16; Retention time: 1.80 min. Example 65 6-(4-(4-isopropylpiperazin-1-yl)phenyl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine Step A. Intermediate Product 65A. Preparation of 8-methyl-2-(4-(methylsulfonyl)phenyl)-6-(4-(piperazin-1-yl)phenyl)imidazo[1,2-a]pyridinedihydrochloride Intermediate product 65A was synthesized according to the procedures described for the preparation of intermediate product 64B (Step AB), substituting intermediate product 7A (0.75 g, 2.1 mmol) when appropriate to obtain the title compound (0.81 g, 1.6 mmol, 76% yield in 2 stages) as a roasted solid. 1H-NMR (500 MHz, DMSO-6) 9, 25 (sa, 1H), 9, 02-8, 93 (m, 1H), 8, 82-8, 74 (m, 1H), 8, 41-8, 29 (m, 2H), 8, 17-8, 08 (m, 2H), 8, 05-7, 93 (m, 1H), 7, 79-7, 63 (m, 2H), 7, 21-7, 09 (m, 2H), 3, 52-3, 48 (m, 4H), 3, 31 (s, 3H), 3, 27-3, 23 (m, 4H) , 2, 73 (s, 3H) CL / EM analytical (method 4): Observed mass: 447.1; Retention time: 0.927 mm. Stage B. Example 65 Example 65 was synthesized according to the procedures described for the preparation of Example 64 (step C), using intermediate product 65A (70 mg, 0.14 mmol) as the starting material. The crude mixture was purified by preparative HPLC (Preparation Method 1) to obtain the title compound (15 mg, 0.031 mmol, 22% yield). 1H-NMR (500 MHz, DMSO-6) 8, 68-8, 62 (m, 1H) , 8, 54 (s, 1H) , 8, 25 (d, J=8, 5 Hz, 2H) , 8, 00 (d, J=8, 5 Hz, 2H) , 7, 58 (da, J=8, 9 Hz, 2H) , 7, 46 (s, 1H) , 7, 04 (da, J=8, 9 Hz, 2H) , 3, 45-3, 33 (m, 1H) , 3, 25 (s, 4H) , 2, 78-2, 67 (m, 1H) , 2, 61 (s, 7H) , 2, 55 (s, 2H) , 1, 03 (d, .J=6, 7 Hz, 6H) . Analytical CL / EM (Method 1): Purity: 100%; Observed mass: 489.35; Retention time: 1.06 min. (Method 2): Purity: 100%; Observed mass: 489.35; Retention time: 1.45 min. Example 66 7-(1-isopropyl-[1,4-bipiperidin]-4-yl)-5-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine Step A. Intermediate Product 66A. Preparation of tert-butyl 2'-amino-6'-methyl-3,6-dihydro-[4,4'-bipyridine]-1-(2H)-carboxylate 4-bromo-6-methylpyridin-2-amine (1.0 g, 5.4 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-tert-butyl carboxylate (2.0 g, 6.4 mmol), XPhos PdG3 (0.23 g, 0.27 mmol), and 1,4-dioxane (50 ml) were added to a 200 ml pear-shaped flask, followed by tribasic potassium phosphate (4.0 g, 19 mmol) dissolved in water (10 ml). The flask was washed with N2 and the reaction mixture was stirred at 85 °C. After 24 h, the reaction mixture was cooled, diluted with water (200 ml), and extracted with EtOAc (2 x 100 ml). The organic phase was combined, washed with brine, dried over MgSO4, filtered, and concentrated. The residue was purified by ultrafast column chromatography (80 g silica gel cartridge; A = DCM, B = MeOH; 30 min gradient; B from 0% to B at 15%; flow rate = 60 ml / min).The fractions containing the product were combined, concentrated, and vacuum dried to obtain the title compound (1.3 g, 4.5 mmol, 83% yield) as a pale yellow solid.1H-NMR (500 MHz, methanol-d4) 6.62-6.55 (m, 1H) , 6.46-6.37 (m, 1H) , 6.31-6.23 (m, 1H) , 4.08 (sa, 2H) , 3.72-3.57 (m, 2H) , 2.53-2.43 (m, 2H) , 2.33 (s, 3H) , 1.51 (s, 9H) . CL / EM analytical (Method 4): Observed mass: 289.9; Retention time: 1,318 min. Step B. Intermediate Product 66B. Preparation of 4-(5-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridin-7-yl)-3,6-dihydropyridin-1(2H)-tert-butyl carboxylate The intermediate product 66A (0.6 g, 2.1 mmol), 2,2-dimethoxy-2-(4-(methylsulfonyl)phenyl)ethyl 4-methylbenzenesulfonate (1.0 g, 2.5 mmol), MeCN (15 ml), followed by scandium(III) riflate (0.051 g, 0.10 mmol) were added to a 20 ml microwave reaction vial. The vial was capped and irradiated at 120 °C. After 15 h, the solvent was concentrated and the residue was purified by ultrafast column chromatography (120 g silica gel cartridge; A = DCM, B = MeOH; 30 min gradient; 0 % B to 10 % B; flow rate = 80 ml / min). The product fractions were combined, concentrated, and vacuum dried to obtain the title compound (100 mg, 0.21 mmol, 10% yield) as a roasted solid.1H-NMR (500 MHz, methanol-d4) 8, 38-8, 32 (m, 1H), 8, 30-8, 19 (m, 2H), 8, 08-8, 00 (m, 2H), 7, 51-7, 44 (m, 1H), 7, 14-7, 07 (m, 1H) , 6, 48-6, 38 (m, 1H) , 4, 22-4, 08 (m, 2H) , 3, 77-3, 66 (m, 2H) , 3, 19 (s, 3H) , 2, 74 (s, 3H) , 2, 68-2, 59 (m, 2H), 1, 53 (s, 9H) . CL / EM analytical (Method 4) : Observed mass: 468, 1; Retention time: 1, 508 min. Step C. Intermediate Product 66C. Preparation of 5-methyl-2-(4-(methylsulfonyl)phenyl)-7-(piperidin-4-yl)imidazo[1,2-a]pyridine hydrochloride To a 250 mL round-bottom flask were added the intermediate product 66B (90 mg, 0.19 mmol), MeOH (30 mL), and Pd-C (wt.% on carbon, wet) (41 mg, 0.019 mmol). The flask was evacuated and purged with N2 (3x) and stirred in H2 at 1 atm. After 6 h, the catalyst was filtered out, and 4 M HCl in dioxane (20 mL) was added to the filtrate, and the mixture was stirred. After 20 min, the solvent was concentrated, the residue was co-evaporated with toluene (2x), and the product was vacuum dried to obtain the title compound (78 mg, 0.19 mmol, 100% yield) as a roasted solid. 1H-NMR (500 MHz, methanol-d4) 8, 88-8, 79 (m, 1H) , 8, 28-8, 19 (m, 4H) , 7, 78-7, 69 (m, 1H) , 7, 47-7, 41 (m, 1H) , 3, 78-3, 75 (m, 2H) , 3, 69 (s1, 4H) , 3, 62-3, 59 (m, 3H) , 3, 23 (s1, 3H) , 2, 96-2, 89 (m, 3H) . Analytical CL / EM (Method 4) : Observed mass: 369, 9; Retention time: 0, 821 min. Stage D. Example 66 To a 40 mL vial were added the intermediate product 66C (50 mg, 0.12 mmol), 1-isopropylpiperidin-4-one (87 mg, 0.62 mmol), AcOH (7.8 µl, 0.14 mmol), magnesium sulfate (220 mg, 1.8 mmol), and DMF (2 mL). The reaction mixture was stirred for 10 min, then sodium triacetoxyborohydride (130 mg, 0.62 mmol) was added, and the reaction mixture was stirred again. After 18 h, the reaction mixture was diluted with 10% IPA / CHC13 (40 mL) and filtered. The filtrate was partitioned into 10% KOH (aq, saturated with solid NaCl) (20 mL), and the phases were separated. The aqueous phase was extracted with 10% IPA (10 ml), the organic phase was combined, washed with brine, dried over MgSO4, filtered and concentrated. The crude material was purified by preparative HPLC (preparation method 1) to provide the title compound (16 mg, 0.032 mmol, 27% yield).1H-NMR (500 MHz, DMSO-6) 8, 51-8, 42 (m, 1H), 8, 31-8, 24 (m, 2H), 8, 06-7, 91 (m, 2H), 7, 35-7, 26 (m, 1H), 6, 86-6, 73 (m, 1H) , 3, 66-3, 62 (m, 6H) , 3, 25-3, 21 (m, 2H) , 3, 07-2, 97 (m, 3H) , 2, 95-2, 86 (m, 1H) , 2, 64-2, 61 (m, 2H) , 2, 46-2, 22 (m, 4H), 1, 89-1, 80 (m, 3H), 1, 74-1, 48 (m, 4H), 1, 19-0, 99 (m, 6H). Analytical LC / MS (Method 1): Purity 95.4%;. Observed mass: 495.17; Retention time: 0.92 min. (Method 2): Purity: 95.6%; Observed mass: 495.17; Retention time: 1.28 min. Example 67 8-fluoro-6-(1-isopropyl-[1,4-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine Step A. Intermediate Product 67A. Preparation of 6-bromo-8-fluoro-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine 5-Bromo-3-fluoropyridin-2-amine (1.0 g, 5.2 mmol), 2-bromo-1-(4-(methylsulfonyl)phenyl)ethan-1-one (1.6 g, 5.8 mmol), and EtOH (15 mL) were added to a 40 mL vial. The container was capped, and the reaction mixture was stirred at 75 °C. After 18 h, a precipitate formed. The reaction vessel was stored at -20 °C for 1 h, and the precipitate was collected by vacuum filtration. The filter cake was washed with a minimal amount of ether and the product was vacuum dried to obtain the title compound (1.0 g, 2.8 mmol, 54% yield) as a light tan solid. 1H-NMR (500 MHz, DMSO-6) 8.88-8.81 (m, 1H) , 8.73-8.64 (m, 1H) , 8.30-8.23 (m, 2H) , 8.067.97 (m, 2H) , 7.62-7.53 (m, 1H) , 3.26 (s, 3H) . Analytical CL / MS (Method 4): Observed mass: 370.7; Retention time: 1.562 min. Step B. Intermediate Product 67B. Preparation of 4-(8-fluoro-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridin-6-yl)-3,6-dihydropyridin-1(2H)-benzylcarboxylate The intermediate product 67 A (1.0 g, 2.8 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-benzyl carboxylate (1.2 g, 3.4 mmol), XPhos Pd G3 (0.12 g, 0.14 mmol), 1,4-dioxane (15 ml) were added to a 40 ml vial, followed by tribasic potassium phosphate (2.1 g, 9.9 mmol) dissolved in water (3 ml). The container was washed thoroughly with N2 and the reaction mixture was stirred at 85 °C. After 18 hours, the reaction mixture was cooled, diluted with water (200 ml), and extracted with ethyl acetate (2 × 100 ml). The organic phase was combined, washed with brine, dried over MgSO4, filtered, and concentrated. The residue was purified by ultrafast column chromatography (120 g silica gel cartridge; A = DCM, B = MeOH; 30 min gradient; B to 0% to B to 15%; flow rate = 80 ml / min).The product fractions were combined, concentrated, and vacuum dried to obtain the title compound (0.41 g, 0.81 mmol, 29% yield) as a pale yellow solid. 1H-NMR (500 MHz, methanol-d4) 8, 50-8, 45 (m, 1H), 8, 40-8, 37 (m, 1H), 8, 22 (s, 2H), 8, 09-8, 01 (m, 2H), 7, 47-7, 31 (m, 6H) , 6, 39-6, 25 (m, 1H) , 5, 20 (s, 2H) , 4, 29-4, 17 (m, 2H) , 3, 86-3, 73 (m, 2H) , 3, 18 (s, 3H) , 2, 65-2, 57 (m, 2H) . CL / EM analytical (Method 4): Observed mass: 506.1; Retention time: 1.947 min. Step C. Intermediate Product 67C. Preparation of 8-fluoro-2-(4-(methylsulfonyl)phenyl)-6-(piperidin-4-yl)imidazo[1,2-a]pyridine The intermediate product 67B (0.41 g, 0.81 mmol), MeOH (30 mL), and DCM (10 mL) were added to a 250 mL round-bottom flask. The flask was evacuated and purged with N2, then Pd-C (5 wt. as carbon, wet) (0.086 g, 0.081 mmol) was added, the flask was evacuated and purged with N2, and the reaction mixture was stirred in H2 at 1 atm. After 18 h, the catalyst was filtered and the filtrate was concentrated. The product was vacuum dried to obtain the title compound (0.30 g, 0.81 mmol, 100% yield) as a light tan solid. 1H-NMR (500 MHz, methanol-d4) 8.50-8.45 (m, 1H) , 8.30-8.27 (m, 1H) , 8.26-8.20 (m, 2H) , 8.07-8.03 (m, 2H) , 7.22-7.13 (m, 1H) , 3.58-3.52 (m, 2H) , 3.19 (s, 5H) , 3.06-2.99 (m, 1H) , 2.25-2.18 (m, 2H) , 2, 00-1, 89 (m, 2H) . Analytical CL / EM (Method 4) : Observed mass: 373, 9; Retention time: 0, 890 min. Stage D. Example 67 To a 40 mL vial were added the intermediate product 67C (75 mg, 0.17 mmol), 1-isopropylpiperidin-4-one (120 mg, 0.84 mmol), AcOH (11 µL, 0.19 mmol), magnesium sulfate (300 mg, 2.5 mmol), and DMF (2 mL). The reaction mixture was stirred for 20 min, then sodium triacetoxyborohydride (180 mg, 0.84 mmol) was added, and the reaction mixture was stirred again. After 18 h, the reaction mixture was diluted with 10% IPA (40 mL) and filtered. The filtrate was partitioned into 10% KOH (acid, saturated with solid NaCl) (20 mL), and the phases were separated. The aqueous phase was extracted with 10% IPA (10 ml), the organic phase was combined, washed with brine, dried over MgSO4, filtered and concentrated. The crude material was purified by preparative HPLC (preparation method 2) to provide the title compound (47 mg, 0.065 mmol, 38% yield).1H-RMN (500 MHz, DMSO-6) 8, 72-8, 63 (m, 1H) , 8, 34-8, 28 (m, 1H) , 8, 25-8, 19 (m, 2H) , 8, 05-7, 97 (m, 2H) , 7, 23-7, 17 (m, 1H), 3, 70-3, 43 (m, 3H), 3, 24 (s, 3H), 3, 21-3, 12 (m, 1H), 3, 10-2, 92 (m, 3H), 2, 55-2, 52 (m, 2H), 2, 40-2, 29 (m, 2H), 2, 18 (da, J=11, 0 Hz, 2H) , 2, 08-1, 84 (m, 4H) , 1, 26 (da, J=6, 7 Hz, 6H) (dos protones oscurecidos) . CL / EM analysis (Método 1): Pure: 100%; Masa observada: 499, 21; Retention time: 0, 91 min. (Método 2): Pureza: 100%; Masa observada: 498, 94; Retention time: 1, 12 minutes. Examples 68 and 69 8-fluoro-6- (1- (8-isopropil-8-azabiciclo[3.2.1]octan-3-il) piperidin-4-il) -2- (4- (metilsulfonil) fenil) imidazo[1, 2-a]piridina Etapa A. Producto intermedio 68A. Preparación de diclorhidrato de 6- (1- (8-azabiciclo[3.2.1]octan-3-il) piperidin-4-il) -8-fluoro-2- (4- (metilsulfonil) fenil) imidazo[1, 2-a]piridina The intermediate product 67C (0.41 g, 1.1 mmol), DCE (10 mL), 1,4-dioxane (10 mL), tert-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (0.99 g, 4.4 mmol), and titanium(IV) isopropoxide (1.6 mL, 5.5 mmol) were added to a 250 mL round-bottom flask. The reaction mixture was stirred at 40 °C under N2. After 18 h, the mixture was cooled to a temperature of 10 °C, then sodium triacetoxyborohydride (0.93 g, 4.4 mmol) was added and the reaction continued. After 1 h, the reaction mixture was filtered and partitioned into 1 M KOH (150 mL) (saturated with solid NaCl) and 10% IPA / chloroform (150 mL). The phases were separated, the aqueous phase was extracted with 10% IPA / chloroform (75 mL), the organic phase was combined, washed with brine, dried over MgSO4, filtered, and concentrated. The residue was purified by ultrafast column chromatography (120 g silica gel cartridge; A = DCM, B = MeOH; 30 min gradient; B from 0% to B' at 30%; flow rate = 80 mL / min).The fractions corresponding to the desired intermediate were combined, concentrated, and vacuum dried. The resulting residue was dissolved in MeOH (20 mL) and 4 M HCl in dioxane (10 mL) and stirred. After 0.5 h, the solvent was concentrated, the residue was co-evaporated with toluene (2x), and the product was vacuum dried to obtain the title compound (0.50 g, 0.90 mmol, 82% yield) as a toasted solid. Analytical CL / MS (Method 4): Observed mass: 483.1 g; Retention time: 0.896 min. Stage B. Examples 68 and 69 Examples 68 and 69 were synthesized according to the procedures described for the preparation of Examples 62 and 63 (step B), using intermediate 68A (100 mg, 0.18 mmol) as the starting material. The crude isomeric mixture was purified by preparative HPLC under the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 pm particles; Mobile phase A: 5:95 acetonitrile:ammonium acetate water; Mobile phase B: 95:5 acetonitrile:ammonium acetate water; Gradient: a 0-minute hold at 2% B, 2–42% B for 20 minutes, then a 0-minute hold at 100% B; Flow rate: 20 mL / min. Column temperature: 25 °C. Fraction collection was activated by EM signals. The fractions corresponding to the respective desired products were combined and dried by centrifugal evaporation. Example 68 (8.4 mg, 0.016 mmol, 9% yield) was isolated as the 1st elution isomer. 1H-NMR (500 MHz, DMSO-6) 8, 63-8, 57 (m, 1H) , 8, 31-8, 27 (m, 1H) , 8, 25- 8, 20 (m, 2H) , 8, 02-7, 96 (m, 2H) , 7, 26-7, 20 (m, 1H) , 3, 55-3, 37 (m, 2H) , 3, 24 (s, 2H) , 3, 05-2, 96 (m, 2H) , 2, 95-2, 85 (m, 1H) , 2, 76-2, 65 (m, 1H) , 2, 59-2, 56 (m, 1H), 2.25-2.17 (m, 2H) , 1.93-1.81 (m, 5H) , 1.63 (sa, 8H) , 1.09 (daa, J=6, 1 Hz, 6H) . Analytical CL / EM (Method 1): Purity: 97.5%; Observed mass: 525.20; Retention time: 0.95 min. (Method 2): Purity: 100%; Observed mass: 525.30; Retention time: 1.23 min. Example 69 (11 mg, 0.021 mmol, 12% yield) was isolated as the 2nd elution isomer. 1H-NMR (500 MHz, DMSO-6) 8, 67-8, 58 (m, 1H) , 8, 34-8, 30 (m, 1H) , 8, 27- 8, 21 (m, 2H) , 8, 06-7, 96 (m, 2H) , 7, 31-7, 22 (m, 1H) , 3, 69-3, 60 (m, 1H) , 3, 36-3, 30 (m, 1H) , 3, 25 (s, 2H) , 2, 90-2, 81 (m, 1H) , 2, 55-2, 52 (m, 3H) , 2, 41-2, 32 (m, 1H), 2.05-1.76 (m, 10H) , 1.74-1.56 (m, 3H) , 1.12 (da, J=6, 1 Hz, 6H) (two obscured protons). Analytical CL / EM (Method 1): Purity: 96.5%; Observed mass: 525.20; Retention time: 0.98 min. (Method 2): Purity: 95.3%; Observed mass: 525.20; Retention time: 1.36 min. Example 70 7-fluoro-6-(1-isopropyl-[1,4-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine Step A. Intermediate Product 70A. Preparation of 7-fluoro-2-(4-(methylsulfonyl)phenyl)-6-(piperidin-4-yl)imidazo[1,2-a]pyridine Intermediate product 70A was synthesized according to the procedures described for the preparation of intermediate product 67C (Steps AC), using 5-bromo-4-fluoropyridin-2-amine (1.0 g, 5.2 mmol) as the starting material to obtain the title compound (0.38 g, 1.0 mmol, 19% yield in 3 steps) as a light tan solid. 1H-NMR (500 MHz, DMSO-6) 8, 96-8, 75 (m, 1H) , 8, 59-8, 49 (m, 2H) , 8, 25-8, 16 (m, 2H) , 7, 99 (d, J=8, 6 Hz, 2H) , 7, 59-7, 49 (m, 1H), 3, 44-3, 38 (m, 2H), 3, 25 (s, 3H), 3, 13-3, 04 (m, 3H), 2, 11-2, 02 (m, 2H), 1, 96-1, 86 (m, 2H). CL / EM analytical (Method 4): Observed mass: 373.9; Retention time: 0.992 min. Stage B. Example 70 Example 70 was synthesized according to the procedures described for the preparation of Example 67 (step D), using intermediate product 70A (65 mg, 0.17 mmol) as the starting material. The crude mixture was purified by preparative HPLC (Preparation Method 1) to obtain the title compound (14 mg, 0.028 mmol, 17% yield). 1H-NMR (500 MHz, DMSO-6) 8, 53-8, 46 (m, 2H) , 8, 21-8, 16 (m, 2H) , 8, 02-7, 95 (m, 2H) , 7, 46-7, 42 (m, 1H) , 3, 24-3, 22 (m, 2H), 3, 17 (s, 3H), 3, 02-2, 97 (m, 2H), 2, 87-2, 82 (m, 2H), 2, 73-2, 62 (m, 3H), 1, 79-1, 64 (m, 6H), 1, 49-1, 39 (m, 4H) , 0, 96 (da, J=6, 7 Hz, 6H) . Analytical CL / EM (Method 1): Purity: 97.4%; Observed mass: 499.12; Retention time: 0.89 min. (Method 2): Purity: 98.7%; Observed mass: 499.0; Retention time: 1.20 min. Examples 71 and 72 8-fluoro-6- (1- (1-isopropylazepan-4-yl) piperidin-4-yl) -2- (4- (methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine Etapa A. Producto intermedio 108A. Preparación de diclorhidrato de 6- (1- (azepan-4-il) piperidin-4-il) -8-fluoro-2- (4- (metilsulfonil) fenil) imidazo[1, 2-a]piridina Intermediate product 67C (1.2 g, 3.3 mmol), tert-butyl 4-oxoazepane-1-carboxylate (3.5 g, 17 mmol), AcOH (0.21 ml, 3.6 mmol), magnesium sulfate (7.9 g, 66 mmol), and DMF (40 ml) were added to a 200 ml pear-shaped flask. The reaction mixture was stirred for 20 min, then sodium triacetoxyborohydride (3.5 g, 17 mmol) was added, and the reaction mixture was stirred in N2. After 18 h, the reaction mixture was diluted with 2 M KOH (sat. with solid NaCl) (200 ml) and extracted with 10% IPA (2 x 100 ml). The organic phase was combined, washed with brine, dried over MgSO4, filtered, and concentrated. The residue was purified by ultrafast column chromatography (80 g silica gel cartridge; A = DCM, B = MeOH; 30 min gradient; B at 0% to B at 10%; flow rate = 60 ml / min). The product fractions were combined, concentrated, and vacuum dried.The resulting intermediate product was dissolved in MeOH (20 ml) and 4 M HCl in dioxane (20 ml) and stirred. After 30 min, the solvent was concentrated and the residue was co-evaporated with toluene (2x) and the product was vacuum dried to obtain the title compound (1.1 g, 2.1 mmol, 64% yield) as a light tan solid. 1H-NMR (500 MHz, methanol-d4) 8, 83-8, 76 (m, 1H) , 8, 69-8, 64 (m, 1H) , 8, 24-8, 17 (m, 4H) , 7, 92-7, 84 (m, 1H) , 3, 74-3, 62 (m, 3H) , 3, 60-3, 53 (m, 1H) , 3, 48-3, 38 (m, 3H) , 3, 31-3, 24 (m, 2H) , 3, 22 (s, 3H) , 2, 65-2, 55 (m, 1H) , 2, 50-2, 43 (m, 1H) , 2, 33 (ad, .J=2, 9 Hz, 5H) , 2, 26-2, 16 (m, 1H) , 2, 10-1, 90 (m, 2H) (one obscured proton) . Analytical CL / EM (Method 4) : Observed mass:471.3; Retention time: 0.889 min. Stage B. Examples 71 and 72 The intermediate product 71A (220 mg, 0.41 mmol), propaneone (120 mg, 2.0 mmol), AcOH (0.025 mL, 0.45 mmol), magnesium sulfate (730 mg, 6.1 mmol), and DMF (2 mL) were added to a 40 mL vial. The reaction mixture was stirred for 20 min, then sodium triacetoxyborohydride (430 mg, 6.1 mmol) was added, and the reaction mixture was stirred again. After 18 h, the reaction mixture was diluted with 10% IPA (40 mL) and filtered. The filtrate was partitioned into 10% KOH (aq, saturated with solid NaCl) (20 mL), and the phases were separated. The aqueous phase was extracted with 10% IPA (10 ml), the organic phase was combined, washed with brine, dried over MgSO4, filtered and concentrated. The crude material was purified by preparative HPLC (Preparation Method 1).The resulting racemic mixture was further purified by chiral SFC chromatography under the following conditions: Instrument: Waters 100 Prep SFC; Column: Chiral AD, 30 x 250 mm, 5 µm; Mobile phase: 65% CO2 / 35% IPA with 0.5% DEA; Flow rate: 100 mL / min; Detector wavelength: 220 nm; Injection details: 500 µg, 100 mg dissolved in 4 mL of MeOH. The fractions corresponding to the respective desired products were combined and dried by centrifugal evaporation. Example 71 (26 mg, 0.051 mmol, 12% yield) was isolated as the 1st elution enantiomer. 1H-NMR (500 MHz, DMSO-6) 8, 65-8, 56 (m, 1H) , 8, 32-8, 27 (m, 1H) , 8, 25-8, 20 (m, 2H) , 8, 05-7, 96 (m, 2H) , 7, 27-7, 21 (m, 1H), 3, 25 (s, 2H), 2, 95-2, 82 (m, 2H), 2, 73-2, 64 (m, 2H), 2, 63-2, 53 (m, 2H), 2, 41-2, 28 (m, 2H), 1, 91 (s, 2H) , 1, 87-1, 69 (m, 5H) , 1, 69-1, 41 (m, 5H) , 0, 98 (dd, J=6, 3, 3, 8 Hz, 6H) (two obscured protons) . Analytical CL / EM (Method 1): Purity: 100%; Observed Mass: 513.20; Retention Time: 0.95 min. (Method 2): Purity: 100%; Observed Mass: 513.30; Retention Time: 1.23 min. Chiral Analytical (Method SFC 6): Purity: >95%; Retention Time: 13.52 min. Example 72 (18 mg, 0.035 mmol, 9% yield) was isolated as the 2nd eluting enantiomer. Hz, 2H) , 8, 00 (d, J=8, 2 Hz, 2H) , 7, 24 (da, J=12, 2 Hz, 1H) , 3, 25 (s, 2H) , 2, 89-2, 79 (m, 3H) , 2, 72-2, 58 (m, 3H) , 2, 39-2, 26 (m, 3H) , 1, 90 (s, 3H) , 1, 86-1, 68 (m, 5H) , 1, 67-1, 37 (m, 5H) , 0, 95 (dd, J=6, 4, 3, 7 Hz, 6H) . Chiral analysis (SFC 6 method): purity: >92%; Retention time: 16, 16 min. Example 73 5-fluoro-6-(1-isopropyl-[1,4-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine Step A. Intermediate product 73 A. Preparation of tert-butyl 6-amino-2-fluoro-3', 6'-dihydro-[3,4'-bipyridin]-1'(2'H)-carboxylate Intermediate product 73A was synthesized according to the procedures described for the preparation of intermediate product 66A, using 5-bromo-6-fluoropyridin-2-amine (1.5 g, 7.9 mmol) as the starting material to obtain the title compound (2.3 g, 7.8 mmol, 99% yield) as a pale yellow solid. 1H-NMR (500 MHz, methanol-d4) 7, 60-7, 39 (m, 1H) , 6, 39 (dd, J=8, 2, 1, 8 Hz, 1H) , 5, 88 (sa, 1H) , 4, 09-4, 01 (m, 2H) , 3, 69-3, 57 (m, 2H), 2, 52-2, 39 (m, 2H), 1, 51 (s, 9H). Analytical LC / MS (Method 4): Observed mass: 294.1; Retention time: 1,684 min. Step B. Intermediate Product 73B. Preparation of tert-butyl 4-(6-amino-2-fluoropyridin-3-yl)piperidin-1-carboxylate The intermediate product 73A (2.3 g, 7.8 mmol), DCM (30 mL), and MeOH (30 mL) were introduced into a 500 mL pear-shaped flask, followed by Pd-C (5 wt. as carbon, wet) (1.7 g, 0.78 mmol). The flask was evacuated and purged with N2, then stirred in H2 at 1 atm. After 18 h, the catalyst was filtered out and the filtrate was concentrated. The product was vacuum-dried to obtain the title compound (2.3 g, 7.8 mmol, 100% yield) as a pale yellow solid. 1H-NMR (500 MHz, methanol-d4) 7.51-7.38 (m, 1H), 6.45-6.31 (m, 1H), 4.28-4.15 (m, 2H), 2.96-2.76 (m, 3H), 1.81-1.72 (m, 2H), 1, 65-1, 51 (m, 2H), 1, 49 (s, 9H). Analytical LC / MS (Method 4) : Observed mass: 240.1 (-t-Bu) ; Retention time: 1,676 min. Step C. Intermediate Product 73C. Preparation of 5-fluoro-2-(4-(methylsulfonyl)phenyl)-6-(piperidin-4-yl)imidazo[1,2-a]pyridine The intermediate product 73B (1.0 g, 3.4 mmol), 2,2-dimethoxy-2-(4-(methylsulfonyl)phenyl)ethyl 4-methylbenzenesulfonate (1.4 g, 3.4 mmol), MeCN (20 ml), followed by scandium(III) triflate (0.083 g, 0.17 mmol) were added to a 20 ml microwave reaction vial. The vial was capped and the reaction mixture was irradiated at 120 °C. After 12 h, the desired cyclization reaction was observed, in addition to the cleavage of Boc. The solvent was concentrated and the residue was purified by ultrafast column chromatography (120 g silica gel cartridge; A = DCM, B = MeOH; 30 min gradient; 0% B to 10% B; flow rate = 80 mL / min). The product fractions were combined, concentrated, and vacuum dried to obtain the title compound (0.14 g, 0.37 mmol, 11% yield) as a light tan solid. Analytical LC / MS (Method 4): Observed mass: 374.1 g; Retention time: 1.008 min. Stage D. Example 73 The intermediate product 73C (72 mg, 0.19 mmol), 1-isopropylpiperidin-4-one (140 mg, 0.96 mmol), AcOH (0.012 mL, 0.21 mmol), magnesium sulfate (350 mg, 2.9 mmol), and DMF (2 mL) were added to a 40 mL vial. The reaction mixture was stirred for 20 min, then sodium triacetoxyborohydride (200 mg, 0.96 mmol) was added, and the reaction mixture was stirred again. After 18 h, the reaction mixture was diluted with 10% IPA (40 mL) and filtered. The filtrate was partitioned into 10% KOH (aq, saturated with solid NaCl) (20 mL), and the phases were separated. The aqueous phase was extracted with 10% IPA (10 ml), the organic phase was combined, washed with brine, dried over MgSO4, filtered and concentrated. The crude material was purified by preparative HPLC (preparation method 2) to provide the title compound (29 mg, 0.040 mmol, 21% yield). 1H-NMR (500 MHz, DMSO-6) 8.76 (sa, 1H), 8.32 (da, J=7, 6 Hz, 2H), 8.01 (da, J=8, 2 Hz, 2H), 7.59 (ad, .J=9, 2 Hz, 1H) , 7, 38-7, 30 (m, 1H) , 3, 63-3, 45 (m, 4H) , 3, 26 (sa, 2H) , 3, 14-3, 04 (m, 2H) , 2, 99-2, 90 (m, 3H) , 2, 40-2, 31 (m, 2H), 2, 07 (da, J=12, 8 Hz, 8H), 1, 57-1, 52 (m, 1H), 1, 21-1, 12 (m, 6H). Analytical LC / MS (Method 1): Purity: 98.1%; Observed mass: 499.30; Retention time: 0.91 min. (Method 2) : Purity: 97.8%; Observed mass: 499.30; Retention time: 1.21 min. Example 74 8-fluoro-7-(1'-isobutyl-[1,4'-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine Step A. Intermediate Product 74A. Preparation of 8-fluoro-2-(4-(methylsulfonyl)phenyl)-7-(piperidin-4-yl)imidazo[1,2-a]pyridine hydrochloride Intermediate product 74A was synthesized according to the methods described for the preparation of intermediate product 66C (Step AC), using 4-bromo-3-fluoropyridin-2-amine (0.50 g, 2.6 mmol) as the starting material to obtain the title compound (0.34 g, 0.83 mmol, 32% yield in 3 steps) as a light tan solid. 1H-NMR (500 MHz, methanol-d4) 8, 81-8, 78 (m, 1H) , 8, 70-8, 65 (m, 1H) , 8, 23-8, 16 (m, 4H) , 7, 50-7, 44 (m, 1H) , 3, 64-3, 58 (m, 3H) , 3, 32-3, 24 (m, 2H) , 3, 22 (s, 3H) , 2, 22-2, 16 (m, 4H) . Analytical CL / EM (Method 4) : Observed mass: 374, 1; Retention time: 0, 894 min. Stage B. Example 74 Example 74 was synthesized according to the methods described for the preparation of Example 66 (step D), using intermediate product 74A (70 mg, 0.17 mmol) as the starting material. The crude mixture was purified by preparative HPLC (Preparation Method 2) to obtain the title compound (33 mg, 0.064 mmol, 38% yield). 1H-NMR (500 MHz, DMSO-6) 8, 66-8, 61 (m, 1H) , 8, 41-8, 34 (m, 1H) , 8, 27-8, 21 (m, 2H) , 8, 05-7, 95 (m, 2H) , 6, 99-6, 91 (m, 1H) , 3, 39-3, 28 (m, 2H) , 3, 05-2, 84 (m, 5H) , 2, 39-2, 13 (m, 3H) , 2, 11-1, 95 (m, 2H) , 1, 91-1, 69 (m, 10H) , 1, 57-1, 43 (m, 2H), 0.85 (d, J=6.5 Hz, 6H). Examples 75 and 76 (6R)-2-(3,4-dimethoxyphenyl)-6-(1-(8-isobutyl-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (absolute stereochemistry arbitrarily drawn) Step A. Intermediate product 75 A. Preparation of (R)-2-(3,4-dimethoxyphenyl)-6-(piperidin-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (absolute stereochemistry arbitrarily extracted) Intermediate product 75 A was obtained as the 1st elution enantiomer from the chiral separation of intermediate product 3 IB (1.0 g, 2.9 mmol) by chiral SFC chromatography under the following conditions: Instrument: Waters 100 Prep SFC; Column: ChiralCel OD-H, 21 x 250 mm, 5 microns; Mobile phase: 55% CO2 / 45% MeOH with 0.1% DEA; Flow conditions: 45 ml / min, 120 bar, 30 °C; Detector wavelength: 220 nm; Injection details: 1000 µl, 1000 mg dissolved in 8 ml of MeOH-MeCN. The fractions containing the desired product were combined and dried by centrifugal evaporation to provide the title compound (0.36 g, 1.1 mmol, 38% yield) as a pale yellow solid.1H-NMR (500 MHz, methanol-d4) 7, 36-7, 31 (m, 1H), 7, 27-7, 19 (m, 2H), 6, 98-6, 92 (m, 1H), 4, 19-4, 13 (m, 1H), 3, 90 (s, 3H) , 3, 85 (s, 3H) , 3, 77-3, 69 (m, 1H) , 3, 19-3, 09 (m, 2H) , 3, 04-2, 96 (m, 1H) , 2, 83-2, 71 (m, 1H) , 2, 70-2, 58 (m, 2H), 2, 24-2, 14 (m, 1H) , 1, 94-1, 76 (m, 3H) , 1, 70-1, 49 (m, 2H) , 1, 45-1, 27 (m, 2H) . CL / EM analytical (Method 4) : Observed mass: 342.1; Retention time: 0.857 min. Chiral analytical (Method SFC 8) : Purity: >95%; Retention time: 6.729 min. Step B. Intermediate product 75B. Preparation of (6R) -6- (1- (8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl dihydrochloride -2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (absolute stereochemistry arbitrarily extracted) The intermediate product 75A (0.36 g, 1.1 mmol), tert-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (0.95 g, 4.2 mmol), DCE (8 ml), and 1,4-dioxane (8 ml) were added to a 40 ml vial. Titanium(IV) isopropoxide (1.6 ml, 5.3 mmol) was added to this mixture, the container was rinsed with N2, capped, and shaken at 40 °C. After 18 h, the mixture was cooled to a temperature of 10°C, then sodium triacetoxyborohydride (0.89 g, 4.2 mmol) was added, and the reaction continued. After 3 h, the reaction mixture was partitioned into 10% KOH (aq, saturated with solid NaCl) (150 mL) and 10% IPA / chloroform (150 mL). The phases were separated, the aqueous phase was extracted with 10% IPA / chloroform (75 mL), the organic phase was combined, washed with brine, dried over MgSO4, filtered, and concentrated. The residue was purified by ultrafast column chromatography (40 g silica gel cartridge; A = DCM, B = MeOH; 30 min gradient; B at 0% to B at 20%; flow rate = 80 mL / min).The fractions corresponding to the desired product were combined, concentrated, and vacuum dried. The resulting residue was dissolved in MeOH (10 mL) and 4 M HCl in dioxane (5 mL) and stirred. After 15 min, the solvent was concentrated, the residue was co-evaporated with toluene, and the product was vacuum dried to obtain the title compound (0.11 g, 0.21 mmol, 19% yield) as a whitish solid. 1H-NMR (500 MHz, methanol-d4) 7, 72-7, 69 (m, 1H), 7, 30-7, 25 (m, 2H), 7, 12-7, 08 (m, 1H), 4, 41-4, 35 (m, 1H), 4, 28-4, 23 (m, 1H) , 4, 22-4, 15 (m, 1H) , 4, 01-3, 95 (m, 1H) , 3, 91 (d, J=12, 9 Hz, 6H) , 3, 79-3, 67 (m, 5H) , 3, 62-3, 59 (m, 1H) , 3, 29-3, 06 (m, 6H) , 2, 31-2, 01 (m, 8H) , 1, 92-1, 77 (m, 4H) . Analytical CL / EM (Method 4) : Observed mass: 451, 1; Retention time: 0, 858 min. Stage C. Examples 75 and 76 The intermediate product 75B (60 mg, 0.12 mmol), isobutyraldehyde (41 mg, 0.57 mmol), AcOH (7.2 µl, 0.13 mmol), magnesium sulfate (210 mg, 1.7 mmol), and DMF (2 mL) were added to a 40 mL vial. The reaction mixture was stirred for 10 min, then sodium triacetoxyborohydride (120 mg, 0.57 mmol) was added, and the reaction mixture was stirred again. After 18 h, the reaction mixture was diluted with 10% IPA / CHCl (40 mL) and filtered. The filtrate was partitioned into 10% KOH (aq, saturated with solid NaCl) (20 mL), and the phases were separated. The aqueous phase was extracted with 10% IPA (10 ml), the organic phase was combined, washed with brine, dried over MgSO4, filtered and concentrated.The crude isomeric mixture was purified by preparative HPLC under the following conditions: Column: XBridge Cl 8, 200 mm x 19 mm, 5-pm particles; mobile phase A: 5:95 acetonitrile:ammonium acetate water; mobile phase B: 95:5 acetonitrile:ammonium acetate water; gradient: a 0-minute hold at 10% B, 10–60% B for 20 minutes, then a 0-minute hold at 100% B; flow rate: 20 mL / min; column temperature: 25 °C. Fraction collection was triggered by EM signals. The fractions corresponding to the respective desired products were combined and dried by centrifugal evaporation. Example 75 (28 mg, 0.055 mmol, 46% yield) was isolated as the 1st elution isomer. 1H-NMR (500 MHz, DMSO-6) 7, 37-7, 32 (m, 1H) , 7, 31-7, 27 (m, 1H) , 7, 21 (ad, .J=7, 9 Hz, 1H) , 6, 94-6, 88 (m, 1H) , 4, 05 (sa, 1H), 3, 78 (s, 3H), 3, 74 (s, 3H), 3, 62-3, 47 (m, 1H), 3, 26-3, 13 (m, 2H), 3, 10-2, 93 (m, 1H), 2, 92-2, 83 (m, 1H) , 2, 72-2, 59 (m, 1H) , 2, 49-2, 31 (m, 3H) , 1, 91 (s, 5H) , 1, 78 (da, J=5, 8 Hz, 7H) , 1, 65 (da, J=7, 6 Hz, 2H) , 1, 58-1, 46 (m, 2H) , 1.38 (da, J=8, 2 Hz, 3H), 0.91 (d, .J=6, 4 Hz, 6H) (one darkened proton). Analytical LC / MS (Method 1) : Purity: 100%; Observed mass: 507.29; Retention time: 0.98 min. (Method 2) : Purity: 94.2%; Observed mass: 506.99; Retention time: 1.24 min. Example 76 (25 mg, 0.049 mmol, 41% yield) was isolated as the 2nd elution isomer. 1H-NMR (500 MHz, DMSO-6) 7.92-7.85 (m, 1H) , 7.35-7.24 (m, 2H) , 7.15-7.05 (m, 1H) , 4.30-4.20 (m, 1H) , 4.00-3.85 (m, 2H) , 3, 82 (d, J=11, 6 Hz, 6H) , 3, 55-3, 41 (m, 2H) , 3, 18 (s, 2H) , 3, 04-2, 91 (m, 2H) , 2, 80-2, 65 (m, 2H) , 2, 28-1, 72 (m, 12H) , 1, 71-1, 34 (m, 5H) , 0, 97 (ad, .J=6, 4 Hz, 6H) (two obscured protons) . Analytical CL / EM (Method 1): Purity: 100%; Observed mass: 507.01; Retention time: 0.98 min. (Method 2): Purity: 100%; Observed mass: 507.0; Retention time: 1.47 min. Examples 77 and 78 (6S)-2-(3,4-dimethoxyphenyl)-6-(1-(8-isobutyl-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (absolute stereochemistry arbitrarily drawn) Step A. Intermediate Product 77A. Preparation of (S)-2-(3,4-dimethoxyphenyl)-6-(piperidin-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (absolute stereochemistry arbitrarily extracted) Intermediate product 77A was obtained as the 2nd elution enantiomer from the chiral separation of intermediate product 31B (1.0 g, 2.9 mmol) by chiral SFC chromatography under the following conditions: Instrument: Waters 100 Prep SFC; Column: ChiralCel OD-H, 21 x 250 mm, 5 microns; Mobile phase: 55% CO2 / 45% MeOH with 0.1% DEA; Flow conditions: 45 ml / min, 120 bar, 30 °C; Detector wavelength: 220 nm; Injection details: 1000 µl, 1000 mg dissolved in 8 ml of MeOH-MeCN. The fractions containing the desired product were combined and dried by centrifugal evaporation to provide the title compound (0.33 g, 0.97 mmol, 33% yield) as a pale yellow solid.1H-NMR (500 MHz, methanol-d4) 7, 36-7, 32 (m, 1H), 7, 28-7, 19 (m, 2H), 6, 98-6, 91 (m, 1H), 4, 25-4, 10 (m, 1H), 3, 90 (s, 3H) , 3, 85 (s, 3H) , 3, 78-3, 72 (m, 1H) , 3, 22-3, 16 (m, 2H) , 3, 05-2, 98 (m, 1H) , 2, 81-2, 67 (m, 3H) , 2, 24-2, 16 (m, 1H), 1, 98-1, 81 (m, 3H) , 1, 71-1, 53 (m, 2H) , 1, 47-1, 32 (m, 2H) . CL / EM analytical (Method 4) : Observed mass: 342.1; Retention time: 0.859 min. Chiral analytical (Method SFC 8) : Purity: >95%; Retention time: 16.297 min. Step B. Intermediate Product 77B. Preparation of (6S)-6-(1-(8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine dihydrochloride (absolute stereochemistry arbitrarily drawn) Intermediate product 77B was synthesized according to the methods described for the preparation of intermediate product 75B, using intermediate product 77A (0.33 g, 0.97 mmol) as a starting material to provide the title compound (0.10 g, 0.19 mmol, 20% yield) as an off-white solid. 1H-NMR (500 MHz, methanol-d4) 7, 71-7, 67 (m, 1H), 7, 28-7, 25 (m, 2H), 7, 24-7, 21 (m, 1H), 4, 43-4, 36 (m, 1H), 4, 30-4, 24 (m, 1H) , 4, 22-4, 13 (m, 1H) , 3, 99-3, 95 (m, 1H) , 3, 93 (s, 3H) , 3, 90 (s, 3H) , 3, 76 (sa, 2H) , 3, 69 (da, J=5, 5 Hz, 5H) , 3, 61 (da, J=5, 0 Hz, 2H) , 3, 28-3, 20 (m, 2H) , 3, 14-3, 01 (m, 3H) , 2, 45-1, 98 (m, 6H) , 1, 92-1, 74 (m, 3H) . Analytical CL / EM (Method 4) : Observed mass: 451, 1; Retention time: 0, 857 min. Stage C. Examples 77 and 78 Examples 77 and 78 were synthesized according to the methods described for the preparation of Examples 75 and 76, using intermediate product 77B (50 mg, 0.096 mmol) as the starting material. The crude isomeric mixture was purified by preparative HPLC under the following conditions: Column: X Bridge Cl 8, 200 mm x 19 mm, 5-pm particles; Mobile phase A: 5:95 acetonitrile:ammonium acetate water; Mobile phase B: 95:5 acetonitrile:ammonium acetate water; Gradient: a 0-minute hold at 11% B, 11–58% B for 20 minutes, then a 0-minute hold at 100% B; Flow rate: 20 mL / min; Column temperature: 25 °C. Fraction collection was triggered by EM signals. The fractions corresponding to the respective desired products were combined and dried by centrifugal evaporation. Example 77 (22 mg, 0.043 mmol, 45% yield) was isolated as the 1st elution isomer. 1H-NMR (500 MHz, DMSO-6) 7, 36-7, 31 (m, 1H) , 7, 31-7, 27 (m, 1H) , 7, 24-7, 18 (m, 1H) , 6, 95-6, 87 (m, 1H) , 4, 10-4, 00 (m, 1H) , 3, 76 (d, J=18, 3 Hz, 6H) , 3, 63-3, 46 (m, 3H) , 3, 21-3, 15 (m, 2H) , 2, 99-2, 78 (m, 3H) , 2, 72-2, 60 (m, 1H) , 2, 18-2, 08 (m, 2H) , 2, 07-1, 96 (m, 3H) , 1, 93-1, 69 (m, 5H) , 1, 68-1, 43 (m, 7H) , 1, 32-1, 16 (m, 3H) , 0, 92-0, 77 (m, 6H) . Analytical CL / EM (Method 1) : Purity: 95.8%; Observed mass: 507.05; Retention time: 1.01 min. (Method 2) : Purity: 96.6%; Observed mass: 507.02; Retention time: 1.38 min. Example 78 (21 mg, 0.041 mmol, 43% yield) was isolated as the 2nd elution isomer. 1H-NMR (500 MHz, DMSO-6) 7, 35-7, 32 (m, 1H), 7, 31-7, 28 (m, 1H), 7, 22-7, 19 (m, 1H), 6, 92-6, 89 (m, 1H), 3, 77 (s, 3H), 3, 75 3, 71 (m, 2H) , 3, 19-3, 05 (m, 5H) , 2, 91-2, 78 (m, 3H) , 2, 71-2, 61 (m, 3H) , 2, 41-2, 28 (m, 3H) , 2, 03-1, 88 (m, 6H) , 1, 77-1, 58 (m, 8H) , 1, 23 (sa, 3H) , 0, 86 (da, J=6, 7 Hz, 6H) . Analytical CL / EM (Method 1): Purity: 99.1%; Observed mass: 506.9; Retention time: 0.94 min. (Method 2): Purity: 100%; Observed mass: 506.9; Retention time: 1.55 min. Examples 79 and 80 (6R) -6- (1- (8-isobutyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl) -2- (4- (methylsulfonyl) phenyl) -5, 6, 7, 8-tetrahydroimidazo[1, 2-a]pyridine (absolute stereochemistry arbitrarily drawn) Step A. Intermediate Product 79A. Preparation of 4-(2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridin-6-yl)-3,6-dihydropyridine-1(2H)-tert-butyl carboxylate Intermediate product 79A was synthesized according to the methods described for the preparation of intermediate product 1B (steps AB), using 5-bromopyridin-2-amine (1.3 g, 7.5 mmol) as starting material 1 and substituting 2-bromo-1-(4-(methylsulfonyl)phenyl)ethan-1-one when appropriate to obtain the title compound (2.8 g, 6.1 mmol, 81% yield in 2 steps) as a pale yellow solid. 1H-NMR (500 MHz, DMSO-6) 68, 60-8, 56 (m, 1H), 8, 53-8, 47 (m, 1H), 8, 25-8, 18 (m, 2H), 8, 00-7, 96 (m, 2H), 7, 62-7, 52 (m, 2H) , 6, 36-6, 26 (m, 1H) , 4, 05 (sa, 2H) , 3, 58 (sa, 2H) , 3, 32 (s, 3H) , 3, 20-3, 17 (m, 1H) , 2, 76-2, 72 (m, 1H) , 1, 45 (s, 9H) . CL / EM analytical (Method 4) : Observed mass: 454, 1; Retention time: 1, 451 min. Step B. Intermediate Product 79B. Preparation of 2-(4-(methylsulfonyl)phenyl)-6-(piperidin-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine hydrochloride Intermediate product 79B was synthesized according to the methods described for the preparation of intermediate product 31B (Steps AB), using intermediate product 79A (2.8 g, 6.1 mmol) as a starting material to obtain the title compound (0.85 g, 2.1 mmol, 34% yield in 2 steps) as an off-white solid. 1H-NMR (500 MHz, methanol-d4) 7.93 (s, 4H), 7.56-7.52 (m, 1H), 4.26-4.18 (m, 1H), 3.84-3.76 (m, 1H), 3.37 (s, 2H), 3. 14 (s, 3H) , 3.06-3.00 (m, 1H) , 2.86-2.75 (m, 1H) , 2.63 (ta, J=12.3 Hz, 2H) , 2.25-2.17 (m, 1H) , 1.89 (da, J=12.2 Hz, 2H), 1, 83-1, 75 (m, 1H) , 1, 72-1, 62 (m, 1H) , 1, 59-1, 49 (m, 1H) , 1, 44-1, 26 (m, 2H) . Analytical CL / EM (Method 4) : Observed mass: 360, 0; Retention time: 0, 752 min. Step C. Intermediate Product 79C. Preparation of (R)-2-(4-(methylsulfonyl)phenyl)-6-(piperidin-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (absolute stereochemistry arbitrarily extracted) Intermediate 79C was obtained as the first elution enantiomer from the chiral separation of intermediate 79B (0.85 g, 2.4 mmol) by chiral SFC chromatography under the following conditions: Instrument: Berger SFC; Column: Chiral OD, 30 x 250 mm, 5 µm; Mobile phase: 70% CO2 / 30% EtOH with 0.1% DEA; Flow rate: 85 mL / min; Detector wavelength: 220 nm; Injection details: 650 µg dissolved in 30 mL of EtOH-DEA. The fractions containing the desired product were combined and dried by centrifugal evaporation to yield the title compound (0.35 g, 0.97 mmol, 41% yield) as a pale yellow solid.1H-NMR (500 MHz, methanol-d4) 7.96-7.89 (m, 4H), 7.57-7.53 (m, 1H), 4.27-4.19 (m, 1H), 3.85-3.74 (m, 1H), 3.14 (s, 4H) , 3, 08-3, 00 (m, 1H) , 2, 85-2, 76 (m, 1H) , 2, 70-2, 61 (m, 2H) , 2, 25-2, 17 (m, 1H) , 1, 95-1, 85 (m, 2H) , 1, 84-1, 77 (m, 1H), 1.73-1.63 (m, 1H) , 1.60-1.51 (m, 1H) , 1.42-1.30 (m, 3H) . CL / EM analytical (Method 4): Observed mass: 360.0; Retention time: 0.816 min. Chiral analytical (Method SFC 9): Purity: >99%; Retention time: 12.01 min. Step D. Intermediate Product 79D. Preparation of (6R)-6-(1-(8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine dihydrochloride (absolute stereochemistry arbitrarily drawn) Intermediate product 79D was synthesized according to the methods described for the preparation of intermediate product 75B, using intermediate product 79C (0.35 g, 0.97 mmol) as a starting material to obtain the title compound (0.50 g, 0.92 mmol, 95% yield) as a pale yellow solid. 1H-NMR (500 MHz, methanol-d4) 8, 14-8, 10 (m, 2H) , 8, 00 (s, 1H) , 7, 96 (d, J=8, 6 Hz, 2H) , 4, 48-4, 41 (m, 2H) , 4, 30-4, 15 (m, 4H), 4, 12-3, 97 (m, 5H), 3, 79-3, 69 (m, 4H), 3, 18-3, 06 (m, 4H), 2, 16-2, 05 (m, 6H), 1, 91-1, 79 (m, 5H). CL / EM analytical (method): Observed mass: 469.1; Retention time: 0.825 min. Stage E. Examples 79 and 80 Examples 79 and 80 were synthesized according to the methods described for the preparation of Examples 75 and 76, using intermediate 79D (110 mg, 0.20 mmol) as the starting material. The crude isomeric mixture was purified by preparative HPLC under the following conditions: Column: X Bridge Cl 8, 200 mm x 19 mm, 5-pm particles; Mobile phase A: 5:95 acetonitrile:ammonium acetate water; Mobile phase B: 95:5 acetonitrile:ammonium acetate water; Gradient: a 0-minute hold at 12% B, 12–52% B for 20 minutes, then a 0-minute hold at 100% B; Flow rate: 20 mL / min; Column temperature: 25 °C. Fraction collection was triggered by EM signals. The fractions corresponding to the respective desired products were combined and dried by centrifugal evaporation. Example 79 (7.4 mg, 0.014 mmol, 7% yield) was isolated as the 1st elution isomer. 1H-NMR (500 MHz, DMSO-6) 7, 97-7, 92 (m, 2H) , 7, 88-7, 82 (m, 2H) , 7, 72-7, 65 (m, 1H) , 4, 20-4, 04 (m, 1H) , 3, 79-3, 60 (m, 1H), 3, 49-3, 32 (m, 1H), 3, 19 (s, 3H), 2, 98-2, 84 (m, 3H), 2, 78-2, 64 (m, 1H), 2, 16-1, 96 (m, 5H), 1, 89-1, 73 (m, 4H) , 1, 72-1, 42 (m, 10H) , 1, 25 (sa, 4H) , 0, 87 (d, J=6, 7 Hz, 6H) . Analytical CL / EM (Method 1): Purity: 93.1%; Observed mass: 524.93; Retention time: 0.89 min. (Method 2): Purity: 95.4%; Observed mass: 525.21; Retention time: 1.17 min. Example 80 (15 mg, 0.029 mmol, 15% yield) was isolated as the 2nd elution isomer. 1H-NMR (500 MHz, DMSO-6) 7.94 (da, J=8.5 Hz, 2H) , 7.85 (d, J=8.5 Hz, 2H) , 7.68 (s, 1H) , 4.18-4.07 (m, 1H) , 3.78-3.66 (m, 1H), 3, 49-3, 35 (m, 1H), 3, 19 (s, 5H), 2, 93-2, 85 (m, 1H), 2, 76-2, 62 (m, 2H), 2, 38-2, 28 (m, 1H), 2, 03 (sa, 4H) , 1, 91 (sa, 3H) , 1, 86-1, 49 (m, 11H) , 1, 25 (sa, 3H) , 0, 87 (da, .J=6, 4 Hz, 6H) . Analytical CL / EM (Method 1) : Purity: 91.7%; Observed mass: 525.21; Retention time: 0.89 min. (Method 2) : Purity: 90.7%; Observed mass: 525.21; Retention time: 1.41 min. Examples 81 and 82 (6S) -6- (1- (8-isobutyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl) -2- (4- (methylsulfonyl) phenyl) -5, 6, 7, 8-tetrahydroimidazo[1, 2-a]pyridine (absolute stereochemistry arbitrarily drawn) Step A. Intermediate product 81 A. Preparation of (S)-2-(4-(methylsulfonyl)phenyl)-6-(piperidin-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (absolute stereochemistry arbitrarily extracted) Intermediate product 81A was obtained as the second enantiomer from the chiral separation of intermediate product 79B (0.85 g, 2.4 mmol) by chiral SFC chromatography under the following conditions: Instrument: Berger SFC; Column: Chiral OD, 30 x 250 mm, 5 µm; Mobile phase: 70% CCh / 30% EtOH with 0.1% DEA; Flow rate: 85 mL / min; Detector wavelength: 220 nm; Injection details: 650 µg, 850 mg dissolved in 30 mL of EtOH-DEA. The fractions containing the desired product were combined and dried by centrifugal evaporation to yield the title compound (0.35 g, 0.97 mmol, 41% yield) as a pale yellow solid.1H-NMR (500 MHz, methanol-d4) 7.98-7.89 (m, 4H), 7.58-7.52 (m, 1H), 4.29-4.16 (m, 1H), 3.87-3.70 (m, 1H), 3.14 (s, 5H) , 3, 07-3, 00 (m, 1H) , 2, 86-2, 75 (m, 1H) , 2, 67-2, 58 (m, 2H) , 2, 24-2, 18 (m, 1H) , 1, 94-1, 86 (m, 2H) , 1, 81-1, 75 (m, 1H), 1.74-1.62 (m, 1H) , 1.59-1.50 (m, 1H) , 1.43-1.33 (m, 2H) . CL / EM analytical (Method 4): Observed mass: 360.0; Retention time: 0.824 min. Chiral analytical (Method SFC 9): Purity: >99%; Retention time: 16.21 min. Step B. Intermediate Product 81B. Preparation of (6S)-6-(1-(8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine dihydrochloride (absolute stereochemistry arbitrarily drawn) Intermediate product 81B was synthesized according to the methods described for the preparation of intermediate product 75B, using intermediate product 81A (0.35 g, 0.97 mmol) as a starting material to obtain the title compound (0.52 g, 0.96 mmol, 99% yield) as a pale yellow solid. 1H-NMR (500 MHz, methanol-d4) 8, 15-8, 08 (m, 2H), 8, 02-7, 94 (m, 3H), 4, 47-4, 41 (m, 1H), 4, 29-4, 17 (m, 3H), 4, 12-4, 05 (m, 5H) , 4, 02-3, 94 (m, 2H) , 3, 76-3, 70 (m, 2H) , 3, 37 (s, 4H) , 3, 16-3, 08 (m, 3H) , 2, 14-2, 08 (m, 7H) , 1, 89-1, 83 (m, 3H) . CL / EM analytical (Method 4): Observed mass: 469.1; Retention time: 0.826 min. Stage C. Examples 81 and 82 Examples 81 and 81 were synthesized according to the methods described for the preparation of Examples 75 and 76, using intermediate product 81B (100 mg, 0.19 mmol) as the starting material. The crude isomeric mixture was purified by preparative HPLC under the following conditions: Column: X Bridge Cl 8, 200 mm x 19 mm, 5-pm particles; Mobile phase A: 5:95 acetonitrile:ammonium acetate water; Mobile phase B: 95:5 acetonitrile:ammonium acetate water; Gradient: a 0-minute hold at 0% B, 0-30% B for 20 minutes, then a 0-minute hold at 100% B; Flow rate: 20 mL / min; Column temperature: 25 °C. Fraction collection was triggered by EM signals. The fractions corresponding to the respective desired products were combined and dried by centrifugal evaporation. Example 81 (1.1 mg, 0.0021 mmol, 1% yield) was isolated as the 1st elution isomer. 1H-NMR (500 MHz, DMSO-6) 8, 00-7, 95 (m, 4H) , 7, 94-7, 91 (m, 1H) , 4, 26- 4, 19 (m, 1H) , 4, 17-4, 06 (m, 2H) , 3, 90-3, 77 (m, 1H) , 3, 50-3, 36 (m, 1H) , 3, 23 (s, 2H) , 3, 10-2, 78 (m, 4H) , 2, 39-1, 82 (m, 15H) , 1, 74-1, 51 (m, 5H) , 0, 99 (da, .J=6, 0Hz, 6H) (two obscured protons). Analytical CL / EM (Method 1): Purity: 100%; Observed mass: 525.29; Retention time: 0.86 min. (Method 2): Purity: 87.3%; Observed mass: 525.31; Retention time: 1.19 min. Example 82 (2.9 mg, 0.0055 mmol, 3% yield) was isolated as the 2nd elution isomer.1H-NMR (500 MHz, DMSO-6) 8, 07 (s, 1H) , 8, 01 (da, J=13, 4 Hz, 4H) , 4, 31- 4, 20 (m, 1H) , 4, 02-3, 93 (m, 1H) , 3, 90-3, 81 (m, 1H) , 3, 64-3, 43 (m, 1H) , 3, 25 (s, 3H) , 3, 16-3, 06 (m, 1H) , 2, 99 (s, 2H) , 2, 77 (sa, 4H) , 2, 31-2, 18 (m, 2H) , 2, 16-1, 86 (m, 9H) , 1, 77-1, 48 (m, 4H) , 0, 97 (da, J=6, 4 Hz, 6H) (four obscured protons) . Analytical CL / EM (Method 1) : Purity: 100 %; Observed Mass: 524, 97; Retention Time: 0, 8 min. (Method 2) : Purity: 95, 6 %; Observed Mass: 525, 30; Retention Time: 1, 42 min. The following examples were prepared in accordance with the general methods described in this document using appropriate starting materials, reagents, and conditions. Example 142 2-(3,4-dimethoxyphenyl)-6-(4-(4-isopropylpiperazin-1-yl)phenyl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine Step A. Intermediate Product 142A. Preparation of 6-bromo-2-(3,4-dimethoxyphenyl)-8-methyl-[1,2,4]triazolo[1,5-a]pyridine Intermediate product 142A was synthesized according to the general methods described for the preparation of intermediate product 60A, using 5-bromo-3-methylpyridin-2-amine (1.0 g, 5.6 mmol) as the starting material. The crude product was purified by ultrafast column chromatography (80 g silica gel cartridge; A = Hex, B = EtOAc; 30 min gradient; 0% B to 100% B; flow rate = 60 mL / min) to provide the title compound (1.3 g, 3.8 mmol, 67% yield) as a whitish solid. 1H-NMR (chloroform-d) : 8.53-8.59 (m, 1H) , 7.88 (dd, J=8.3, 1.9 Hz, 1H) , 7.79 (d, J=1.8 Hz, 1H) , 7.36 (s, 1H) , 6.97 (d, J=8, 2 Hz, 1H), 4.02 (s, 3H), 3.95 (s, 3H), 2.68 (s, 3H). Analytical LC / MS (Method 5) : Observed mass: 347.8; Retention time: 0. 99 min. Step B. Example 142 A 20 ml vial was added intermediate product 142A (17 mg, 0.050 mmol), 1-isopropyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine (17 mg, 0.050 mmol), followed by 1,4-dioxane (3 ml) and 2 M potassium phosphate (88 u1, 0.18 mmol). The vial was purged with N2, then XPhos Pd G3 (4.2 mg, 5.0 mol) was added. The vial was purged again with N2 and the reaction was stirred at 85 °C. After 15 h, the reaction mixture was cooled, diluted with water (5 ml) and extracted with EtOAc (2 x 5 ml). The organic phase was combined, washed with brine, dried over MgSO4, filtered and concentrated. The residue was purified by ultrafast column chromatography (24 g silica gel cartridge; A = Hex, B = EtOAc; 30 min gradient; B from 0% to B from 100%; flow rate = 30 ml / min). The pure fractions were combined, concentrated, and vacuum dried to obtain the title compound (16 mg, 0.033 mmol, 67% yield) as a whitish solid.1H-NMR (500 MHz, chloroform) 68, 73-8, 61 (m, 1H) , 7, 92 (dd, J=8, 4, 2, 0 Hz, 1H) , 7, 83 (d, J=2, 0 Hz, 1H) , 7, 77-7, 70 (m, 1H) , 7, 57 (d, J=8, 7 Hz, 2H) , 7, 08 (d, J=8, 7 Hz, 2H) , 7, 04 (d, J=8, 4 Hz, 1H) , 4, 03 (s, 3H) , 4.00 (s, 3H) , 3.83 (m, 2H) , 3.70 (m, 3H) , 3.46 (m, 2H) , 3.12 (m, 2H) , 2.81 (s, 3H) , 1.46 (d, J=6, 7 Hz, 6H) .CL / EM analytical (Method 5): Observed mass: 472.1; Retention time: 0.80 min. Example 143 2-(3,4-dimethoxyphenyl)-6-(4-(4-isopropylpiperazin-1-yl)cyclohexyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine To a hydrogenation flask were added Example 142 (30 mg, 0.064 mmol), 3 M HCl in dioxane (0.21 mL, 0.64 mmol), platinum(IV) oxide (7 mg), methanol (5 mL), and THF (5 mL). The suspension was stirred at 30 PSI under hydrogen. After 3 h, the reaction mixture was filtered, the filter cake was washed with MeOH (10 mL), and the filtrate was concentrated. The crude product was purified by preparative HPLC (Preparation Method 1) to obtain the title compound (4.7 mg, 9.6 mol, 15% yield). 1H-NMR (DMSO-6) : 7.53 (dd, J=8.4.1.7 Hz, 1H) , 7.49 (d, J=L7 Hz, 1H) , 7.02 (d, J=8.5 Hz, 1H) , 4.19-4.43 (m, 2H) , 3.78 (s, 3H), 3, 75 (s, 3H), 2, 89-3, 05 (m, 4H), 2, 50-2, 53 (m, 6H), 2, 14-2, 30 (m, 2H), 1, 82-1, 96 (m, 4H), 1, 68-1, 82 (m, 6H) , 1, 55 (sa, 4H) , 1, 24 (d, J=6, 6 Hz, 6H) . Analytical CL / EM (Method 1) : Purity: 98.5%; Observed mass: 482.0; Retention time: 1.46 min.(Method 2) : Purity: 99.0%; Observed mass: 482.0; Retention time: 1, 12 min. Example 144 2-(3,4-dimethoxyphenyl)-6-(4-(4-isopropylpiperazin-1-yl)phenyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine Example 142 (30 mg, 0.064 mmol), Pd / C (7 mg), methanol (5 mL), and THF (5 mL) were added to a hydrogenation flask. The suspension was stirred at 15 PSI under hydrogen. After 12 h, the reaction mixture was filtered, the filter cake was washed with MeOH (10 mL), and the filtrate was concentrated. The crude product was purified by preparative HPLC (preparation method 1) to obtain the compound of title (6.5 mg, 0.013 mmol, 21% yield). 1H-NMR (DMSO-6) : 7.56 (dd, J=8.2, 1.8 Hz, 1H) , 7.51 (d, J=1.5 Hz, 1H) , 7.24 (da, J=8.5 Hz, 2H) , 7.03 (d, J=8.5 Hz, 1H) , 6.91 (da, J=8, 5 Hz, 2H) , 4, 26-4, 40 (m, 1H) , 4, 05 (s, 1H) , 3, 81 (s, 3H) , 3, 79 (s, 3H) , 3, 44-3, 61 (m, 2H) , 3, 30 (sa, 1H) , 3, 043, 18 (m, 4H) , 2.65 (dt, J=13.0.6, 3 Hz, 2H) , 2.13 (da, J=8.2 Hz, 2H) , 1.79-1.94 (m, 2H) , 1.40 (d, J=7.0 Hz, 3H) , 1.01 (d, J=6, 4 Hz, 6H) . Analytical LC / MS (Method 1): Purity: 98.1%; Observed mass: 476.3. Example 145 6- (8- (1-cyclopropylpiperidin-4-yl) -8-azabicyclo[3.2.1]octan-3-yl) -2- (3, 4- dimethoxyphenyl) -5, 6, 7, 8-tetrahydro-[1, 2, 4]triazolo[1, 5-a]pyridine Step A. Intermediate Product 145A Preparation of 6-bromo-2-(3,4-dimethoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridine Intermediate product 145A was synthesized according to the general methods described for the preparation of intermediate product 60A, using 5-bromo-pyridin-2-amine (1.0 g, 5.8 mmol) as the starting material. The crude product was purified by ultrafast column chromatography (80 g silica gel cartridge; A = Hex, B = EtOAc; 30 min gradient; 0% B to 100% B; flow rate = 60 mL / min) to obtain the title compound (1.2 g, 3.7 mmol, 64% yield) as a pale yellow solid. 1H-NMR (chloroform-d) 6: 8.68–8.79 (m, 1H), 7.89 (dd, J = 8.4, 1.7 Hz, 1H), 7.80 (d, J = 1.6 Hz, 1H), 7.63–7.68 (m, 1H), 7.60 (d, J = 1.6 Hz, 1H), 7.01 (d, J=8, 2 Hz, 1H) , 4, 04 (s, 3H) , 3, 98 (s, 3H) . Analytical CL / EM (Method 5) : Observed mass: 334, 0; Retention time: 0, 91 min. Step B. Intermediate Product 145B. Preparation of tert-butyl 3-(2-(3,4-dimethoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate Intermediate product 145B was synthesized according to the general methods described for the preparation of example 142 (step B), using intermediate product 145A (100 mg, 0.30 mmol) as the starting material and substituting (1R, 5S)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-8-azabicyclo[3.2.1] tert-butyl oct-2-ene-8-carboxylate (100 mg, 0.30 mmol), where appropriate. The crude product was purified by ultrafast column chromatography (40 g silica gel cartridge; A = Hex, B = EtOAc; 20 min gradient; 0% B to 100% B; flow rate = 40 ml / min) to provide the title compound (130 mg, 0.27 mmol, 91% yield) as a gum.1H-NMR (chloroform-d) 6: 8, 48 (s, 1H) , 7, 88 (dd, J=8, 3, 1, 9 Hz, 1H) , 7, 79 (d, J=2, 0 Hz, 1H) , 7, 58-7, 69 (m, 2H) , 6, 99 (d, J=8, 4 Hz, 1H) , 6, 57 (sa, 1H) , 4, 57 (sa, 2H) , 4, 02 (s, 3H) , 3, 96 (s, 3H) , 2, 14-2, 34 (m, 2H) , 1, 91-2, 12 (m, 2H) , 1, 60-1, 78 (m, 2H) , 1, 46 (s, 9H) .CL / EM analytical (Method 5): Observed mass: 463.0; Retention time: 1.03 min. Step C. Intermediate Product 145C. Preparation of tert-butyl 3-(2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate Intermediate product 145C was synthesized according to the general methods described for the preparation of example 144, using intermediate product 145B (120 mg, 0.260 mmol) as the starting material. The crude product was purified by preparative HPLC (Preparation Method 1) to obtain the title compound (63 mg, 0.130 mmol, 52% yield) as a gum.1H-NMR (chloroform-d) 6: 7, 64-7, 64 (m, 1H) , 7, 57 (d, J=1, 7 Hz, 1H) , 6, 97 (d, J=8, 5 Hz, 1H) , 4, 19-4, 48 (m, 3H) , 3, 96 (s, 3H) , 3, 95 (s, 3H) , 3, 73-3, 94 (m, 2H) , 3, 37-3, 73 (m, 1H) , 3, 35-3, 35 (m, 1H) , 2, 94-3, 15 (m, 1H) , 2, 25 (da, J=8, 5 Hz, 2H) , 1, 98-2, 16 (m, 2H) , 1, 881, 92 (m, 1H) , 1, 55-1, 70 (m, 5H) , 1, 50 (s, 9H) . Analytical LC / MS (Method 5) : Observed mass: 469.1; Retention time: 0. 938 min. Step D. Intermediate Product 145D. Preparation of 6-(8-azabicyclo[3.2.1]octan-3-yl)-2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine hydrochloride The intermediate product 145D was synthesized according to the general methods described for the preparation of example 60 (step D), using the intermediate product 145C (100 mg, 0.21 mmol) as the starting material. The crude product was used directly without further purification.1H-NMR (methanol-d4) 8: 8, 16-8, 25 (m, 1H) , 7, 81-7, 84 (m, 1H) , 7, 737, 77 (m, 1H) , 4, 29-4, 48 (m, 3H) , 4, 16 (s, 3H) , 4, 05 (s, 3H) , 3, 73-3, 99 (m, 2H) , 3, 37-3, 73 (m, 1H) , 3, 05-3, 35 (m, 1H) , 2, 98-3, 15 (m, 1H) , 2, 45 (da, J=8, 5 Hz, 2H) , 1, 98-2, 10 (m, 2H) , 1, 82-1, 92 (m, 1H) , 1, 66-1, 70 (m, 5H) . Analytical CL / EM (Method 5) : Observed mass: 369, 2; Retention time: 0, 663 min. Stage E. Example 145 Example 145 was synthesized according to the general methods described for the preparation of Example 60 (step E), using intermediate 145D (30 mg, 0.062 mmol) and l-cyclopropylpiperidin-4-one (26 mg, 0.190) as starting materials. The crude product was purified by preparative HPLC (Preparation Method 1) to obtain the title compound (17 mg, 0.035 mmol, 57% yield) as a gum. 1H-NMR (DMSO-6) 8: 7, 50-7, 55 (m, 1H), 7, 41-7, 49 (m, 1H), 7, 02 (d, J=8, 5 Hz, 1H), 4, 20 (dd a, J=12, 2, 4, 6 Hz, 1H), 3, 81 (s, 3H) , 3, 78 (s, 3H) , 3, 53-3, 66 (m, 2H) , 2, 92 (da, J=8, 2 Hz, 3H) , 2, 27-2, 46 (m, 1H) , 2, 16 (ta, J= ll.l Hz, 3H) , 1, 98-2, 09 (m, 2H) , 1, 81-1, 95 (m, 7H) , 1, 44-1, 66 (m, 6H) , 1, 27 (da, J=12, 5 Hz, 3H) , 0, 33-0, 46 (m, 2H) , 0, 29 (sa, 2H) . Analytical CL / EM (Method 1) : Purity: 100 %; Observed Mass: 492, 3; Retention Time: 1, 284 min.(Method 2): Purity: 100%; Observed mass: 492.3; Retention time: 1,048 min. Example 146 6-(8-(1-cyclopropylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-2-(3,4-dimethoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridine Step A. Intermediate product 146 A. Preparation of tert-butyl 3-(2-(3,4-dimethoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate Intermediate product 146A was synthesized according to the general methods described for the preparation of example 144, using intermediate product 145B (120 mg, 0.26 mmol) as the starting material. The crude product was purified by preparative HPLC (Preparation Method 1) to obtain the title compound (55 mg, 0.12 mmol, 47% yield) as a gum.1H-NMR (chloroform-d): 8.51 (s, 1H) , 8.27 (da, J=9, 3 Hz, 1H) , 7.86 (da, J=8, 5 Hz, 1H) , 7.78 (d, J=1, 5 Hz, 2H) , 7.04 (d, J=8, 6 Hz, 1H) , 4.02 (s, 3H) , 3.99 (s, 3H) , 3.22-3.39 (m, 1H) , 2.72-2.99 (m, 1H) , 2, 52-2, 67 (m, 1H) , 2, 39 (sa, 1H) , 2, 05-2, 24 (m, 3H) , 1, 86-1, 95 (m, 3H) , 1, 63-1, 69 (m, 1H) , 1, 53 (s, 9H) . Analytical CL / EM (Method 5) : Observed mass: 465.1; Retention time: 1.018 min. Step B. Intermediate Product 146B. Preparation of 6-(8-azabicyclo[3.2.1]octan-3-yl)-2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine hydrochloride Intermediate product 146B was synthesized according to the general methods described for the preparation of example 60 (step D), using intermediate product 146A (100 mg, 0.21 mmol) as the starting material. The crude product was used directly without further purification.1H-NMR (methanol-d4) : 8, 57 (s, 1H) , 8, 25 (da, J=9, 3 Hz, 1H) , 7, 84 (da, J=8, 5 Hz, 1H) , 7, 75 (d, J=1, 5 Hz, 2H) , 7, 02 (d, J=8, 6 Hz, 1H) , 4, 00 (s, 3H) , 3, 96 (s, 3H) , 3, 20-3, 37 (m, 1H) , 2, 71-2, 95 (m, 1H) , 2, 49-2, 63 (m, 1H) , 2, 36 (sa, 1H) , 2, 00-2, 16 (m, 3H) , 1, 80-1, 91 (m, 3H) , 1, 60-1, 66 (m, 1H) . Analytical CL / EM (Method 5) : Observed mass: 365, 1; Retention time: 0, 690 min. Stage C. Example 146 Example 146 was synthesized according to the general methods described for the preparation of Example 60 (step E), using intermediate product 146B (30 mg, 0.063 mmol) and l-cyclopropylpiperidin-4-one (26 mg, 0.19) as starting materials. The crude product was purified by preparative HPLC (Preparation Method 1) to obtain the title compound (29 mg, 0.060 mmol, 96% yield) as a gum. 1H-NMR (DMSO-6) : 8.88 (s, 1H) , 8.78 (s, 1H) , 7.75 (dd a, J=9.5, 4.6 Hz, 2H) , 7.64-7.72 (m, 2H) , 7.11 (d, J=8.5 Hz, 1H) , 3, 86 (s, 2H) , 3, 83 (s, 3H) , 3, 05-3, 23 (m, 2H) , 2, 88-2, 97 (m, 2H) , 2, 08-2, 24 (m, 3H) , 1, 74-1, 98 (m, 8H) , 1, 53-1, 63 (m, 2H) , 1, 42 (da, J=7, 3 Hz, 1H) , 1, 18-1, 33 (m, 3H) , 0, 35-0, 46 (m, 2H) , 0, 30 (sa, 2H) . Analytical CL / EM (Method 1): Purity: 100%; Observed Mass: 488.3; Retention Time: 1.375 min. (Method 2): Purity: 100%; Observed Mass: 488.3; Retention Time: 1.110 min. Example 147 6- (4- (4-isopropylpiperazin-1-yl) phenyl) -8-methyl-2- (4- (methylsulfonyl) phenyl) - [1, 2, 4]triazole[1, 5 -a] pyridine Stage A. Intermediate product 147A. Preparation of 6-bromo-8-methyl-2- (4- (methylsulfonyl) phenyl) -[1, 2, 4]triazole[1, 5-a]pyridine Intermediate product 147A was synthesized according to the general methods described for the preparation of intermediate product 60A, using 5-bromo-3-methylpyridin-2-amine (2.0 g, 11 mmol) and 4-(methylsulfonyl)benzenitrile (2.3 g, 13 mmol) as starting materials. The crude product was purified by ultrafast column chromatography (80 g silica gel cartridge; A = Hex, B = EtOAc; 30 min gradient; 0% B to 100% B; flow rate = 60 mL / min) to provide the title compound (2.3 g, 6.3 mmol, 59% yield) as a roasted solid. 1H-NMR (chloroform- d) : 8.63 (s, 1H) , 8.46-8.56 (m, J=8.5 Hz, 2H) , 8.08 (d, J=8.5 Hz, 2H) , 7.45 (s, 1H) , 3.13 (s, 3H) , 2. 72 (s, 3H) . Analytical LC / MS (method 5) : Observed mass: 365.7; Retention time: 0. 936 min. Stage B. Example 147 Example 147 was synthesized according to the general methods described for the preparation of Example 142 (step B), using intermediate product 147A (110 mg, 0.30 mmol) as the starting material. The crude product was purified by preparative HPLC (preparation method 1) to provide the title compound (120 mg, 0.24 mmol, 81% yield) as a white solid. 1H-NMR (chloroform-d): 8.63 (s, 1H), 8.54 (d, J=8, 2 Hz, 2H), 8.09 (d, J=8, 3 Hz, 2H), 7.53-7.59 (m, 3H), 7.06 (d, J=8, 6 Hz, 2H), 3.79 (da, J=12, 9 Hz, 2H), 3.63 (da, J=10, 7 Hz, 2H), 3.42-3.58 (m, 3H), 3, 14 (s, 3H) , 3, 09 (s, 2H) , 2, 78 (s, 3H) , 1, 45 (d, J=6, 7 Hz, 6H) . Analytical CL / EM (Method 1): Purity: 100%; Observed mass: 492.3; Retention time: 1.284 min. (Method 2): Purity: 100%; Observed mass: 490.2; Retention time: 0.722 min. The following examples were prepared according to the general methods described elsewhere in this document using appropriate starting materials, reagents, and conditions. Biological assays The pharmacological properties of the compounds in this disclosure can be confirmed by a series of biological assays. The biological assays described below have been performed with compounds from this disclosure. TLR7 / 8 / 9 Inhibition Indicator Assays HEK-Blue™ cells (Invivogen) that overexpress human TLR7, TLR8, or TLR9 receptors were used to detect inhibitors of these receptors using an inducible SEAP 10 (secreted embryonic alkaline phosphatase) reporter gene under the control of the minimal IFN-P promoter fused to five NF-KB and AP-1 binding sites. In summary, cells are seeded in 384-well Greiner plates (15,000 cells per well for TLR7, 20,000 for TLR8, and 25,000 for TLR9) and then treated with test compounds in DMSO to produce a final dose response concentration range of 0.05 nM - 50 pM. After a 30-minute compound pretreatment at room temperature, cells are stimulated with a TLR7 ligand (gardiquimod at a final concentration of 7.5 pM), TLR8 ligand (R848 at a final concentration of 15.9 pM), or TLR9 ligand (ODN2006 at a final concentration of 5 nM) to activate NF-KB and AP-1, which induce SEAP production.After a 22-hour incubation at 37°C, 5% CO2, SEAP levels are determined by adding HEK-Blue™ detection reagent (Invivogen), a cell culture medium that allows for SEAP detection, according to the manufacturer's specifications. The percentage of inhibition is determined as the percentage reduction in the HEK-Blue signal present in wells treated with agonist plus DMSO alone compared to wells treated with a known inhibitor. Table 1

Claims

1. Compound of formula (II): or stereoisomers, tautomers, solvates or salts thereof, wherein: X is N or CR3; one of Q1 and Q2 is A and the other of Q1 and Q2 is R5; G is phenyl substituted with 1 to 3 substituents independently selected from -S(O)2CH3, -S(O)2(phenyl), -S(O)2NRxRx and -S(O)(NH)NRXRX; A is cyclohexyl, piperidinyl, phenyl, pyridinyl, pyrimidinyl, 6-azabicyclo[3.2.1]octanyl or azabicyclo[3.2.1]octanyl, each substituted with -L-R4 and zero to 1 R4b; L is a linker, -CRxRx- or -C(O)(CRxRx)0-2-; R3 is hydrogen, F, CI, C1-3 alkyl, C1-2 fluoroalkyl, or C3-4 cycloalkyl; R4 is: (i) -N(CH3)2; (ii) pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, pyridinyl, azaspiro[3.3]heptanyl, azabicyclo[3.2.1]octanyl, or diazabicyclo[3.2.1]octanyl, each substituted with zero to 2 R4a; or each R4a is independently C1-6 alkyl, C1-3 fluoroalkyl, -(CH2)0-2O (C1-2 alkyl), C3-6 cycloalkyl, -CH2 (C3-6 cycloalkyl), -C(O) (C1-4 alkyl),-C(O) (C3-6 cycloalkyl), -C(O) (phenyl), -C(O)CH2 (C3-6 cycloalkyl), -C(O)CH2 (phenyl), -C(O)O (C1-4 alkyl), oxethanyl, tetrahydrofuran or tetrahydropyranyl; R4b is F, Cl or -CH3; each R4C is independently C1-6 alkyl, C1-3 fluoroalkyl, -CH2 (C3-6 cycloalkyl), -C(O) (C1-4 alkyl), -C(O) (phenyl), -C(O)CH2 (phenyl), -C(O)OCH2CH3 or C3-6 cycloalkyl; each R5 is independently hydrogen, F, Cl, C1-3 alkyl, C1-2 fluoroalkyl or C3-4 cycloalkyl; each Rx is independently hydrogen or -CH3; m is zero, 1, or 2; n is zero, 1, or 2; and q is 1 or 2.

2. Compound according to claim 1 or stereoisomers, tautomers, solvates, or salts thereof, wherein G is phenyl substituted with -S(O)2CH3, -S(O)2(phenyl), -S(O)2NRxRx, or -S(O)(NH)NRxRx.

3. Compound according to claim 1 or stereoisomers, tautomers, solvates, or salts thereof, wherein X is CR3.

4. Compound according to claim 1 or stereoisomers,tautomers, solvates or salts thereof, wherein X is N.

5. Compound according to claim 1 or stereoisomers, tautomers, solvates or salts thereof, wherein: G is phenyl substituted with 1 to 2 substituents selected from -S(O)2CH3; A is cyclohexyl, piperidinyl, phenyl or 6-azabicyclo[3.2.1]octanyl, each substituted with -L-R4; L is a bond; R3 is hydrogen; R4 is piperidinyl, piperazinyl, azepanyl, azaspiro[3.3]heptanyl, azabicyclo[3.2.1]octanyl or diazabicyclo[3.2.1]octanyl, each substituted with R4a; R4a is -CH(CH3)2, -CH2CH(CH3)2, -CH2CH2OCH3, -C(O)CH(CH3)2, -C(O)(cyclopropyl), -CH2(cyclopropyl), -CH2(cyclobutyl), cyclopropyl, cyclobutyl, oxethanyl, or tetrahydropyranyl; and each R5 is hydrogen, F, or -CH3.

6. Compound according to claim 1 or stereoisomers, tautomers, solvates, or salts thereof, wherein G is 7. Compound according to claim 1 or stereoisomers, tautomers, solvates, or salts thereof,en donde dicho compuesto es: 6- (T-cyclopropyl-[1, 4'-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (7) ; 6- (T-isopropyl-[1, 4'-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (8) ; 6- (T-isobutyl-[1, 4'-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (9) ; 6- (1- (8-isopropyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl) -8-methyl-2- (4- (methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (62-63) ; 7-(T-isopropyl-[1, 4'-bipiperidin]-4-yl)-5-methyl-2- (4-(methylsulfonyl)phenyl) imidazo[1, 2-a]pyridine (66) ; 8-fluoro-6-(T-isopropyl-[1, 4'-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl) imidazo[1, 2-a]pyridine (67) ; 8-fluoro-6-(l-(8-isopropyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (68-69); 7-fluoro-6-(1-isopropyl-[1, 4'-bipiperidin]-4-yl)-2-(4-(m ethylsulfonyl)phenyl)imidazo[1,2-a]pyridine (70) ; 8-fluoro-6- (1- (1-isopropylazepan-4-yl) piperidin-4-yl) -2- (4- (methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (71-72) ; 5 -fluoro-6- (1'-isopropyl-[1, 4'-bipiperidin] -4-yl) -2- (4- (methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (73) ; 8-fluoro-7- (1'-isobutyl-[1, 4'-bipiperidin]-4-yl) -2- (4- (methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (74) ; 6- (1- (8-ciclobutil-8-azabiciclo[3.2.1]octan-3-yl)piperidin-4-yl)-8-methyl-2- (4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (83-84) ; 6- (1- (8-isobutyl-8-azabiciclo[3.2.1]octan-3-yl)piperidin-4-yl)-8-methyl-2- (4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (85-86) ; 6- (1- (8- (ciclopropylmethyl) -8-azabiciclo[3.2.1]octan-3-yl) piperidin-4-yl) -8-methyl-2- (4-(methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (87-88) ; 6- (1- (8- (ciclobutylmethyl) -8-azabiciclo[3.2.1]octan-3-yl) piperidin-4-yl) -8-methyl-2- (4-(methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (89-90) ; 6-(1-cyclobutyl-[1,4'-bipiperidin]-4-yl) -8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (91) ; 6-(1'- (cyclopropylmethyl)-[1, 4'-bipiperidin]-4-yl) -8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (92) ; 6-(1-(cyclobutylmethyl)-[1, 4'-bipiperidin]-4-yl) -8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (93) ; 6-(4-(4-isobutylpiperazin-1-yl)phenyl) -8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (99) ; 6- (4- (4- (cyclopropylmethyl) piperazin-1-yl) phenyl) -8-methyl-2- (4- (methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (100) ; 6- (4- (4- (cyclobutylmethyl) piperazin-1-yl) phenyl) -8-methyl-2- (4- (methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (101) ; 6-(4-(4-cyclobutylpiperazin-1-yl)phenyl)-8-methyl-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (102) ; 8-methyl-2-(4-(methylsulfonyl)phenyl)-6-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyridine (103) ; 8-methyl-2- (4- (methylsulfonyl) phenyl) -6- (4- (4- (tetrahydro-2H-pyran-4-yl) piperazin-1-yl) phenyl) imidazo[1, 2-a]pyridine (104) ; 6- (4- (4- (2-methoxyethyl) piperazin-1-yl) phenyl) -8-methyl-2- (4- (methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (105) ; 7- (1-isobutyl-[1, 4'-bipiperidin]-4-yl)-5-methyl-2- (4- (methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (106) ; 8-fluoro-6-(1-isobutyl-[1,4'-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (107) ; 6-(1-cyclopropyl-[1,4'-bipiperidin]-4-yl)-8-fluoro-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (108) ; 6-(1-(cyclopropylmethyl)-[1,4'-bipiperidin]-4-yl)-8-fluoro-2-(4-(methylsulfonyl)phenyl)imidazo[1,2-a]pyridine (109) ; 6-(1-cyclobutyl-[1, 4'-bipiperidin]-4-yl)-8-fluoro-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (110) ; 8-fluoro2-(4-(methylsulfonyl)phenyl)-6-(1-(oxetan-3-yl)-[1, 4'-bipiperidin]-4-yl)imidazo[1,2-a]pyridine (111) ; 8-fluoro-2- (4- (methylsulfonyl) phenyl) -6- (1- (tetrahydro-2H-pyran-4-yl) -[1, d'-bipiperidin]-4-yl) imidazo[1, 2-a]pyridine (112) ; 8-fluoro-6- (1- (8-isobutyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl) -2- (4-(methylsulfonyl)phenyl) imidazo[1, 2-a]pyridine (113-114) ; 6-(1-(8-(cyclopropylmethyl)-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-8-fluoro-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (115-116) ; 6-(1-(8-cyclobutyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl)-8-fluoro-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (117) ; 6- (1- (8-cyclobutyl-8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl) -8-fluoro-2- (4- (methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (118) ; 8-fluoro-2- (4- (methylsulfonyl) phenyl) -6- (1- (8- (oxetan-3-yl) -8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl) imidazo[1,2-a]pyridine (119-120) ; 8-fluoro-2- (4- (methylsulfonyl) phenyl) -6- (1- (8- (tetrahydro-2H-pyran-4-yl) -8-azabicyclo[3.2.1]octan-3-yl) piperidin-4-yl) imidazo[1, 2-a]pyridine (121-122) ; 7-fluoro-6- (1-isobutyl-[1, 4'-bipiperidin]-4-yl) -2- (4- (methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (123) ; 6- (1-cyclopropyl-[1, 4'-bipiperidin]-4-yl) -7-fluoro-2- (4- (methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (124) ; 8-fluoro-6- (1- (1-isobutylazepan-4-yl) piperidin-4-yl) -2- (4- (methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (125-126) ; 6- (l- (1- (cyclopropylmethyl) azepan-4-yl) piperidin-4-yl) -8-fluoro-2- (4- (methylsulfonyl) phenyl) imidazo[1, 2-a]pyridine (127-128) ; 8-fluoro-2- (4- (methylsulfonyl) phenyl) -6- (1- (1- (tetrahydro-2H-pyran-4-yl) azepan- 4-yl) piperidin-4-yl) imidazo[1, 2-a]pyridine (129-130) ; 5-fluoro-6-(1-isobutyl-[1, 4'-bipiperidin]-4-yl)-2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (131); 8-fluoro-7-(1'-isopropyl-[1,4'-bipiperidin] -4-yl) -2-(4-(methylsulfonyl)phenyl)imidazo[1, 2-a]pyridine (132) ; 8-fluoro-2-(4-(methylsulfonyl)phenyl)-7-(1-(tetrahydro-2H-pyran-4-yl)-[1, 4'-bipiperidin]-4-yl)imidazo[1, 2-a]pyridine (133) ; 6-(4-(4-isopropylpiperazin-1-yl)phenyl)-8-methyl-2-(4-(methylsulfonyl)phenyl)-[1, 2, 4]triazolo[1, 5-a]pyridine (147) ; 6- (4- (8-isopropyl-3, 8-diazabicyclo[3.2.1]octan-3-yl) phenyl)-8-methyl-2- (4-(methylsulfonyl) phenyl)-[1, 2, 4]triazolo[1, 5-a]pyridine (153) ; 6- (8- (1-ciclopropylpiperidin-4-yl)-8-azabiciclo[3.2.1]octan-3-yl)-8-methyl-2- (4-(methylsulfonyl)phenyl)-[1, 2, 4]triazolo[1, 5-a]pyridine (159) ; 6-(8-(1-isopropylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-3-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)-[1, 2, 4]triazolo[1, 5-a]pyridine (160) ; 6-(1-cyclopropyl-[1, 4'-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)-[1, 2, 4]triazolo[1, 5-a]pyridine (161) ; 6-(1-isopropyl-[1,4'-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine (162) ; 6-(1-isobutyl-[1,4'-bipiperidin]-4-yl)-8-methyl-2-(4-(methylsulfonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine (163) ; or 6-(4-(4-isopropylpiperazin-1-yl)phenyl)-2-(4-(methylsulfonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine (167).

8. A pharmaceutical composition comprising one or more compounds according to any one of claims 1 to 7 or pharmaceutically acceptable stereoisomers, tautomers, solvates, or salts thereof; and a pharmaceutically acceptable carrier.

9. A compound according to any one of claims 1 to 7 or pharmaceutically acceptable stereoisomers, tautomers, solvates, or salts thereof, or a pharmaceutical composition according to claim 8, for use in the treatment of pathological fibrosis.

10. A compound or pharmaceutically acceptable stereoisomers, tautomers, solvates, or salts thereof,or pharmaceutically acceptable salts thereof, or the pharmaceutical composition, for use according to claim 9, wherein said pathological fibrosis is hepatic fibrosis, renal fibrosis, biliary fibrosis, or pancreatic fibrosis.

11. A compound according to any one of claims 1 to 7, or pharmaceutically acceptable stereoisomers, tautomers, solvates, or salts thereof, or a pharmaceutical composition according to claim 8, for use in the treatment of non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC), or primary biliary cirrhosis (PBC).

12. A compound according to any one of claims 1 to 7, or pharmaceutically acceptable stereoisomers, tautomers, solvates, or salts thereof, or a pharmaceutical composition according to claim 8,for use in the treatment of idiopathic pulmonary fibrosis (IPF).